Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
Patent Information
- Application Number
- ZA201902834
- Authority / Receiving Office
- ZA · ZA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-11-15
- Filing Date
- 2019-05-06
- Publication Date
- 2026-10-28
- Estimated Expiration
- 2037-11-15
AI Technical Summary
There is a long-standing need for new 5-HT7 modulators that can effectively treat diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, such as circadian rhythm disorders, depression, schizophrenia, and other CNS-related conditions, as existing treatments are inadequate in providing therapeutic relief.
Development of novel 5-hydroxytryptamine receptor 7 (5-HT7) activity modulators, including specific compounds and compositions, to treat or prevent diseases related to 5-HT7 dysregulation by administering effective amounts of these compounds, either alone or in combination with excipients, to address the underlying receptor activity imbalances.
The novel 5-HT7 modulators demonstrate the potential to ameliorate or control diseases associated with 5-HT7 dysregulation, offering therapeutic benefits for conditions like depression, schizophrenia, and other CNS disorders by modulating receptor activity effectively.
Abstract
Description
NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7AND THEIR METHOD OF USECROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional application No. 62 / 422,344, filed November 15, 2016, which is herein incorporated by reference in its entirety.STATEMENT OF FEDERALLY FUNDED RESEARCH
[0002] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grant number HHSN-271-2008-00025-C awarded by the National Institute of Mental Health.FIELD OF INVENTION
[0003] Embodiments of the invention are directed to novel compounds useful as modulators of 5 -hydroxy tryptamine receptor 7 (5-HT7) activity and their method of use. Embodiments are further directed to a novel chemotype useful for the treatment diseases that are associated with dysregulation of 5 -hydroxy tryptamine receptor 7 activity.BACKGROUND OF THE INVENTION
[0004] Serotonin was discovered in the late 1940s and is present in both the peripheral and central nervous systems [Physiol. Res, 60 (2011) 15-25; Psychopharmacology 213 (2011) 167-169]. Serotonin or 5 -hydroxy tryptamine (5-HT) is a monoamine neurotransmitter of the indolalkylamine group that acts at synapses of nerve cells. Seven distinct families of serotonin receptors have been identified and at least 20 subpopulations have been cloned on the basis of sequence similarity, signal transduction coupling and pharmacological characteristics. The seven families of 5-HT receptor are named 5-HT^ 5-HT2, 5-HT3, 5-HT4, 5-HTs, 5-ΗΤδ, and 5-HT7 and each of these receptors in turn has subfamilies or subpopulations. The signal transduction mechanism for all seven families have been studied and it is known that activation of 5-HTi and 5-HT5receptors causes a decrease in intracellular cAMP whereas activation of 5-HT2, 5-HT3, 5-HT4, 5-HT6, and 5-HT7results in an increase in intracellular IP3 and DAG. The 5-HT pathways in the brain are important targets for drug development in the area of CNS disorders. The neurotransmitter binds to its a G-protein coupled receptor and is involved in a wide variety of actions including cognition, mood, anxiety, attention, appetite, cardiovascular function, vasoconstriction, sleep (ACS Medicinal Chemistry Letters, 2011, 2, 929-932; Physiological Research, 2011, 60, 15-25), inflammatory bowel disease (IBD), and intestinal inflammation (WO 2012058769, Khan, W. I., et. al. Journal of Immunology, 2013, 190, 4795-4804),epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, and alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9) among others.BRIEF SUMMARY OF THE INVENTION
[0005] The present invention is directed toward novel 5 -hydroxy tryptamine receptor 7 (5-HT7) activity modulators, compounds of formula (I),Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:A is selected from a groupcons st ng oX is selected from the group consisting of O, S, SO, SO2, NR;n1is 0, 1, 2;n2is 0, 1, 2;R is selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,, COR2, C02R2a, CONR2bR2c, S02NR2bR2c, and S02R2d;Rla, Rlb, Rlc, Rld, and Rleare at each occurrence independently selected from the group consisting of H, OH, NO2, halogen, CN, Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, Ci-e linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, Ci-e linear haloalkyl, C3-7 branched haloalkyl, Ci-e linear haloalkoxy, -S(Ci-6linear alkyl), S(C3-7branched alkyl), -S(C3-7cycloalkyl), COR6, C02R7,CONR8aR8b, S02NR8aR8b, NR9aR9b, NR9aCOR10, NR9aS02Rn, and NR9aS02NR12aR12b;R2is selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;Rais selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl; R2bis selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R2cis selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R2dis selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, Ci-eR3is selected from a group consisting of Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,o tionally substituted aryl,R4is an optionally substituted aryl;R5aand R5bare each independently optionally substituted aryl;R6is at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R7is at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R8ais at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R8bis at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R9ais at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R9bis at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R10is at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;Rnis at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R12ais at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R12bis at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R13is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R14is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl; n is 1, 2, or 3;m is 1 or 2;and q is 1, 2, or 3;
[0006] The present invention further relates to compositions comprising:an effective amount of one or more compounds according to the present invention and an excipient.
[0007] The present invention also relates to a method for treating or preventing diseases that involve dysregulation of 5 -hydroxy tryptamine receptor 7 activity, including, for example, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction said method comprising administering to a subject an effective amount of a compound or composition according to the present invention.
[0008] The present invention yet further relates to a method for treating or preventing diseases that involve dysregulation of 5 -hydroxy tryptamine receptor 7 activity, including, for example, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar, disorder inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.
[0009] The present invention also relates to a method for treating or preventing diseases or conditions associated with circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction and diseases that involve dysregulation of 5 -hydroxy tryptamine receptor 7 activity. Said methods comprise administering to a subject an effective amount of a compound or composition according to the present invention.
[0010] The present invention yet further relates to a method for treating or preventing diseases or conditions associated with circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, and bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction and diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity, wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.
[0011] The present invention also relates to a method for treating or preventing diseases or conditions associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. Said methodscomprise administering to a subject an effective amount of a compound or composition according to the present invention.
[0012] The present invention yet further relates to a method for treating or preventing diseases or conditions associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.
[0013] The present invention further relates to a process for preparing the 5- hydroxytryptamine receptor 7 activity modulators of the present invention.
[0014] These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (° C) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.DETAILED DESCRIPTION OF THE INVENTION
[0015] There is evidence that suggests a role for the 5-HT7receptor in a number of medical disorders. 5-HT7receptor activity modulators are likely to have a beneficial effect on patients suffering from these disorders. The disorders in which 5-HT7dysregulation plays a role and modulation of 5-HT7receptor activity by a therapeutic agent may be a viable approach to therapeutic relief include, but are not limited to, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine (Vanhoenacker, P. et al. Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder (WO20100197700) attention deficit / hyperactivity disorder (ADHD) (WO20100069390), anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), intestinal inflammation (WO 2012058769, Khan, W. I., et. al. Journal of Immunology, 2013, 190, 4795-4804), epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, and alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9).
[0016] There is a long felt need for new 5-HT7modulators that will provide therapeutic relief from patients suffering from diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The invention addresses the need to identify novel 5-HT7 modulators capable of treating disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The presentinvention addresses the need to develop new therapeutic agents for the treatment and prevention of circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation epilepsy, seizure disorders, drug addiction, and alcohol addiction.
[0017] The 5-hydroxytryptamine receptor 7 activity modulators of the present invention are capable of treating and preventing diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, for example circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction. It has been discovered that the 5-hydroxytryptamine receptor 7 play a role in a number of medical disorders, and therefore, 5-HT7receptor activity modulators are likely to have a beneficial effect on patients suffering from these disorders. The disorders in which 5-HT7dysregulation plays a role and modulation of 5-HT7receptor activity by a therapeutic agent may be a viable approach to therapeutic relief include, but are not limited to, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine (Vanhoenacker, P.et. al. Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder (WO20100197700) attention deficit / hyperactivity disorder (ADHD) (WO20100069390), anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), intestinal inflammation (WO 2012058769) epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, and alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9)..
[0018] Without wishing to be limited by theory, it is believed that 5-hydroxytryptamine receptor 7 receptor activity modulators of the present invention can ameliorate, abate, otherwise cause to be controlled, diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The diseases include, but are not limited to circadian rhythm disorder, depression, schizophrenia,neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction.
[0019] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that compositions of the present teachings also consist essentially of, or consist of, the recited components, and that the processes of the present teachings also consist essentially of, or consist of, the recited processing steps.
[0020] In the application, where an element or component is said to be included in and / or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components and can be selected from a group consisting of two or more of the recited elements or components.
[0021] The use of the singular herein includes the plural (and vice versa) unless specifically stated otherwise. In addition, where the use of the term "about" is before a quantitative value, the present teachings also include the specific quantitative value itself, unless specifically stated otherwise.
[0022] It should be understood that the order of steps or order for performing certain actions is immaterial so long as the present teachings remain operable. Moreover, two or more steps or actions can be conducted simultaneously.
[0023] As used herein, the term "halogen" shall mean chlorine, bromine, fluorine and iodine.
[0024] As used herein, unless otherwise noted, "alkyl" and / or "aliphatic" whether used alone or as part of a substituent group refers to straight and branched carbon chains having 1 to 20 carbon atoms or any number within this range, for example 1 to 6 carbon atoms or 1 to 4 carbon atoms. Designated numbers of carbon atoms (e.g. Ci-6) shall refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyl-containing substituent. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, zso-propyl, n-butyl, sec-butyl, / so-butyl, fert-butyl, and the like. Alkyl groups can be optionally substituted. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1- chloroethyl, 2-hydroxy ethyl, 1,2-difluoroethyl, 3-carboxypropyl, and the like. In substituent groups with multiple alkyl groups such as (Ci-6alkyl)2amino, the alkyl groups may be the same or different.
[0025] As used herein, the terms "alkenyl" and "alkynyl" groups, whether used alone or as part of a substituent group, refer to straight and branched carbon chains having 2 or more carbon atoms, preferably 2 to 20, wherein an alkenyl chain has at least one double bond in the chain and an alkynyl chain has at least one triple bond in the chain. Alkenyl and alkynyl groups can be optionally substituted. Nonlimiting examples of alkenyl groups include ethenyl, 3-propenyl, 1-propenyl (also 2- methylethenyl), isopropenyl (also 2-methylethen-2-yl), buten-4-yl, and the like. Nonlimiting examples of substituted alkenyl groups include 2-chloroethenyl (also 2-chlorovinyl), 4-hydroxybuten- 1-yl, 7-hydroxy-7-methyloct-4-en-2-yl, 7-hydroxy-7-methyloct-3,5-dien-2-yl, and the like. Nonlimiting examples of alkynyl groups include ethynyl, prop-2-ynyl (also propargyl), propyn-l-yl, and 2-methyl-hex-4-yn-l-yl. Nonlimiting examples of substituted alkynyl groups include, 5-hydroxy- 5-methylhex-3-ynyl, 6-hydroxy-6-methylhept-3-yn-2-yl, 5-hydroxy-5-ethylhept-3-ynyl, and the like.
[0026] As used herein, "cycloalkyl," whether used alone or as part of another group, refers to a non-aromatic carbon-containing ring including cyclized alkyl, alkenyl, and alkynyl groups, e.g., having from 3 to 14 ring carbon atoms, preferably from 3 to 7 or 3 to 6 ring carbon atoms, or even 3 to 4 ring carbon atoms, and optionally containing one or more (e.g., 1, 2, or 3) double or triple bond. Cycloalkyl groups can be monocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused, bridged, and / or spiro ring systems), wherein the carbon atoms are located inside or outside of the ring system. Any suitable ring position of the cycloalkyl group can be covalently linked to the defined chemical structure. Cycloalkyl rings can be optionally substituted. Nonlimiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-l-yl, octahydropentalenyl, octahydro-li / -indenyl, 3a,4,5,6,7,7a-hexahydro- 3i / -inden-4-yl, decahydroazulenyl; bicyclo[6.2.0]decanyl, decahydronaphthalenyl, and dodecahydro- li / -fluorenyl. The term "cycloalkyl" also includes carbocyclic rings which are bicyclic hydrocarbon rings, non-limiting examples of which include, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, l,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.
[0027] "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen. Haloalkyl groups include perhaloalkyl groups, wherein all hydrogens of an alkyl group have been replaced with halogens (e.g., -CF3, -CF2CF3). Haloalkyl groups can optionally be substituted with one or more substituents in addition to halogen. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl groups.
[0028] The term "alkoxy" refers to the group -O-alkyl, wherein the alkyl group is as defined above. Alkoxy groups optionally may be substituted. The term C3-C6 cyclic alkoxy refers to a ring containing 3 to 6 carbon atoms and at least one oxygen atom (e.g., tetrahydrofuran, tetrahydro-2H- pyran). C3-C6 cyclic alkoxy groups optionally may be substituted.
[0029] The term "haloalkoxy" refers to the group -O-haloalkyl, wherein the haloalkyl group is as defined above. Examples of haloalkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and pentafluoroethoxyl.
[0030] The term "aryl," wherein used alone or as part of another group, is defined herein as an unsaturated, aromatic monocyclic ring of 6 carbon members or to an unsaturated, aromatic poly cyclic ring of from 10 to 14 carbon members. Aryl rings can be, for example, phenyl or naphthyl ring each optionally substituted with one or more moieties capable of replacing one or more hydrogen atoms. Non-limiting examples of aryl groups include: phenyl, naphthylen-l-yl, naphthylen-2-yl, 4- fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl, 2-(N,N- diethylamino)phenyl, 2-cyanophenyl, 2,6-di- / er / -butylphenyl, 3-methoxyphenyl, 8- hydroxynaphthylen-2-yl 4,5-dimethoxynaphthylen-l-yl, and 6-cyano-naphthylen-l-yl. Aryl groups also include, for example, phenyl or naphthyl rings fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa-l,3,5-trienyl, indanyl), which can be substituted at one or more carbon atoms of the aromatic and / or saturated or partially saturated rings.
[0031] The term "arylalkyl" or "aralkyl" refers to the group -alkyl-aryl, where the alkyl and aryl groups are as defined herein. Aralkyl groups of the present invention are optionally substituted. Examples of arylalkyl groups include, for example, benzyl, 1-phenylethyl, 2-phenylethyl, 3- phenylpropyl, 2-phenylpropyl, fluorenylmethyl and the like.
[0032] The terms "heterocyclic" and / or "heterocycle" and / or "heterocylyl," whether used alone or as part of another group, are defined herein as one or more ring having from 3 to 20 atoms wherein at least one atom in at least one ring is a heteroatom selected from nitrogen (N), oxygen (O), or sulfur (S), and wherein further the ring that includes the heteroatom is non-aromatic. In heterocycle groups that include 2 or more fused rings, the non-heteroatom bearing ring may be aryl (e.g., indolinyl, tetrahydroquinolinyl, chromanyl). Exemplary heterocycle groups have from 3 to 14 ring atoms of which from 1 to 5 are heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heterocycle group can be oxidized. Heterocycle groups can be optionally substituted.
[0033] Non-limiting examples of heterocyclic units having a single ring include: diazirinyl, aziridinyl, urazolyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolidinyl, isothiazolyl, isothiazolinyl oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl,tetrahydropyranyl, piperidin-2-onyl (valerolactam), 2,3,4,5-tetrahydro-li / -azepinyl, 2,3-dihydro-li / - indole, and 1,2,3,4-tetrahydro-quinoline. Non-limiting examples of heterocyclic units having 2 or more rings include: hexahydro-li / -pyrrolizinyl, 3a,4,5,6,7,7a-hexahydro-li / -benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-li / -indolyl, 1,2,3,4-tetrahydroquinolinyl, chromanyl, isochromanyl, indolinyl, isoindolinyl, and decahydro-li / -cycloocta[b]pyrrolyl.
[0034] The term "heteroaryl," whether used alone or as part of another group, is defined herein as one or more rings having from 5 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), and wherein further at least one of the rings that includes a heteroatom is aromatic. In heteroaryl groups that include 2 or more fused rings, the non-heteroatom bearing ring may be a carbocycle (e.g., 6,7-Dihydro-5i / - cyclopentapyrimidine) or aryl (e.g., benzofuranyl, benzothiophenyl, indolyl). Exemplary heteroaryl groups have from 5 to 14 ring atoms and contain from 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heteroaryl group can be oxidized. Heteroaryl groups can be substituted. Non-limiting examples of heteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl, [l,2,3]triazolyl, [l,2,4]triazolyl, triazinyl, thiazolyl, \H- imidazolyl, oxazolyl, furanyl, thiopheneyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3- methylpyridinyl, and 4-dimethylaminopyridinyl. Non-limiting examples of heteroaryl rings containing 2 or more fused rings include: benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7i / -purinyl, 9i / -purinyl, 6- amino-9i / -purinyl, 5i / -pyrrolo[3,2-rf|pyrimidinyl, 7i / -pyrrolo[2,3-rf|pyrimidinyl, pyrido[2,3- rf]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, li / -indolyl, 4,5,6,7-tetrahydro-l-i / -indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, lH-benzo[d]imidazol-2(3H)- onyl, lH-benzo[d]imidazolyl, and isoquinolinyl.
[0035] One non-limiting example of a heteroaryl group as described above is C1-C5 heteroaryl, which has 1 to 5 carbon ring atoms and at least one additional ring atom that is a heteroatom (preferably 1 to 4 additional ring atoms that are heteroatoms) independently selected from nitrogen (N), oxygen (O), or sulfur (S). Examples of C1-C5 heteroaryl include, but are not limited to, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-l-yl, li / -imidazol-2-yl, li / -imidazol-4-yl, isoxazolin-5- yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5- yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.
[0036] Unless otherwise noted, when two substituents are taken together to form a ring having a specified number of ring atoms (e.g., R2and R3taken together with the nitrogen (N) to which they are attached to form a ring having from 3 to 7 ring members), the ring can have carbon atoms and optionally one or more (e.g., 1 to 3) additional heteroatoms independently selected from nitrogen (N),oxygen (O), or sulfur (S). The ring can be saturated or partially saturated and can be optionally substituted.
[0037] For the purposed of the present invention fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be considered to belong to the cyclic family corresponding to the heteroatom containing ring. For example, 1,2,3,4- tetrahydroquinoline having the formula:00is, for the purposes of the present invention, considered a heterocyclic unit. 6,7-Dihydro-5i / - cyclopentapyrimidine having the formula:is, for the purposes of the present invention, considered a heteroaryl unit. When a fused ring unit contains heteroatoms in both a saturated and an aryl ring, the aryl ring will predominate and determine the type of category to which the ring is assigned. For example, l,2,3,4-tetrahydro-[l,8]naphthyridine having the formula:is, for the purposes of the present invention, considered a heteroaryl unit.
[0038] Whenever a term or either of their prefix roots appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for "alkyl" and "aryl."
[0039] The term "substituted" is used throughout the specification. The term "substituted" is defined herein as a moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several (e.g., 1 to 10) substituents as defined herein below. The substituents are capable of replacing one or two hydrogen atoms of a single moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety or unit. For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. A two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like. The term "substituted" is used throughout the present specification to indicate that a moiety can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as "substituted" any number of the hydrogen atoms may be replaced. For example,difluoromethyl is a substituted Ci alkyl; trifluoromethyl is a substituted Ci alkyl; 4-hydroxyphenyl is a substituted aromatic ring; ( ,N-dimethyl-5-amino)octanyl is a substituted Cg alkyl; 3-guanidinopropyl is a substituted C3 alkyl; and 2-carboxypyridinyl is a substituted heteroaryl.
[0040] The variable groups defined herein, e.g., alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whether used alone or as part of another group, can be optionally substituted. Optionally substituted groups will be so indicated.
[0041] The following are non-limiting examples of substituents which can substitute for hydrogen atoms on a moiety: halogen (chlorine (CI), bromine (Br), fluorine (F) and iodine(I)), -CN, - N02, oxo (=0), -OR15, -SR15, -N(R15)2, -NR15C(0)R15, -S02R15, -SO2OR15, -S02N(R15)2, -C(0)R15, -C(0)OR15, -C(0)N(R15)2, Ci-6 alkyl, Ci-6haloalkyl, Ci-6alkoxy, C2-8alkenyl, C2-8alkynyl, C3-14 cycloalkyl, aryl, heterocycle, or heteroaryl, wherein each of the alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocycle, and heteroaryl groups is optionally substituted with 1-10 (e.g., 1-6 or 1-4) groups selected independently from halogen, -CN, -N02, oxo, and R15; wherein R15, at each occurrence, independently is hydrogen, -OR16, -SR16, -C(0)R16, -C(0)OR16, -C(0)N(R16)2, - S02R16, -S(0)2OR16, -N(R16)2, -NR16C(0)R16, Ci-6alkyl, Ci-6haloalkyl, C2-8alkenyl, C2-8alkynyl, cycloalkyl (e.g., C3-6 cycloalkyl), aryl, heterocycle, or heteroaryl, or two R15units taken together with the atom(s) to which they are bound form an optionally substituted carbocycle or heterocycle wherein said carbocycle or heterocycle has 3 to 7 ring atoms; wherein R16, at each occurrence, independently is hydrogen, Ci-6 alkyl, Ci-6 haloalkyl, C2-g alkenyl, C2-g alkynyl, cycloalkyl (e.g., C3-6 cycloalkyl), aryl, heterocycle, or heteroaryl, or two R16units taken together with the atom(s) to which they are bound form an optionally substituted carbocycle or heterocycle wherein said carbocycle or heterocycle preferably has 3 to 7 ring atoms.
[0042] In some embodiments, the substituents are selected fromi) -OR17; for example, -OH, -OCH3, -OCH2CH3, -OCH2CH2CH3;ii) -C(0)R17; for example, -COCH3, -COCH2CH3, -COCH2CH2CH3;iii) -C(0)OR17; for example, -C02CH3, -C02CH2CH3, -C02CH2CH2CH3;iv) -C(0)N(R17)2; for example, -CONH2, -CONHCH3, -CON(CH3)2;v) -N(R17)2; for example, -NH2, -NHCH3, -N(CH3)2, -NH(CH2CH3);vi) halogen: -F, -CI, -Br, and -I;vii) -CHeXg; wherein X is halogen, m is from 0 to 2, e+g =3; for example, -CH2F, - CHF2, -CF3, -CCI3, or -CBr3;viii) -S02R17; for example, -S02H; -S02CH3; -S02C6H5;ix) C1-C6 linear, branched, or cyclic alkyl;x) Cyanoxi) Nitro;xii) N(R17)C(0)R17;xiii) Oxo (=0);xiv) Heterocycle; andxv) Heteroaryl.wherein each R17is independently hydrogen, optionally substituted Ci-Ce linear or branched alkyl (e.g., optionally substituted C1-C4 linear or branched alkyl), or optionally substituted C3-C6 cycloalkyl (e.g optionally substituted C3-C4 cycloalkyl); or two R17units can be taken together to form a ring comprising 3-7 ring atoms. In certain aspects, each R17is independently hydrogen, Ci-Ce linear or branched alkyl optionally substituted with halogen or C3-C6 cycloalkyl or C3-C6 cycloalkyl.
[0043] At various places in the present specification, substituents of compounds are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges. For example, the term "C1-5 alkyl" is specifically intended to individually disclose Ci, C2, C3, C4, C5, Ce, Ci-Ce, C1-C5, C1-C4, Ci- C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6, alkyl.
[0044] For the purposes of the present invention the terms "compound," "analog," and "composition of matter" stand equally well for the 5-hydroxytryptamine receptor 7 activity modulators described herein, including all enantiomeric forms, diastereomeric forms, salts, and the like, and the terms "compound," "analog," and "composition of matter" are used interchangeably throughout the present specification.
[0045] Compounds described herein can contain an asymmetric atom (also referred as a chiral center), and some of the compounds can contain one or more asymmetric atoms or centers, which can thus give rise to optical isomers (enantiomers) and diastereomers. The present teachings and compounds disclosed herein include such enantiomers and diastereomers, as well as the racemic and resolved, enantiomerically pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Optical isomers can be obtained in pure form by standard procedures known to those skilled in the art, which include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. The present teachings also encompass cis and trans isomers of compounds containing alkenyl moieties (e.g., alkenes and imines). It is also understood that the present teachings encompass all possible regioisomers, and mixtures thereof, which can be obtained in pure form by standard separation procedures known to those skilled in the art, and include, but are not limited to, column chromatography, thin-layer chromatography, and high-performance liquid chromatography.
[0046] Pharmaceutically acceptable salts of compounds of the present teachings, which can have an acidic moiety, can be formed using organic and inorganic bases. Both mono and polyanionic salts are contemplated, depending on the number of acidic hydrogens available for deprotonation.Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts; ammonia salts and organic amine salts, such as those formed with morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine (e.g., ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine), or a mono-, di-, or trihydroxy lower alkylamine (e.g., mono-, di- or triethanolamine). Specific non- limiting examples of inorganic bases include NaHCC , Na2C03, KHCO3, K2CO3, CS2CO3, LiOH, NaOH, KOH, NaH2P04, Na2HP04, and NasPC . Internal salts also can be formed. Similarly, when a compound disclosed herein contains a basic moiety, salts can be formed using organic and inorganic acids. For example, salts can be formed from the following acids: acetic, propionic, lactic, benzenesulfonic, benzoic, camphorsulfonic, citric, tartaric, succinic, dichloroacetic, ethenesulfonic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, malonic, mandelic, methanesulfonic, mucic, napthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phosphoric, phthalic, propionic, succinic, sulfuric, tartaric, toluenesulfonic, and camphorsulfonic as well as other known pharmaceutically acceptable acids.
[0047] When any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence (e.g., in N(R9)2, each R9may be the same or different than the other). Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0048] The terms "treat" and "treating" and "treatment" as used herein, refer to partially or completely alleviating, inhibiting, ameliorating and / or relieving a condition from which a patient is suspected to suffer.
[0049] As used herein, "therapeutically effective" and "effective dose" refer to a substance or an amount that elicits a desirable biological activity or effect.
[0050] Except when noted, the terms "subject" or "patient" are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats, and mice, and other animals. Accordingly, the term "subject" or "patient" as used herein means any mammalian patient or subject to which the compounds of the invention can be administered. In an exemplary embodiment of the present invention, to identify subject patients for treatment according to the methods of the invention, accepted screening methods are employed to determine risk factors associated with a targeted or suspected disease or condition or to determine the status of an existing disease or condition in a subject. These screening methods include, for example, conventional work-ups to determine risk factors that may be associated with the targeted or suspected disease or condition. These and other routine methods allow the clinician to select patients in need of therapy using the methods and compounds of the present invention.The 5-Hydroxytryptamine Receptor 7 Activity Modulators
[0051] The 5-hydroxytryptamine receptor 7 activity modulators of the present invention include all enantiomeric and diastereomeric forms alts thereof having the formulaIncluding hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof,A is selected from a group consistingX is selected from the group consisting of O, S, SO, SO2, NR;n1is 0, 1, 2;n2is 0, 1, 2;R is selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,, COR2, C02R2a, CONR2bR2c, S02NR2bR2c, and S02R2d;Rla, Rlb, Rlc, Rld, and Rleare at each occurrence independently selected from the group consisting of H, OH, NO2, halogen, CN, Ci-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, Ci-6 linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, Ci-6 linear haloalkyl, C3-7 branched haloalkyl, Ci-6 linear haloalkoxy, -S(Ci-6linear alkyl), S(C3-7branched alkyl), -S(C3-7cycloalkyl), COR6, C02R7,CONR8aR8b, S02NR8aR8b, NR9aR9b, NR9aCOR10, NR9aS02Rn, and NR9aS02NR12aR12b;R2is selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R2ais selected from the group consisting of Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl; R2bis selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R2cis selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, Ci-eR3is selected from a group consisting of Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,o tionally substituted aryl,R4is an optionally substituted aryl;R5aand R5bare each independently optionally substituted aryl;R6is at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R7is at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R8ais at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R8bis at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;Rais at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R9bis at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R10is at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;Rnis at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R12ais at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R12bis at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R13is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R14is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl; n is 1, 2, or 3;m is 1 or 2;and q is 1, 2, or 3;
[0052] The embodiments of the present invention include compounds having formula (II):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0053] The embodiments of the present invention include compounds having formula (III):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0054] The embodiments of the present invention include compounds having formula (IV):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0055] The embodiments of the present invention include compounds having formula (V):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0056] The embodiments of the present invention include compounds having formula (VI):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0057] The embodiments of the present invention include compounds having formula (VII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0058] The embodiments of the present invention include compounds having formula (VIII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0059] The embodiments of the present invention include compounds having formula (IX):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0060] The embodiments of the present invention include compounds having formula (X):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0061] The embodiments of the present invention include compounds having formula (XI):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0062] The embodiments of the present invention include compounds having formula (XII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0063] The embodiments of the present invention include compounds having formula (XIII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0064] The embodiments of the present invention include compounds having formula (XIV):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0065] The embodiments of the present invention include compounds having formula (XV):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0066] The embodiments of the present invention include compounds having formula (XVI):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.
[0067] In some embodiments A is ¾ ^— '
[0068] In some embodiments A is- N N-R3
[0069] In some embodiments A is^- ^~ / In some embodiments[n some embodiments Ais[n some embodiments X is 0.[n some embodiments X is S.[n some embodiments X is SO.[n some embodiments X is S02[n some embodiments X is NR[n some embodiments n1is 0.[n some embodiments n1is 1.[n some embodiments n1is 2.[n some embodiments n2is 0.[n some embodiments n2is 1.[n some embodiments n2is 2.[n some embodiments R is H.[n some embodiments R is Ci-6 linear alkyl.[n some embodiments R is C3-7 branched alkyl.[n some embodiments R is C3-7 cycloalkyl.
[0087] In some embodiments R is,
[0088] In some embodiments R is COR2.
[0089] In some embodiments R is C02R2a.
[0090] In some embodiments R is CONR2bR2c.
[0091] In some embodiments R is S02NR2bR2c.
[0092] In some embodiments R is S02R2d.
[0093] In some embodiments Rlais H.
[0094] In some embodiments Rlais OH.
[0095] In some embodiments Rlais NO2.
[0096] In some embodiments Rlais halogen.
[0097] In some embodiments Rlais CN.
[0098] In some embodiments Rlais Ci-6 linear alkyl.
[0099] In some embodiments Rlais C3-7 branched alkyl.
[0100] In some embodiments Rlais C3-7 cycloalkyl.
[0101] In some embodiments Rlais C 1-6 linear alkoxy.
[0102] In some embodiments Rlais C3-7 branched alkoxy.
[0103] In some embodiments Rlais C3-7 cycloalkoxy.
[0104] In some embodiments Rlais Ci-6 linear haloalkyl.
[0105] In some embodiments Rlais C3-7 branched haloalkyl
[0106] In some embodiments Rlais C 1-6 linear haloalkoxy.
[0107] In some embodiments Rlais-S(Ci-6 linear alkyl).
[0108] In some embodiments Rlais S(C3-7 branched alkyl).
[0109] In some embodiments Rlais-S(C3-7 cycloalkyl).
[0110] In some embodiments Rlais COR6
[0111] In some embodiments Rlais C02R7.
[0112] In some embodiments Rlais CONR8aR8b.
[0113] In some embodiments Rlais S02NR8aR8b.
[0114] In some embodiments Rlais NR9aR9b.
[0115] In some embodiments Rlais NR9aCOR10.
[0116] In some embodiments Rlais NR9aS02Rn.
[0117] In some embodiments Rlais NR9aS02NR12aR12b.
[0118] In some embodiments Rlbis H.
[0119] In some embodiments Rlbis OH.
[0120] In some embodiments Rlbis N02.
[0121] In some embodiments Rlbis halogen.
[0122] In some embodiments Rlbis CN.
[0123] In some embodiments Rlbis Ci-6 linear alkyl.
[0124] In some embodiments Rlbis C3-7 branched alkyl.
[0125] In some embodiments Rlbis C3-7 cycloalkyl.
[0126] In some embodiments Rlbis Ci-6 linear alkoxy.
[0127] In some embodiments Rlbis C3-7 branched alkoxy.
[0128] In some embodiments Rlbis C3-7 cycloalkoxy.
[0129] In some embodiments Rlbis Ci-6 linear haloalkyl.
[0130] In some embodiments Rlbis C3-7 branched haloalkyl.
[0131] In some embodiments Rlbis Ci-6 linear haloalkoxy.
[0132] In some embodiments Rlbis-S(Ci-6 linear alkyl).
[0133] In some embodiments Rlbis S(C3-7 branched alkyl).
[0134] In some embodiments Rlbis-S(C3-7 cycloalkyl).
[0135] In some embodiments Rlbis COR6.
[0136] In some embodiments Rlbis C02R7.
[0137] In some embodiments Rlbis CONR8aR8b.
[0138] In some embodiments Rlbis S02NR8aR8b.
[0139] In some embodiments Rlbis NR9aR9b.
[0140] In some embodiments Rlbis NR9aCOR10.
[0141] In some embodiments Rlbis NR9aS02Rn.
[0142] In some embodiments Rlbis NR9aS02NR12aR12b.
[0143] In some embodiments Rlcis H.
[0144] In some embodiments Rlcis OH.
[0145] In some embodiments Rlcis N02.
[0146] In some embodiments Rlcis halogen.
[0147] In some embodiments Rlcis CN.
[0148] In some embodiments Rlcis Ci-6 linear alkyl.
[0149] In some embodiments Rlcis C3-7 branched alkyl.
[0150] In some embodiments Rlcis C3-7 cycloalkyl.
[0151] In some embodiments Rlcis C 1-6 linear alkoxy.
[0152] In some embodiments Rlcis C3-7 branched alkoxy.
[0153] In some embodiments Rlcis C3-7 cycloalkoxy.
[0154] In some embodiments Rlcis Ci-6 linear haloalkyl.
[0155] In some embodiments Rlcis C3-7 branched haloalkyl.
[0156] In some embodiments Rlcis C 1-6 linear haloalkoxy.
[0157] In some embodiments Rlcis-S(Ci-6 linear alkyl).
[0158] In some embodiments Rlcis S(C3-7 branched alkyl).
[0159] In some embodiments Rlcis-S(C3-7 cycloalkyl).
[0160] In some embodiments Rlcis COR6
[0161] In some embodiments Rlcis C02R7.
[0162] In some embodiments Rlcis CONR8aR8b.
[0163] In some embodiments Rlcis S02NR8aR8b.
[0164] In some embodimentsRlc is NR9aR9b.
[0165] In some embodimentsRlc is NR9aCOR10.
[0166] In some embodimentsRlc is NR9aS02Rn.
[0167] In some embodimentsRlc is NR9aS02NR12aR12b
[0168] In some embodimentsRld is H.
[0169] In some embodimentsRld is OH.
[0170] In some embodimentsRld is N02.
[0171] In some embodimentsRld is halogen.
[0172] In some embodimentsRld is CN.
[0173] In some embodimentsRld is Ci-6 linear alkyl.
[0174] In some embodimentsRld is C3-7 branched alkyl.
[0175] In some embodimentsRld is C3-7 cycloalkyl.
[0176] In some embodimentsRld is Ci-6 linear alkoxy.
[0177] In some embodimentsRld is C3-7 branched alkoxy.
[0178] In some embodimentsRld is C3-7 cycloalkoxy.
[0179] In some embodimentsRld is Ci-6 linear haloalkyl.
[0180] In some embodimentsRld is C3-7 branched haloalkyl.
[0181] In some embodimentsRld is Ci-6 linear haloalkoxy.
[0182] In some embodimentsRld is-S(Ci-6 linear alkyl).
[0183] In some embodimentsRld is S(C3-7 branched alkyl).
[0184] In some embodimentsRld is-S(C3-7 cycloalkyl).
[0185] In some embodimentsRld is COR6.
[0186] In some embodimentsRld is C02R7.
[0187] In some embodimentsRld is CONR8aR8b.
[0188] In some embodimentsRld is S02NR8aR8b.
[0189] In some embodiments Rld is NR9aR9b.
[0190] In some embodiments Rld is NR9aCOR10.
[0191] In some embodiments Rld is NR9aS02Rn.
[0192] In some embodiments Rld is NR9aS02NR12aR12b.
[0193] In some embodiments Rle is H.
[0194] In some embodiments Rle is OH.
[0195] In some embodiments Rle is N02.
[0196] In some embodiments Rle is halogen.
[0197] In some embodiments Rle is CN.
[0198] In some embodiments Rleis Ci-e linear alkyl.
[0199] In some embodiments Rleis C3-7 branched alkyl.
[0200] In some embodiments Rleis C3-7 cycloalkyl.
[0201] In some embodiments Rleis C 1-6 linear alkoxy.
[0202] In some embodiments Rleis C3-7 branched alkoxy.
[0203] In some embodiments Rleis C3-7 cycloalkoxy.
[0204] In some embodiments Rleis Ci-e linear haloalkyl.
[0205] In some embodiments Rleis C3-7 branched haloalkyl.
[0206] In some embodiments Rleis C 1-6 linear haloalkoxy.
[0207] In some embodiments Rleis-S(Ci-6 linear alkyl).
[0208] In some embodiments Rleis S(C3-7 branched alkyl).
[0209] In some embodiments Rleis-S(C3-7 cycloalkyl).
[0210] In some embodiments Rleis COR6
[0211] In some embodiments Rleis C02R7.
[0212] In some embodiments Rleis CONR8aR8b.
[0213] In some embodiments Rleis S02NR8aR8b.
[0214] In some embodiments Rleis NR9aR9b.
[0215] In some embodiments Rleis NR9aCOR10.
[0216] In some embodiments Rleis NR9aS02Rn.
[0217] In some embodiments Rleis NR9aS02NR12aR12b.
[0218] In some embodiments R2is H.
[0219] In some embodiments R2is Ci-e linear alkyl.
[0220] In some embodiments R2is, C3-7 branched alkyl.
[0221] In some embodiments R2is C3-7 cycloalkyl.
[0222] In some embodiments R2ais Ci-e linear alkyl.
[0223] In some embodiments R2ais C3-7 branched alkyl.
[0224] In some embodiments R2ais C3-7 cycloalkyl.
[0225] In some embodiments R2bis H.
[0226] In some embodiments R2bis Ci-e linear alkyl.
[0227] In some embodiments R2bis, C3-7 branched alkyl.
[0228] In some embodiments R2bis C3-7 cycloalkyl.
[0229] In some embodiments R2cis H.
[0230] In some embodiments R2cis Ci-e linear alkyl.
[0231] In some embodiments R2cis, C3-7 branched alkyl.In some embodiments R2cis C3-7 cycloalkyl.In some embodiments R2dis Ci-e linear alkyl.In some embodiments R2dis C3-7 branched alkyl.In some embodiments R2dis C3-7 cycloalkyl.In some embodiments R2dis Ci-e linear haloalkyl.In some embodiments R2dis C3-7 branched haloalkyl.In some embodiments R2dis -(CH2)qCN.In some embodiments R2dis -(CH2)qS02R13.In some embodiments R2dis -(CH2)qOR14.In some embodiments R is
[0242] In some embodiments R2dis
[0243] In some embodiments R2dis
[0244] In some embodiments R isIn some embodiments R is
[0247] In some embodiments R2dis
[0248] In some embodiments R 2d ii es
[0249] In some embodiments R2dis
[0250] In some embodiments R2dis
[0251] In some embodiments R2dis
[0252] In some embodiments R2dis
[0253] In some embodiments R3is Ci-e linear alkyl.
[0254] In some embodiments R3is C3-7 branched alkyl.
[0255] In some embodiments R3is C3-7 cycloalkyl.
[0256] In some embodiments R3is optionally substituted aryl.
[0257] In some embodiments R3is phenyl.
[0258] In some embodiments R3is an optionally aryl substituted with 1 to 4 units independently selected from the group consisting of OH, NO2. halogen, CN, Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl. Ci-e linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, Ci-e linear haloalkyl, C3-7 branched haloalkyl, Ci-e linear haloalkoxy, -S(Ci-e linear alkyl), S(C3-7, NR9aR9b, NR9aCOR10,
[0259] In some embodiments R3is R
[0260] In some embodiments R3
[0261] In some embodiments R3
[0262] In some embodiments R3
[0263] In some embodiments R3
[0264] In some embodiments R3
[0265] In some embodiments R3
[0266] In some embodiments R3
[0267] In some embodiments R
[0268] In some embodiments R3
[0269] In some embodiments R4is optionally substituted aryl.
[0270] In some embodiments R4is an optionally substituted aryl substituted with 1 to 4 vmits independently selected from the group consisting of OH, NO2, halogen. CN, Ci-e linear alkyl. C3-7branched alkyl, C3-7 cycloalkyl, Ci-e linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, Ci-e linear haloalkyl, C3-7 branched haloalkyl, Ci-e linear haloalkoxy, -S(Ci-e linear alkyl), S(C3-7 branched alkyl), -S(C3-7cycloalk6, C02R7, CONR8aR8b, S02NR8aR8b, NR9aR9b, NR9aCOR10,9aS02R" , NR9aS02NR12aR12b,
[0271] In some embodiments R5is optionally substituted
[0272] In some embodiments R5is optionally substituted
[0273] In some embodiments R6is H.
[0274] In some embodiments R6is Ci- s linear alkyl.
[0275] In some embodiments R6is C3- 7 branched alkyl.
[0276] In some embodiments R6is C3- 7 cycloalkyl.
[0277] In some embodiments R7is Ci- s linear alkyl.
[0278] In some embodiments R7is C3- 7 branched alkyl.
[0279] In some embodiments R7is C3- 7 cycloalkyl.
[0280] In some embodiments R8ais H.
[0281] In some embodiments R8ais Ci- 6 linear alkyl.
[0282] In some embodiments R8ais C3-7 branched alkyl.
[0283] In some embodiments R8ais C3-7 cycloalkyl.
[0284] In some embodiments R8bis H.
[0285] In some embodiments R8bis Ci- 6 linear alkyl.
[0286] In some embodiments R8bis C3-7 branched alkyl.
[0287] In some embodiments R8bis C3-7 cycloalkyl.
[0288] In some embodiments R9ais H.
[0289] In some embodiments R9ais Ci- 6 linear alkyl.
[0290] In some embodiments R9ais C3-7 branched alkyl.
[0291] In some embodiments R9ais C3-7 cycloalkyl.
[0292] In some embodiments R9bis H.
[0293] In some embodiments R9bis d- 6 linear alkyl.
[0294] In some embodiments R9bis C3-7 branched alkyl.
[0295] In some embodiments R9bis C3-7 cycloalkyl.
[0296] In some embodiments R10is H.
[0297] In some embodiments R10is Cr 6 linear alkyl.
[0298] In some embodiments R10is C3-7 branched alkyl.
[0299] In some embodiments R10is C3-7 cycloalkyl.
[0300] In some embodiments Rnis Ci- 6 linear alkyl.
[0301] In some embodiments Rnis C3- 7 branched alkyl.
[0302] In some embodiments Rnis C3- 7 cycloalkyl.
[0303] In some embodiments R10is Ci- 6 linear alkyl.
[0304] In some embodiments R10is C3- 7 branched alkyl.
[0305] In some embodiments R10is C3- 7 cycloalkyl.
[0306] In some embodiments R12ais Ci -6 linear alkyl.
[0307] In some embodiments R12ais C; -7 branched alkyl.
[0308] In some embodiments R12ais C; -7 cycloalkyl.
[0309] In some embodiments R12bis Ci -6 linear alkyl.
[0310] In some embodiments R12bis C; -7 branched alkyl.
[0311] In some embodiments R12bis C; -7 cycloalkyl.
[0312] In some embodiments R13is Ci- 6 linear alkyl.
[0313] In some embodiments R13is C3- 7 branched alkyl.
[0314] In some embodiments R13is C3- 7 cycloalkyl.
[0315] In some embodiments R14is Ci- 6 linear alkyl.
[0316] In some embodiments R14is C3- 7 branched alkyl.
[0317] In some embodiments R14is C3- 7 cycloalkyl.
[0318] In some embodiments n is 1.
[0319] In some embodiments n is 2.
[0320] In some embodiments n is 3.
[0321] In some embodiments m is 1.
[0322] In some embodiments m is 2.
[0323] In some embodiments q is 1.
[0324] In some embodiments q is 2.
[0325] In some embodiments q is 3.
[0326] Exemplary embodiments include compounds having the formula (XVII)itically acceptable salt form thereof defined herein below in Table 1.Table 1Entry n R R3Entry n R R31 1 H Phenyl 622 1 H 4-OH-Phenyl2 2 H Phenyl 623 2 H 4-OH-Phenyl3 3 H Phenyl 624 3 H 4-OH-Phenyl4 1 Me Phenyl 625 1 Me 4-OH-Phenyl5 2 Me Phenyl 626 2 Me 4-OH-Phenyl6 3 Me Phenyl 627 3 Me 4-OH-Phenyl7 1 CH2Ph Phenyl 628 1 CH2Ph 4-OH-Phenyl8 2 CH2Ph Phenyl 629 2 CH2Ph 4-OH-Phenyl9 3 CH2Ph Phenyl 630 3 CH2Ph 4-OH-Phenyl10 1 COMe Phenyl 631 1 COMe 4-OH-Phenyl11 2 COMe Phenyl 632 2 COMe 4-OH-Phenyl12 3 COMe Phenyl 633 3 COMe 4-OH-Phenyl13 1 C02Me Phenyl 634 1 C02Me 4-OH-Phenyl14 2 C02Me Phenyl 635 2 C02Me 4-OH-Phenyl15 3 C02Me Phenyl 636 3 C02Me 4-OH-Phenyl16 1 C02tBu Phenyl 637 1 C02tBu 4-OH-Phenyl17 2 C02tBu Phenyl 638 2 C02tBu 4-OH-Phenyl18 3 C02tBu Phenyl 639 3 C02tBu 4-OH-Phenyl19 1 CONHMe Phenyl 640 1 CONHMe 4-OH-Phenyl20 2 CONHMe Phenyl 641 2 CONHMe 4-OH-Phenyl21 3 CONHMe Phenyl 642 3 CONHMe 4-OH-Phenyl22 1 S02Me Phenyl 643 1 S02Me 4-OH-Phenyl23 2 S02Me Phenyl 644 2 S02Me 4-OH-Phenyl24 3 S02Me Phenyl 645 3 S02Me 4-OH-Phenyl25 1 S02NH2Phenyl 646 1 S02NH24-OH-Phenyl26 2 S02NH2Phenyl 647 2 S02NH24-OH-Phenyl3 SO2NH2 Phenyl 648 3 S02NH24-OH-Phenyl1 H 3-OH-Phenyl 649 1 H 2-OH-Phenyl2 H 3-OH-Phenyl 650 2 H 2-OH-Phenyl3 H 3-OH-Phenyl 651 3 H 2-OH-Phenyl1 Me 3-OH-Phenyl 652 1 Me 2-OH-Phenyl2 Me 3-OH-Phenyl 653 2 Me 2-OH-Phenyl3 Me 3-OH-Phenyl 654 3 Me 2-OH-Phenyl1 CH2Ph 3-OH-Phenyl 655 1 CH2Ph 2-OH-Phenyl2 CH2Ph 3-OH-Phenyl 656 2 CH2Ph 2-OH-Phenyl3 CH2Ph 3-OH-Phenyl 657 3 CH2Ph 2-OH-Phenyl1 COMe 3-OH-Phenyl 658 1 COMe 2-OH-Phenyl2 COMe 3-OH-Phenyl 659 2 COMe 2-OH-Phenyl3 COMe 3-OH-Phenyl 660 3 COMe 2-OH-Phenyl1 C02Me 3-OH-Phenyl 661 1 C02Me 2-OH-Phenyl2 C02Me 3-OH-Phenyl 662 2 C02Me 2-OH-Phenyl3 C02Me 3-OH-Phenyl 663 3 C02Me 2-OH-Phenyl1 C02tBu 3-OH-Phenyl 664 1 C02tBu 2-OH-Phenyl2 C02tBu 3-OH-Phenyl 665 2 C02tBu 2-OH-Phenyl3 C02tBu 3-OH-Phenyl 666 3 C02tBu 2-OH-Phenyl1 CONHMe 3-OH-Phenyl 667 1 CONHMe 2-OH-Phenyl2 CONHMe 3-OH-Phenyl 668 2 CONHMe 2-OH-Phenyl3 CONHMe 3-OH-Phenyl 669 3 CONHMe 2-OH-Phenyl1 S02Me 3-OH-Phenyl 670 1 S02Me 2-OH-Phenyl2 S02Me 3-OH-Phenyl 671 2 S02Me 2-OH-Phenyl3 S02Me 3-OH-Phenyl 672 3 S02Me 2-OH-Phenyl1 S02NH23-OH-Phenyl 673 1 S02NH22-OH-Phenyl2 SO2NH2 3-OH-Phenyl 674 2 S02NH22-OH-Phenyl3 SO2NH2 3-OH-Phenyl 675 3 S02NH22-OH-Phenyl1 H 4-N02-Phenyl 676 1 H 4-OMe-Phenyl2 H 4-N02-Phenyl 677 2 H 4-OMe-Phenyl3 H 4-N02-Phenyl 678 3 H 4-OMe-Phenyl1 Me 4-N02-Phenyl 679 1 Me 4-OMe-Phenyl2 Me 4-N02-Phenyl 680 2 Me 4-OMe-Phenyl3 Me 4-N02-Phenyl 681 3 Me 4-OMe-Phenyl1 CH2Ph 4-N02-Phenyl 682 1 CH2Ph 4-OMe-Phenyl2 CH2Ph 4-N02-Phenyl 683 2 CH2Ph 4-OMe-Phenyl3 CH2Ph 4-N02-Phenyl 684 3 CH2Ph 4-OMe-Phenyl1 COMe 4-N02-Phenyl 685 1 COMe 4-OMe-Phenyl2 COMe 4-N02-Phenyl 686 2 COMe 4-OMe-Phenyl3 COMe 4-N02-Phenyl 687 3 COMe 4-OMe-Phenyl1 C02Me 4-N02-Phenyl 688 1 C02Me 4-OMe-Phenyl2 C02Me 4-N02-Phenyl 689 2 C02Me 4-OMe-Phenyl3 C02Me 4-N02-Phenyl 690 3 C02Me 4-OMe-Phenyl1 C02tBu 4-N02-Phenyl 691 1 C02tBu 4-OMe-Phenyl2 C02tBu 4-N02-Phenyl 692 2 C02tBu 4-OMe-Phenyl3 C02tBu 4-N02-Phenyl 693 3 C02tBu 4-OMe-Phenyl1 CONHMe 4-N02-Phenyl 694 1 CONHMe 4-OMe-Phenyl2 CONHMe 4-N02-Phenyl 695 2 CONHMe 4-OMe-Phenyl3 CONHMe 4-N02-Phenyl 696 3 CONHMe 4-OMe-Phenyl1 S02Me 4-N02-Phenyl 697 1 S02Me 4-OMe-Phenyl2 S02Me 4-N02-Phenyl 698 2 S02Me 4-OMe-Phenyl3 S02Me 4-N02-Phenyl 699 3 S02Me 4-OMe-Phenyl79 1 SO2NH2 4-N02-Phenyl 700 1 S02NH24-OMe-Phenyl80 2 SO2NH2 4-N02-Phenyl 701 2 S02NH24-OMe-Phenyl81 3 SO2NH2 4-N02-Phenyl 702 3 S02NH24-OMe-Phenyl82 1 H 3-OMe-Phenyl 703 1 H 2-OMe-Phenyl83 2 H 3-OMe-Phenyl 704 2 H 2-OMe-Phenyl84 3 H 3-OMe-Phenyl 705 3 H 2-OMe-Phenyl85 1 Me 3-OMe-Phenyl 706 1 Me 2-OMe-Phenyl86 2 Me 3-OMe-Phenyl 707 2 Me 2-OMe-Phenyl87 3 Me 3-OMe-Phenyl 708 3 Me 2-OMe-Phenyl88 1 CH2Ph 3-OMe-Phenyl 709 1 CH2Ph 2-OMe-Phenyl89 2 CH2Ph 3-OMe-Phenyl 710 2 CH2Ph 2-OMe-Phenyl90 3 CH2Ph 3-OMe-Phenyl 711 3 CH2Ph 2-OMe-Phenyl91 1 COMe 3-OMe-Phenyl 712 1 COMe 2-OMe-Phenyl92 2 COMe 3-OMe-Phenyl 713 2 COMe 2-OMe-Phenyl93 3 COMe 3-OMe-Phenyl 714 3 COMe 2-OMe-Phenyl94 1 C02Me 3-OMe-Phenyl 715 1 C02Me 2-OMe-Phenyl95 2 C02Me 3-OMe-Phenyl 716 2 C02Me 2-OMe-Phenyl96 3 C02Me 3-OMe-Phenyl 717 3 C02Me 2-OMe-Phenyl97 1 C02tBu 3-OMe-Phenyl 718 1 C02tBu 2-OMe-Phenyl98 2 C02tBu 3-OMe-Phenyl 719 2 C02tBu 2-OMe-Phenyl99 3 C02tBu 3-OMe-Phenyl 720 3 C02tBu 2-OMe-Phenyl100 1 CONHMe 3-OMe-Phenyl 721 1 CONHMe 2-OMe-Phenyl101 2 CONHMe 3-OMe-Phenyl 722 2 CONHMe 2-OMe-Phenyl102 3 CONHMe 3-OMe-Phenyl 723 3 CONHMe 2-OMe-Phenyl103 1 S02Me 3-OMe-Phenyl 724 1 S02Me 2-OMe-Phenyl104 2 S02Me 3-OMe-Phenyl 725 2 S02Me 2-OMe-Phenyl105 3 S02Me 3-OMe-Phenyl 726 3 S02Me 2-OMe-Phenyl106 1 SO2NH2 3-OMe-Phenyl 727 1 S02NH22-OMe-Phenyl107 2 SO2NH2 3-OMe-Phenyl 728 2 S02NH22-OMe-Phenyl108 3 SO2NH2 3-OMe-Phenyl 729 3 S02NH22-OMe-Phenyl109 1 H 4-CN-Phenyl 730 1 H 3-CN-Phenyl110 2 H 4-CN-Phenyl 731 2 H 3-CN-Phenyl111 3 H 4-CN-Phenyl 732 3 H 3-CN-Phenyl112 1 Me 4-CN-Phenyl 733 1 Me 3-CN-Phenyl113 2 Me 4-CN-Phenyl 734 2 Me 3-CN-Phenyl114 3 Me 4-CN-Phenyl 735 3 Me 3-CN-Phenyl115 1 CH2Ph 4-CN-Phenyl 736 1 CH2Ph 3-CN-Phenyl116 2 CH2Ph 4-CN-Phenyl 737 2 CH2Ph 3-CN-Phenyl117 3 CH2Ph 4-CN-Phenyl 738 3 CH2Ph 3-CN-Phenyl118 1 COMe 4-CN-Phenyl 739 1 COMe 3-CN-Phenyl119 2 COMe 4-CN-Phenyl 740 2 COMe 3-CN-Phenyl120 3 COMe 4-CN-Phenyl 741 3 COMe 3-CN-Phenyl121 1 C02Me 4-CN-Phenyl 742 1 C02Me 3-CN-Phenyl122 2 C02Me 4-CN-Phenyl 743 2 C02Me 3-CN-Phenyl123 3 C02Me 4-CN-Phenyl 744 3 C02Me 3-CN-Phenyl124 1 C02tBu 4-CN-Phenyl 745 1 C02tBu 3-CN-Phenyl125 2 C02tBu 4-CN-Phenyl 746 2 C02tBu 3-CN-Phenyl126 3 C02tBu 4-CN-Phenyl 747 3 C02tBu 3-CN-Phenyl127 1 CONHMe 4-CN-Phenyl 748 1 CONHMe 3-CN-Phenyl128 2 CONHMe 4-CN-Phenyl 749 2 CONHMe 3-CN-Phenyl129 3 CONHMe 4-CN-Phenyl 750 3 CONHMe 3-CN-Phenyl130 1 S02Me 4-CN-Phenyl 751 1 S02Me 3-CN-Phenyl131 2 S02Me 4-CN-Phenyl 752 2 S02Me 3-CN-Phenyl132 3 S02Me 4-CN-Phenyl 753 3 S02Me 3-CN-Phenyl133 1 SO2NH2 4-CN-Phenyl 754 1 S02NH23-CN-Phenyl134 2 SO2NH2 4-CN-Phenyl 755 2 S02NH23-CN-Phenyl135 3 SO2NH2 4-CN-Phenyl 756 3 S02NH23-CN-Phenyl136 1 H 2-CN-Phenyl 757 1 H 2-Me-Phenyl137 2 H 2-CN-Phenyl 758 2 H 2-Me-Phenyl138 3 H 2-CN-Phenyl 759 3 H 2-Me-Phenyl139 1 Me 2-CN-Phenyl 760 1 Me 2-Me-Phenyl140 2 Me 2-CN-Phenyl 761 2 Me 2-Me-Phenyl141 3 Me 2-CN-Phenyl 762 3 Me 2-Me-Phenyl142 1 CH2Ph 2-CN-Phenyl 763 1 CH2Ph 2-Me-Phenyl143 2 CH2Ph 2-CN-Phenyl 764 2 CH2Ph 2-Me-Phenyl144 3 CH2Ph 2-CN-Phenyl 765 3 CH2Ph 2-Me-Phenyl145 1 COMe 2-CN-Phenyl 766 1 COMe 2-Me-Phenyl146 2 COMe 2-CN-Phenyl 767 2 COMe 2-Me-Phenyl147 3 COMe 2-CN-Phenyl 768 3 COMe 2-Me-Phenyl148 1 C02Me 2-CN-Phenyl 769 1 C02Me 2-Me-Phenyl149 2 C02Me 2-CN-Phenyl 770 2 C02Me 2-Me-Phenyl150 3 C02Me 2-CN-Phenyl 771 3 C02Me 2-Me-Phenyl151 1 C02tBu 2-CN-Phenyl 772 1 C02tBu 2-Me-Phenyl152 2 C02tBu 2-CN-Phenyl 773 2 C02tBu 2-Me-Phenyl153 3 C02tBu 2-CN-Phenyl 774 3 C02tBu 2-Me-Phenyl154 1 CONHMe 2-CN-Phenyl 775 1 CONHMe 2-Me-Phenyl155 2 CONHMe 2-CN-Phenyl 776 2 CONHMe 2-Me-Phenyl156 3 CONHMe 2-CN-Phenyl 777 3 CONHMe 2-Me-Phenyl157 1 S02Me 2-CN-Phenyl 778 1 S02Me 2-Me-Phenyl158 2 S02Me 2-CN-Phenyl 779 2 S02Me 2-Me-Phenyl159 3 S02Me 2-CN-Phenyl 780 3 S02Me 2-Me-Phenyl160 1 SO2NH2 2-CN-Phenyl 781 1 S02NH22-Me-Phenyl161 2 SO2NH2 2-CN-Phenyl 782 2 S02NH22-Me-Phenyl162 3 SO2NH2 2-CN-Phenyl 783 3 S02NH22-Me-Phenyl163 1 H 3-Me-Phenyl 784 1 H 4-Me-Phenyl164 2 H 3-Me-Phenyl 785 2 H 4-Me-Phenyl165 3 H 3-Me-Phenyl 786 3 H 4-Me-Phenyl166 1 Me 3-Me-Phenyl 787 1 Me 4-Me-Phenyl167 2 Me 3-Me-Phenyl 788 2 Me 4-Me-Phenyl168 3 Me 3-Me-Phenyl 789 3 Me 4-Me-Phenyl169 1 CH2Ph 3-Me-Phenyl 790 1 CH2Ph 4-Me-Phenyl170 2 CH2Ph 3-Me-Phenyl 791 2 CH2Ph 4-Me-Phenyl171 3 CH2Ph 3-Me-Phenyl 792 3 CH2Ph 4-Me-Phenyl172 1 COMe 3-Me-Phenyl 793 1 COMe 4-Me-Phenyl173 2 COMe 3-Me-Phenyl 794 2 COMe 4-Me-Phenyl174 3 COMe 3-Me-Phenyl 795 3 COMe 4-Me-Phenyl175 1 C02Me 3-Me-Phenyl 796 1 C02Me 4-Me-Phenyl176 2 C02Me 3-Me-Phenyl 797 2 C02Me 4-Me-Phenyl177 3 C02Me 3-Me-Phenyl 798 3 C02Me 4-Me-Phenyl178 1 C02tBu 3-Me-Phenyl 799 1 C02tBu 4-Me-Phenyl179 2 C02tBu 3-Me-Phenyl 800 2 C02tBu 4-Me-Phenyl180 3 C02tBu 3-Me-Phenyl 801 3 C02tBu 4-Me-Phenyl181 1 CONHMe 3-Me-Phenyl 802 1 CONHMe 4-Me-Phenyl182 2 CONHMe 3-Me-Phenyl 803 2 CONHMe 4-Me-Phenyl183 3 CONHMe 3-Me-Phenyl 804 3 CONHMe 4-Me-Phenyl184 1 S02Me 3-Me-Phenyl 805 1 S02Me 4-Me-Phenyl185 2 S02Me 3-Me-Phenyl 806 2 S02Me 4-Me-Phenyl186 3 S02Me 3-Me-Phenyl 807 3 S02Me 4-Me-Phenyl187 1 SO2NH2 3-Me-Phenyl 808 1 S02NH24-Me-Phenyl188 2 SO2NH2 3-Me-Phenyl 809 2 S02NH24-Me-Phenyl189 3 SO2NH2 3-Me-Phenyl 810 3 S02NH24-Me-Phenyl190 1 H 2-F-Phenyl 811 1 H 3-F-Phenyl191 2 H 2-F-Phenyl 812 2 H 3-F-Phenyl192 3 H 2-F-Phenyl 813 3 H 3-F-Phenyl193 1 Me 2-F-Phenyl 814 1 Me 3-F-Phenyl194 2 Me 2-F-Phenyl 815 2 Me 3-F-Phenyl195 3 Me 2-F-Phenyl 816 3 Me 3-F-Phenyl196 1 CH2Ph 2-F-Phenyl 817 1 CH2Ph 3-F-Phenyl197 2 CH2Ph 2-F-Phenyl 818 2 CH2Ph 3-F-Phenyl198 3 CH2Ph 2-F-Phenyl 819 3 CH2Ph 3-F-Phenyl199 1 COMe 2-F-Phenyl 820 1 COMe 3-F-Phenyl200 2 COMe 2-F-Phenyl 821 2 COMe 3-F-Phenyl201 3 COMe 2-F-Phenyl 822 3 COMe 3-F-Phenyl202 1 C02Me 2-F-Phenyl 823 1 C02Me 3-F-Phenyl203 2 C02Me 2-F-Phenyl 824 2 C02Me 3-F-Phenyl204 3 C02Me 2-F-Phenyl 825 3 C02Me 3-F-Phenyl205 1 C02tBu 2-F-Phenyl 826 1 C02tBu 3-F-Phenyl206 2 C02tBu 2-F-Phenyl 827 2 C02tBu 3-F-Phenyl207 3 C02tBu 2-F-Phenyl 828 3 C02tBu 3-F-Phenyl208 1 CONHMe 2-F-Phenyl 829 1 CONHMe 3-F-Phenyl209 2 CONHMe 2-F-Phenyl 830 2 CONHMe 3-F-Phenyl210 3 CONHMe 2-F-Phenyl 831 3 CONHMe 3-F-Phenyl211 1 S02Me 2-F-Phenyl 832 1 S02Me 3-F-Phenyl212 2 S02Me 2-F-Phenyl 833 2 S02Me 3-F-Phenyl213 3 S02Me 2-F-Phenyl 834 3 S02Me 3-F-Phenyl214 1 SO2NH2 2-F-Phenyl 835 1 S02NH23-F-Phenyl215 2 SO2NH2 2-F-Phenyl 836 2 S02NH23-F-Phenyl216 3 SO2NH2 2-F-Phenyl 837 3 S02NH23-F-Phenyl217 1 H 4-F-Phenyl 838 1 H 2-Cl-Phenyl218 2 H 4-F-Phenyl 839 2 H 2-Cl-Phenyl219 3 H 4-F-Phenyl 840 3 H 2-Cl-Phenyl220 1 Me 4-F-Phenyl 841 1 Me 2-Cl-Phenyl221 2 Me 4-F-Phenyl 842 2 Me 2-Cl-Phenyl222 3 Me 4-F-Phenyl 843 3 Me 2-Cl-Phenyl223 1 CH2Ph 4-F-Phenyl 844 1 CH2Ph 2-Cl-Phenyl224 2 CH2Ph 4-F-Phenyl 845 2 CH2Ph 2-Cl-Phenyl225 3 CH2Ph 4-F-Phenyl 846 3 CH2Ph 2-Cl-Phenyl226 1 COMe 4-F-Phenyl 847 1 COMe 2-Cl-Phenyl227 2 COMe 4-F-Phenyl 848 2 COMe 2-Cl-Phenyl228 3 COMe 4-F-Phenyl 849 3 COMe 2-Cl-Phenyl229 1 C02Me 4-F-Phenyl 850 1 C02Me 2-Cl-Phenyl230 2 C02Me 4-F-Phenyl 851 2 C02Me 2-Cl-Phenyl231 3 C02Me 4-F-Phenyl 852 3 C02Me 2-Cl-Phenyl232 1 C02tBu 4-F-Phenyl 853 1 C02tBu 2-Cl-Phenyl233 2 C02tBu 4-F-Phenyl 854 2 C02tBu 2-Cl-Phenyl234 3 C02tBu 4-F-Phenyl 855 3 C02tBu 2-Cl-Phenyl235 1 CONHMe 4-F-Phenyl 856 1 CONHMe 2-Cl-Phenyl236 2 CONHMe 4-F-Phenyl 857 2 CONHMe 2-Cl-Phenyl237 3 CONHMe 4-F-Phenyl 858 3 CONHMe 2-Cl-Phenyl238 1 S02Me 4-F-Phenyl 859 1 S02Me 2-Cl-Phenyl239 2 S02Me 4-F-Phenyl 860 2 S02Me 2-Cl-Phenyl240 3 S02Me 4-F-Phenyl 861 3 S02Me 2-Cl-Phenyl241 1 SO2NH2 4-F-Phenyl 862 1 S02NH22-Cl-Phenyl242 2 SO2NH2 4-F-Phenyl 863 2 S02NH22-Cl-Phenyl243 3 SO2NH2 4-F-Phenyl 864 3 S02NH22-Cl-Phenyl244 1 H 3-Cl-Phenyl 865 1 H 4-Cl-Phenyl245 2 H 3-Cl-Phenyl 866 2 H 4-Cl-Phenyl246 3 H 3-Cl-Phenyl 867 3 H 4-Cl-Phenyl247 1 Me 3-Cl-Phenyl 868 1 Me 4-Cl-Phenyl248 2 Me 3-Cl-Phenyl 869 2 Me 4-Cl-Phenyl249 3 Me 3-Cl-Phenyl 870 3 Me 4-Cl-Phenyl250 1 CH2Ph 3-Cl-Phenyl 871 1 CH2Ph 4-Cl-Phenyl251 2 CH2Ph 3-Cl-Phenyl 872 2 CH2Ph 4-Cl-Phenyl252 3 CH2Ph 3-Cl-Phenyl 873 3 CH2Ph 4-Cl-Phenyl253 1 COMe 3-Cl-Phenyl 874 1 COMe 4-Cl-Phenyl254 2 COMe 3-Cl-Phenyl 875 2 COMe 4-Cl-Phenyl255 3 COMe 3-Cl-Phenyl 876 3 COMe 4-Cl-Phenyl256 1 C02Me 3-Cl-Phenyl 877 1 C02Me 4-Cl-Phenyl257 2 C02Me 3-Cl-Phenyl 878 2 C02Me 4-Cl-Phenyl258 3 C02Me 3-Cl-Phenyl 879 3 C02Me 4-Cl-Phenyl259 1 C02tBu 3-Cl-Phenyl 880 1 C02tBu 4-Cl-Phenyl260 2 C02tBu 3-Cl-Phenyl 881 2 C02tBu 4-Cl-Phenyl261 3 C02tBu 3-Cl-Phenyl 882 3 C02tBu 4-Cl-Phenyl262 1 CONHMe 3-Cl-Phenyl 883 1 CONHMe 4-Cl-Phenyl263 2 CONHMe 3-Cl-Phenyl 884 2 CONHMe 4-Cl-Phenyl264 3 CONHMe 3-Cl-Phenyl 885 3 CONHMe 4-Cl-Phenyl265 1 S02Me 3-Cl-Phenyl 886 1 S02Me 4-Cl-Phenyl266 2 S02Me 3-Cl-Phenyl 887 2 S02Me 4-Cl-Phenyl267 3 S02Me 3-Cl-Phenyl 888 3 S02Me 4-Cl-Phenyl268 1 S02NH23-Cl-Phenyl 889 1 S02NH24-Cl-Phenyl269 2 S02NH23-Cl-Phenyl 890 2 S02NH24-Cl-Phenyl270 3 S02NH23-Cl-Phenyl 891 3 S02NH24-Cl-Phenyl271 1 H 2-Br-Phenyl 892 1 H 3-Br-Phenyl272 2 H 2-Br-Phenyl 893 2 H 3-Br-Phenyl273 3 H 2-Br-Phenyl 894 3 H 3-Br-Phenyl274 1 Me 2-Br-Phenyl 895 1 Me 3-Br-Phenyl275 2 Me 2-Br-Phenyl 896 2 Me 3-Br-Phenyl276 3 Me 2-Br-Phenyl 897 3 Me 3-Br-Phenyl277 1 CH2Ph 2-Br-Phenyl 898 1 CH2Ph 3-Br-Phenyl278 2 CH2Ph 2-Br-Phenyl 899 2 CH2Ph 3-Br-Phenyl279 3 CH2Ph 2-Br-Phenyl 900 3 CH2Ph 3-Br-Phenyl280 1 COMe 2-Br-Phenyl 901 1 COMe 3-Br-Phenyl281 2 COMe 2-Br-Phenyl 902 2 COMe 3-Br-Phenyl282 3 COMe 2-Br-Phenyl 903 3 COMe 3-Br-Phenyl283 1 C02Me 2-Br-Phenyl 904 1 C02Me 3-Br-Phenyl284 2 C02Me 2-Br-Phenyl 905 2 C02Me 3-Br-Phenyl285 3 C02Me 2-Br-Phenyl 906 3 C02Me 3-Br-Phenyl286 1 C02tBu 2-Br-Phenyl 907 1 C02tBu 3-Br-Phenyl287 2 C02tBu 2-Br-Phenyl 908 2 C02tBu 3-Br-Phenyl288 3 C02tBu 2-Br-Phenyl 909 3 C02tBu 3-Br-Phenyl289 1 CONHMe 2-Br-Phenyl 910 1 CONHMe 3-Br-Phenyl290 2 CONHMe 2-Br-Phenyl 911 2 CONHMe 3-Br-Phenyl291 3 CONHMe 2-Br-Phenyl 912 3 CONHMe 3-Br-Phenyl292 1 S02Me 2-Br-Phenyl 913 1 S02Me 3-Br-Phenyl293 2 S02Me 2-Br-Phenyl 914 2 S02Me 3-Br-Phenyl294 3 S02Me 2-Br-Phenyl 915 3 S02Me 3-Br-Phenyl295 1 S02NH22-Br-Phenyl 916 1 S02NH23-Br-Phenyl296 2 S02NH22-Br-Phenyl 917 2 S02NH23-Br-Phenyl297 3 S02NH22-Br-Phenyl 918 3 S02NH23-Br-Phenyl298 1 H 4-Br-Phenyl 919 1 H 2-CF3-Phenyl299 2 H 4-Br-Phenyl 920 2 H 2-CF3-Phenyl300 3 H 4-Br-Phenyl 921 3 H 2-CF3-Phenyl301 1 Me 4-Br-Phenyl 922 1 Me 2-CF3-Phenyl302 2 Me 4-Br-Phenyl 923 2 Me 2-CF3-Phenyl303 3 Me 4-Br-Phenyl 924 3 Me 2-CF3-Phenyl304 1 CH2Ph 4-Br-Phenyl 925 1 CH2Ph 2-CF3-Phenyl305 2 CH2Ph 4-Br-Phenyl 926 2 CH2Ph 2-CF3-Phenyl306 3 CH2Ph 4-Br-Phenyl 927 3 CH2Ph 2-CF3-Phenyl307 1 COMe 4-Br-Phenyl 928 1 COMe 2-CF3-Phenyl308 2 COMe 4-Br-Phenyl 929 2 COMe 2-CF3-Phenyl309 3 COMe 4-Br-Phenyl 930 3 COMe 2-CF3-Phenyl310 1 C02Me 4-Br-Phenyl 931 1 C02Me 2-CF3-Phenyl311 2 C02Me 4-Br-Phenyl 932 2 C02Me 2-CF3-Phenyl312 3 C02Me 4-Br-Phenyl 933 3 C02Me 2-CF3-Phenyl313 1 C02tBu 4-Br-Phenyl 934 1 C02tBu 2-CF3-Phenyl314 2 C02tBu 4-Br-Phenyl 935 2 C02tBu 2-CF3-Phenyl315 3 C02tBu 4-Br-Phenyl 936 3 C02tBu 2-CF3-Phenyl316 1 CONHMe 4-Br-Phenyl 937 1 CONHMe 2-CF3-Phenyl317 2 CONHMe 4-Br-Phenyl 938 2 CONHMe 2-CF3-Phenyl318 3 CONHMe 4-Br-Phenyl 939 3 CONHMe 2-CF3-Phenyl319 1 S02Me 4-Br-Phenyl 940 1 S02Me 2-CF3-Phenyl320 2 S02Me 4-Br-Phenyl 941 2 S02Me 2-CF3-Phenyl321 3 S02Me 4-Br-Phenyl 942 3 S02Me 2-CF3-Phenyl322 1 S02NH24-Br-Phenyl 943 1 S02NH22-CF3-Phenyl323 2 S02NH24-Br-Phenyl 944 2 S02NH22-CF3-Phenyl324 3 S02NH24-Br-Phenyl 945 3 S02NH22-CF3-Phenyl325 1 H 3-CF3-Phenyl 946 1 H 4-CF3-Phenyl326 2 H 3-CF3-Phenyl 947 2 H 4-CF3-Phenyl327 3 H 3-CF3-Phenyl 948 3 H 4-CF3-Phenyl328 1 Me 3-CF3-Phenyl 949 1 Me 4-CF3-Phenyl329 2 Me 3-CF3-Phenyl 950 2 Me 4-CF3-Phenyl330 3 Me 3-CF3-Phenyl 951 3 Me 4-CF3-Phenyl331 1 CH2Ph 3-CF3-Phenyl 952 1 CH2Ph 4-CF3-Phenyl332 2 CH2Ph 3-CF3-Phenyl 953 2 CH2Ph 4-CF3-Phenyl333 3 CH2Ph 3-CF3-Phenyl 954 3 CH2Ph 4-CF3-Phenyl334 1 COMe 3-CF3-Phenyl 955 1 COMe 4-CF3-Phenyl335 2 COMe 3-CF3-Phenyl 956 2 COMe 4-CF3-Phenyl336 3 COMe 3-CF3-Phenyl 957 3 COMe 4-CF3-Phenyl337 1 C02Me 3-CF3-Phenyl 958 1 C02Me 4-CF3-Phenyl338 2 C02Me 3-CF3-Phenyl 959 2 C02Me 4-CF3-Phenyl339 3 C02Me 3-CF3-Phenyl 960 3 C02Me 4-CF3-Phenyl340 1 C02tBu 3-CF3-Phenyl 961 1 C02tBu 4-CF3-Phenyl341 2 C02tBu 3-CF3-Phenyl 962 2 C02tBu 4-CF3-Phenyl342 3 C02tBu 3-CF3-Phenyl 963 3 C02tBu 4-CF3-Phenyl343 1 CONHMe 3-CF3-Phenyl 964 1 CONHMe 4-CF3-Phenyl344 2 CONHMe 3-CF3-Phenyl 965 2 CONHMe 4-CF3-Phenyl345 3 CONHMe 3-CF3-Phenyl 966 3 CONHMe 4-CF3-Phenyl346 1 S02Me 3-CF3-Phenyl 967 1 S02Me 4-CF3-Phenyl347 2 S02Me 3-CF3-Phenyl 968 2 S02Me 4-CF3-Phenyl348 3 S02Me 3-CF3-Phenyl 969 3 S02Me 4-CF3-Phenyl349 1 S02NH23-CF3-Phenyl 970 1 S02NH24-CF3-Phenyl350 2 S02NH23-CF3-Phenyl 971 2 S02NH24-CF3-Phenyl351 3 S02NH23-CF3-Phenyl 972 3 S02NH24-CF3-Phenyl352 1 H 2-iPr-Phenyl 973 1 H 3-iPr-Phenyl353 2 H 2-iPr-Phenyl 974 2 H 3-iPr-Phenyl354 3 H 2-iPr-Phenyl 975 3 H 3-iPr-Phenyl355 1 Me 2-iPr-Phenyl 976 1 Me 3-iPr-Phenyl356 2 Me 2-iPr-Phenyl 977 2 Me 3-iPr-Phenyl357 3 Me 2-iPr-Phenyl 978 3 Me 3-iPr-Phenyl358 1 CH2Ph 2-iPr-Phenyl 979 1 CH2Ph 3-iPr-Phenyl359 2 CH2Ph 2-iPr-Phenyl 980 2 CH2Ph 3-iPr-Phenyl360 3 CH2Ph 2-iPr-Phenyl 981 3 CH2Ph 3-iPr-Phenyl361 1 COMe 2-iPr-Phenyl 982 1 COMe 3-iPr-Phenyl362 2 COMe 2-iPr-Phenyl 983 2 COMe 3-iPr-Phenyl363 3 COMe 2-iPr-Phenyl 984 3 COMe 3-iPr-Phenyl364 1 C02Me 2-iPr-Phenyl 985 1 C02Me 3-iPr-Phenyl365 2 C02Me 2-iPr-Phenyl 986 2 C02Me 3-iPr-Phenyl366 3 C02Me 2-iPr-Phenyl 987 3 C02Me 3-iPr-Phenyl367 1 C02tBu 2-iPr-Phenyl 988 1 C02tBu 3-iPr-Phenyl368 2 C02tBu 2-iPr-Phenyl 989 2 C02tBu 3-iPr-Phenyl369 3 C02tBu 2-iPr-Phenyl 990 3 C02tBu 3-iPr-Phenyl370 1 CONHMe 2-iPr-Phenyl 991 1 CONHMe 3-iPr-Phenyl371 2 CONHMe 2-iPr-Phenyl 992 2 CONHMe 3-iPr-Phenyl372 3 CONHMe 2-iPr-Phenyl 993 3 CONHMe 3-iPr-Phenyl373 1 S02Me 2-iPr-Phenyl 994 1 S02Me 3-iPr-Phenyl374 2 S02Me 2-iPr-Phenyl 995 2 S02Me 3-iPr-Phenyl375 3 S02Me 2-iPr-Phenyl 996 3 S02Me 3-iPr-Phenyl376 1 S02NH22-iPr-Phenyl 997 1 S02NH23-iPr-Phenyl377 2 S02NH22-iPr-Phenyl 998 2 S02NH23-iPr-Phenyl378 3 S02NH22-iPr-Phenyl 999 3 S02NH23-iPr-Phenyl379 1 H 4-iPr-Phenyl 1000 1 H 4-NH2-Phenyl380 2 H 4-iPr-Phenyl 1001 2 H 4-NH2-Phenyl381 3 H 4-iPr-Phenyl 1002 3 H 4-NH2-Phenyl382 1 Me 4-iPr-Phenyl 1003 1 Me 4-NH2-Phenyl383 2 Me 4-iPr-Phenyl 1004 2 Me 4-NH2-Phenyl384 3 Me 4-iPr-Phenyl 1005 3 Me 4-NH2-Phenyl385 1 CH2Ph 4-iPr-Phenyl 1006 1 CH2Ph 4-NH2-Phenyl386 2 CH2Ph 4-iPr-Phenyl 1007 2 CH2Ph 4-NH2-Phenyl387 3 CH2Ph 4-iPr-Phenyl 1008 3 CH2Ph 4-NH2-Phenyl388 1 COMe 4-iPr-Phenyl 1009 1 COMe 4-NH2-Phenyl389 2 COMe 4-iPr-Phenyl 1010 2 COMe 4-NH2-Phenyl390 3 COMe 4-iPr-Phenyl 1011 3 COMe 4-NH2-Phenyl391 1 C02Me 4-iPr-Phenyl 1012 1 C02Me 4-NH2-Phenyl392 2 C02Me 4-iPr-Phenyl 1013 2 C02Me 4-NH2-Phenyl393 3 C02Me 4-iPr-Phenyl 1014 3 C02Me 4-NH2-Phenyl394 1 C02tBu 4-iPr-Phenyl 1015 1 C02tBu 4-NH2-Phenyl395 2 C02tBu 4-iPr-Phenyl 1016 2 C02tBu 4-NH2-Phenyl396 3 C02tBu 4-iPr-Phenyl 1017 3 C02tBu 4-NH2-Phenyl397 1 CONHMe 4-iPr-Phenyl 1018 1 CONHMe 4-NH2-Phenyl398 2 CONHMe 4-iPr-Phenyl 1019 2 CONHMe 4-NH2-Phenyl399 3 CONHMe 4-iPr-Phenyl 1020 3 CONHMe 4-NH2-Phenyl400 1 S02Me 4-iPr-Phenyl 1021 1 S02Me 4-NH2-Phenyl401 2 S02Me 4-iPr-Phenyl 1022 2 S02Me 4-NH2-Phenyl402 3 S02Me 4-iPr-Phenyl 1023 3 S02Me 4-NH2-Phenyl403 1 S02NH24-iPr-Phenyl 1024 1 S02NH24-NH2-Phenyl404 2 S02NH24-iPr-Phenyl 1025 2 S02NH24-NH2-Phenyl405 3 S02NH24-iPr-Phenyl 1026 3 S02NH24-NH2-Phenyl406 1 H 3-NH2-Phenyl 1027 1 H 2-NH2-Phenyl407 2 H 3-NH2-Phenyl 1028 2 H 2-NH2-Phenyl408 3 H 3-NH2-Phenyl 1029 3 H 2-NH2-Phenyl409 1 Me 3-NH2-Phenyl 1030 1 Me 2-NH2-Phenyl410 2 Me 3-NH2-Phenyl 1031 2 Me 2-NH2-Phenyl411 3 Me 3-NH2-Phenyl 1032 3 Me 2-NH2-Phenyl412 1 CH2Ph 3-NH2-Phenyl 1033 1 CH2Ph 2-NH2-Phenyl413 2 CH2Ph 3-NH2-Phenyl 1034 2 CH2Ph 2-NH2-Phenyl414 3 CH2Ph 3-NH2-Phenyl 1035 3 CH2Ph 2-NH2-Phenyl415 1 COMe 3-NH2-Phenyl 1036 1 COMe 2-NH2-Phenyl416 2 COMe 3-NH2-Phenyl 1037 2 COMe 2-NH2-Phenyl417 3 COMe 3-NH2-Phenyl 1038 3 COMe 2-NH2-Phenyl418 1 C02Me 3-NH2-Phenyl 1039 1 C02Me 2-NH2-Phenyl419 2 C02Me 3-NH2-Phenyl 1040 2 C02Me 2-NH2-Phenyl420 3 C02Me 3-NH2-Phenyl 1041 3 C02Me 2-NH2-Phenyl421 1 C02tBu 3-NH2-Phenyl 1042 1 C02tBu 2-NH2-Phenyl422 2 C02tBu 3-NH2-Phenyl 1043 2 C02tBu 2-NH2-Phenyl423 3 C02tBu 3-NH2-Phenyl 1044 3 C02tBu 2-NH2-Phenyl424 1 CONHMe 3-NH2-Phenyl 1045 1 CONHMe 2-NH2-Phenyl425 2 CONHMe 3-NH2-Phenyl 1046 2 CONHMe 2-NH2-Phenyl426 3 CONHMe 3-NH2-Phenyl 1047 3 CONHMe 2-NH2-Phenyl427 1 S02Me 3-NH2-Phenyl 1048 1 S02Me 2-NH2-Phenyl428 2 S02Me 3-NH2-Phenyl 1049 2 S02Me 2-NH2-Phenyl429 3 S02Me 3-NH2-Phenyl 1050 3 S02Me 2-NH2-Phenyl430 1 S02NH23-NH2-Phenyl 1051 1 S02NH22-NH2-Phenyl431 2 S02NH23-NH2-Phenyl 1052 2 S02NH22-NH2-Phenyl432 3 S02NH23-NH2-Phenyl 1053 3 S02NH22-NH2-Phenyl433 1 H 2,4-di-Me-Phenyl 1054 1 H 2,6-di-Me-Phenyl434 2 H 2,4-di-Me-Phenyl 1055 2 H 2,6-di-Me-Phenyl435 3 H 2,4-di-Me-Phenyl 1056 3 H 2,6-di-Me-Phenyl436 1 Me 2,4-di-Me-Phenyl 1057 1 Me 2,6-di-Me-Phenyl437 2 Me 2,4-di-Me-Phenyl 1058 2 Me 2,6-di-Me-Phenyl438 3 Me 2,4-di-Me-Phenyl 1059 3 Me 2,6-di-Me-Phenyl439 1 CH2Ph 2,4-di-Me-Phenyl 1060 1 CH2Ph 2,6-di-Me-Phenyl440 2 CH2Ph 2,4-di-Me-Phenyl 1061 2 CH2Ph 2,6-di-Me-Phenyl441 3 CH2Ph 2,4-di-Me-Phenyl 1062 3 CH2Ph 2,6-di-Me-Phenyl442 1 COMe 2,4-di-Me-Phenyl 1063 1 COMe 2,6-di-Me-Phenyl443 2 COMe 2,4-di-Me-Phenyl 1064 2 COMe 2,6-di-Me-Phenyl444 3 COMe 2,4-di-Me-Phenyl 1065 3 COMe 2,6-di-Me-Phenyl445 1 C02Me 2,4-di-Me-Phenyl 1066 1 C02Me 2,6-di-Me-Phenyl446 2 C02Me 2,4-di-Me-Phenyl 1067 2 C02Me 2,6-di-Me-Phenyl447 3 C02Me 2,4-di-Me-Phenyl 1068 3 C02Me 2,6-di-Me-Phenyl448 1 C02tBu 2,4-di-Me-Phenyl 1069 1 C02tBu 2,6-di-Me-Phenyl449 2 C02tBu 2,4-di-Me-Phenyl 1070 2 C02tBu 2,6-di-Me-Phenyl450 3 C02tBu 2,4-di-Me-Phenyl 1071 3 C02tBu 2,6-di-Me-Phenyl451 1 CONHMe 2,4-di-Me-Phenyl 1072 1 CONHMe 2,6-di-Me-Phenyl452 2 CONHMe 2,4-di-Me-Phenyl 1073 2 CONHMe 2,6-di-Me-Phenyl453 3 CONHMe 2,4-di-Me-Phenyl 1074 3 CONHMe 2,6-di-Me-Phenyl454 1 S02Me 2,4-di-Me-Phenyl 1075 1 S02Me 2,6-di-Me-Phenyl455 2 S02Me 2,4-di-Me-Phenyl 1076 2 S02Me 2,6-di-Me-Phenyl456 3 S02Me 2,4-di-Me-Phenyl 1077 3 S02Me 2,6-di-Me-Phenyl457 1 S02NH22,4-di-Me-Phenyl 1078 1 S02NH22,6-di-Me-Phenyl458 2 S02NH22,4-di-Me-Phenyl 1079 2 S02NH22,6-di-Me-Phenyl459 3 S02NH22,4-di-Me-Phenyl 1080 3 S02NH22,6-di-Me-Phenyl460 1 H 2,6-di-iPr-Phenyl 1081 1 H 2-Ph-Phenyl461 2 H 2,6-di-iPr-Phenyl 1082 2 H 2-Ph-Phenyl462 3 H 2,6-di-iPr-Phenyl 1083 3 H 2-Ph-Phenyl463 1 Me 2,6-di-iPr-Phenyl 1084 1 Me 2-Ph-Phenyl464 2 Me 2,6-di-iPr-Phenyl 1085 2 Me 2-Ph-Phenyl465 3 Me 2,6-di-iPr-Phenyl 1086 3 Me 2-Ph-Phenyl466 1 CH2Ph 2,6-di-iPr-Phenyl 1087 1 CH2Ph 2-Ph-Phenyl467 2 CH2Ph 2,6-di-iPr-Phenyl 1088 2 CH2Ph 2-Ph-Phenyl468 3 CH2Ph 2,6-di-iPr-Phenyl 1089 3 CH2Ph 2-Ph-Phenyl469 1 COMe 2,6-di-iPr-Phenyl 1090 1 COMe 2-Ph-Phenyl470 2 COMe 2,6-di-iPr-Phenyl 1091 2 COMe 2-Ph-Phenyl471 3 COMe 2,6-di-iPr-Phenyl 1092 3 COMe 2-Ph-Phenyl472 1 C02Me 2,6-di-iPr-Phenyl 1093 1 C02Me 2-Ph-Phenyl473 2 C02Me 2,6-di-iPr-Phenyl 1094 2 C02Me 2-Ph-Phenyl474 3 C02Me 2,6-di-iPr-Phenyl 1095 3 C02Me 2-Ph-Phenyl475 1 C02tBu 2,6-di-iPr-Phenyl 1096 1 C02tBu 2-Ph-Phenyl476 2 C02tBu 2,6-di-iPr-Phenyl 1097 2 C02tBu 2-Ph-Phenyl477 3 C02tBu 2,6-di-iPr-Phenyl 1098 3 C02tBu 2-Ph-Phenyl478 1 CONHMe 2,6-di-iPr-Phenyl 1099 1 CONHMe 2-Ph-Phenyl479 2 CONHMe 2,6-di-iPr-Phenyl 1100 2 CONHMe 2-Ph-Phenyl480 3 CONHMe 2,6-di-iPr-Phenyl 1101 3 CONHMe 2-Ph-Phenyl481 1 S02Me 2,6-di-iPr-Phenyl 1102 1 S02Me 2-Ph-Phenyl482 2 S02Me 2,6-di-iPr-Phenyl 1103 2 S02Me 2-Ph-Phenyl483 3 S02Me 2,6-di-iPr-Phenyl 1104 3 S02Me 2-Ph-Phenyl484 1 S02NH22,6-di-iPr-Phenyl 1105 1 S02NH22-Ph-Phenyl485 2 S02NH22,6-di-iPr-Phenyl 1106 2 S02NH22-Ph-Phenyl486 3 S02NH22,6-di-iPr-Phenyl 1107 3 S02NH22-Ph-Phenyl487 1 H 3-Ph-Phenyl 1108 1 H 4-Ph-Phenyl488 2 H 3-Ph-Phenyl 1109 2 H 4-Ph-Phenyl489 3 H 3-Ph-Phenyl 1110 3 H 4-Ph-Phenyl490 1 Me 3-Ph-Phenyl 1111 1 Me 4-Ph-Phenyl491 2 Me 3-Ph-Phenyl 1112 2 Me 4-Ph-Phenyl492 3 Me 3-Ph-Phenyl 1113 3 Me 4-Ph-Phenyl493 1 CH2Ph 3-Ph-Phenyl 1114 1 CH2Ph 4-Ph-Phenyl494 2 CH2Ph 3-Ph-Phenyl 1115 2 CH2Ph 4-Ph-Phenyl495 3 CH2Ph 3-Ph-Phenyl 1116 3 CH2Ph 4-Ph-Phenyl496 1 COMe 3-Ph-Phenyl 1117 1 COMe 4-Ph-Phenyl497 2 COMe 3-Ph-Phenyl 1118 2 COMe 4-Ph-Phenyl498 3 COMe 3-Ph-Phenyl 1119 3 COMe 4-Ph-Phenyl499 1 C02Me 3-Ph-Phenyl 1120 1 C02Me 4-Ph-Phenyl500 2 C02Me 3-Ph-Phenyl 1121 2 C02Me 4-Ph-Phenyl501 3 C02Me 3-Ph-Phenyl 1122 3 C02Me 4-Ph-Phenyl502 1 C02tBu 3-Ph-Phenyl 1123 1 C02tBu 4-Ph-Phenyl503 2 C02tBu 3-Ph-Phenyl 1124 2 C02tBu 4-Ph-Phenyl504 3 C02tBu 3-Ph-Phenyl 1125 3 C02tBu 4-Ph-Phenyl505 1 CONHMe 3-Ph-Phenyl 1126 1 CONHMe 4-Ph-Phenyl506 2 CONHMe 3-Ph-Phenyl 1127 2 CONHMe 4-Ph-Phenyl507 3 CONHMe 3-Ph-Phenyl 1128 3 CONHMe 4-Ph-Phenyl508 1 S02Me 3-Ph-Phenyl 1129 1 S02Me 4-Ph-Phenyl509 2 S02Me 3-Ph-Phenyl 1130 2 S02Me 4-Ph-Phenyl510 3 S02Me 3-Ph-Phenyl 1131 3 S02Me 4-Ph-Phenyl511 1 S02NH23-Ph-Phenyl 1132 1 S02NH24-Ph-Phenyl512 2 S02NH23-Ph-Phenyl 1133 2 S02NH24-Ph-Phenyl513 3 S02NH23-Ph-Phenyl 1134 3 S02NH24-Ph-Phenyl514 1 H 2-morpholino-phenyl 1135 1 H 3 -morpholino -pheny 1515 2 H 2-morpholino-phenyl 1136 2 H 3 -moφholino -pheny 1516 3 H 2-morpholino-phenyl 1137 3 H 3 -morpholino -pheny 1517 1 Me 2 -morpholino-pheny 1 1138 1 Me 3 -morpholino -pheny 1518 2 Me 2 -morpholino-pheny 1 1139 2 Me 3 -morpholino -pheny 1519 3 Me 2 -morpholino-pheny 1 1140 3 Me 3 -morpholino -pheny 1520 1 CH2Ph 2-morpholino-phenyl 1141 1 CH2Ph 3 -morpholino -pheny 1521 2 CH2Ph 2-morpholino-phenyl 1142 2 CH2Ph 3 -morpholino -pheny 1522 3 CH2Ph 2-morpholino-phenyl 1143 3 CH2Ph 3 -morpholino -pheny 1523 1 COMe 2-morpholino-phenyl 1144 1 COMe 3 -morpholino-pheny 1524 2 COMe 2-morpholino-phenyl 1145 2 COMe 3 -morpholino-pheny 1525 3 COMe 2-morpholino-phenyl 1146 3 COMe 3 -morpholino-pheny 1526 1 C02Me 2 -morpholino-pheny 1 1147 1 C02Me 3-morpholino-phenyl527 2 C02Me 2 -morpholino-pheny 1 1148 2 C02Me 3-morpholino-phenyl528 3 C02Me 2 -morpholino-pheny 1 1149 3 C02Me 3-morpholino-phenyl529 1 C02tBu 2-morpholino-phenyl 1150 1 C02tBu 3 -morpholino -pheny 1530 2 C02tBu 2-morpholino-phenyl 1151 2 C02tBu 3 -morpholino -pheny 1531 3 C02tBu 2-morpholino-phenyl 1152 3 C02tBu 3 -morpholino -pheny 1532 1 CONHMe 2-morpholino-phenyl 1153 1 CONHMe 3-morpholino-phenyl533 2 CONHMe 2-morpholino-phenyl 1154 2 CONHMe 3-morpholino-phenyl534 3 CONHMe 2-morpholino-phenyl 1155 3 CONHMe 3-morpholino-phenyl535 1 S02Me 2 -morpholino-pheny 1 1156 1 S02Me 3 -morpholino-pheny 1536 2 S02Me 2 -morpholino-pheny 1 1157 2 S02Me 3 -morpholino -pheny 1537 3 S02Me 2 -morpholino-pheny 1 1158 3 S02Me 3 -morpholino -pheny 1538 1 S02NH22-morpholino-phenyl 1159 1 S02NH23 -morpholino -pheny 1539 2 S02NH22-morpholino-phenyl 1160 2 S02NH23 -morpholino -pheny 1540 3 S02NH22-morpholino-phenyl 1161 3 S02NH23 -morpholino -pheny 1541 1 H 4-morpholino-phenyl 1162 1 H 2-pyrazinyl542 2 H 4-morpholino-phenyl 1163 2 H 2-pyrazinyl543 3 H 4-morpholino-phenyl 1164 3 H 2-pyrazinyl544 1 Me 4 -morpholino-pheny 1 1165 1 Me 2-pyrazinyl545 2 Me 4 -morpholino-pheny 1 1166 2 Me 2-pyrazinyl546 3 Me 4 -morpholino-pheny 1 1167 3 Me 2-pyrazinyl547 1 CH2Ph 4-morpholino-phenyl 1168 1 CH2Ph 2-pyrazinyl548 2 CH2Ph 4-morpholino-phenyl 1169 2 CH2Ph 2-pyrazinyl549 3 CH2Ph 4-morpholino-phenyl 1170 3 CH2Ph 2-pyrazinyl550 1 COMe 4-morpholino-phenyl 1171 1 COMe 2-pyrazinyl551 2 COMe 4-morpholino-phenyl 1172 2 COMe 2-pyrazinyl552 3 COMe 4-morpholino-phenyl 1173 3 COMe 2-pyrazinyl553 1 C02Me 4 -morpholino-pheny 1 1174 1 C02Me 2-pyrazinyl554 2 C02Me 4 -morpholino-pheny 1 1175 2 C02Me 2-pyrazinyl555 3 C02Me 4 -morpholino-pheny 1 1176 3 C02Me 2-pyrazinyl556 1 C02tBu 4-morpholino-phenyl 1177 1 C02tBu 2-pyrazinyl557 2 C02tBu 4-morpholino-phenyl 1178 2 C02tBu 2-pyrazinyl558 3 C02tBu 4-morpholino-phenyl 1179 3 C02tBu 2-pyrazinyl559 1 CONHMe 4-morpholino-phenyl 1180 1 CONHMe 2-pyrazinyl560 2 CONHMe 4-morpholino-phenyl 1181 2 CONHMe 2-pyrazinyl561 3 CONHMe 4-morpholino-phenyl 1182 3 CONHMe 2-pyrazinyl562 1 S02Me 4 -morpholino-pheny 1 1183 1 S02Me 2-pyrazinyl563 2 S02Me 4 -morpholino-pheny 1 1184 2 S02Me 2-pyrazinyl564 3 S02Me 4 -morpholino-pheny 1 1185 3 S02Me 2-pyrazinyl565 1 S02NH24-morpholino-phenyl 1186 1 S02NH22-pyrazinyl566 2 S02NH24-morpholino-phenyl 1187 2 S02NH22-pyrazinyl567 3 S02NH24-morpholino-phenyl 1188 3 S02NH22-pyrazinyl568 1 H 2-pyrimidinyl 1189 1 H 5-indolyl569 2 H 2-pyrimidinyl 1190 2 H 5-indolyl570 3 H 2-pyrimidinyl 1191 3 H 5-indolyl571 1 Me 2-pyrimidinyl 1192 1 Me 5-indolyl572 2 Me 2-pyrimidinyl 1193 2 Me 5-indolyl573 3 Me 2-pyrimidinyl 1194 3 Me 5-indolyl574 1 CH2Ph 2-pyrimidinyl 1195 1 CH2Ph 5-indolyl575 2 CH2Ph 2-pyrimidinyl 1196 2 CH2Ph 5-indolyl576 3 CH2Ph 2-pyrimidinyl 1197 3 CH2Ph 5-indolyl577 1 COMe 2-pyrimidinyl 1198 1 COMe 5-indolyl578 2 COMe 2-pyrimidinyl 1199 2 COMe 5-indolyl579 3 COMe 2-pyrimidinyl 1200 3 COMe 5-indolyl580 1 C02Me 2-pyrimidinyl 1201 1 C02Me 5-indolyl581 2 C02Me 2-pyrimidinyl 1202 2 C02Me 5-indolyl582 3 C02Me 2-pyrimidinyl 1203 3 C02Me 5-indolyl583 1 C02tBu 2-pyrimidinyl 1204 1 C02tBu 5-indolyl584 2 C02tBu 2-pyrimidinyl 1205 2 C02tBu 5-indolyl585 3 C02tBu 2-pyrimidinyl 1206 3 C02tBu 5-indolyl586 1 CONHMe 2-pyrimidinyl 1207 1 CONHMe 5-indolyl587 2 CONHMe 2-pyrimidinyl 1208 2 CONHMe 5-indolyl588 3 CONHMe 2-pyrimidinyl 1209 3 CONHMe 5-indolyl589 1 S02Me 2-pyrimidinyl 1210 1 S02Me 5-indolyl590 2 S02Me 2-pyrimidinyl 1211 2 S02Me 5-indolyl591 3 S02Me 2-pyrimidinyl 1212 3 S02Me 5-indolyl592 1 S02NH22-pyrimidinyl 1213 1 S02NH25-indolyl593 2 S02NH22-pyrimidinyl 1214 2 S02NH25-indolyl594 3 S02NH22-pyrimidinyl 1215 3 S02NH25-indolyl2-methyl-lH- 1216 1 H-benzo [d] imidazol-595 1 H 1 Hbenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1217 1 H-benzo [d] imidazol-596 2 H 2 Hbenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1218 1 H-benzo [d] imidazol-597 3 H 3 Hbenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1219 1 H-benzo [d] imidazol-598 1 Me 1 Mebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1220 1 H-benzo [d] imidazol-599 2 Me 2 Mebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1221 1 H-benzo [d] imidazol-600 3 Me 3 Mebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1222 1 H-benzo [d] imidazol-601 1 CH2Ph 1 CH2Phbenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1223 1 H-benzo [d] imidazol-602 2 CH2Ph 2 CH2Phbenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1224 1 H-benzo [d] imidazol-603 3 CH2Ph 3 CH2Phbenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1225 1 H-benzo [d] imidazol-604 1 COMe 1 COMebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1226 1 H-benzo [d] imidazol-605 2 COMe 2 COMebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1227 1 H-benzo [d] imidazol-606 3 COMe 3 COMebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1228 1 H-benzo [d] imidazol-607 1 C02Me 1 C02Mebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1229 1 H-benzo [d] imidazol-608 2 C02Me 2 C02Mebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1230 1 H-benzo [d] imidazol-609 3 C02Me 3 C02Mebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1231 1 H-benzo [d] imidazol-610 1 C02tBu 1 C02tBubenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1232 1 H-benzo [d] imidazol-611 2 C02tBu 2 C02tBubenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1233 1 H-benzo [d] imidazol-612 3 C02tBu 3 C02tBubenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1234 1 H-benzo [d] imidazol-613 1 CONHMe 1 CONHMebenzo [d] imidazol-4-y 1 4-yl2-methyl-lH- 1235 1 H-benzo [d] imidazol-614 2 CONHMe 2 CONHMebenzo [d] imidazol-4-y 1 4-yl
[0327] Exemplary embodiments include compounds having the formula (XVIII)or a pharmaceutically acceptable salt form thereof defined herein below in Table 2.Table 23 CH2Ph Phenyl 630 3 CH2Ph 4-OH-Phenyl1 COMe Phenyl 631 1 COMe 4-OH-Phenyl2 COMe Phenyl 632 2 COMe 4-OH-Phenyl3 COMe Phenyl 633 3 COMe 4-OH-Phenyl1 C02Me Phenyl 634 1 C02Me 4-OH-Phenyl2 C02Me Phenyl 635 2 C02Me 4-OH-Phenyl3 C02Me Phenyl 636 3 C02Me 4-OH-Phenyl1 C02tBu Phenyl 637 1 C02tBu 4-OH-Phenyl2 C02tBu Phenyl 638 2 C02tBu 4-OH-Phenyl3 C02tBu Phenyl 639 3 C02tBu 4-OH-Phenyl1 CONHMe Phenyl 640 1 CONHMe 4-OH-Phenyl2 CONHMe Phenyl 641 2 CONHMe 4-OH-Phenyl3 CONHMe Phenyl 642 3 CONHMe 4-OH-Phenyl1 S02Me Phenyl 643 1 S02Me 4-OH-Phenyl2 S02Me Phenyl 644 2 S02Me 4-OH-Phenyl3 S02Me Phenyl 645 3 S02Me 4-OH-Phenyl1 S02NH2Phenyl 646 1 S02NH24-OH-Phenyl2 S02NH2Phenyl 647 2 S02NH24-OH-Phenyl3 S02NH2Phenyl 648 3 S02NH24-OH-Phenyl1 H 3-OH-Phenyl 649 1 H 2-OH-Phenyl2 H 3-OH-Phenyl 650 2 H 2-OH-Phenyl3 H 3-OH-Phenyl 651 3 H 2-OH-Phenyl1 Me 3-OH-Phenyl 652 1 Me 2-OH-Phenyl2 Me 3-OH-Phenyl 653 2 Me 2-OH-Phenyl3 Me 3-OH-Phenyl 654 3 Me 2-OH-Phenyl1 CH2Ph 3-OH-Phenyl 655 1 CH2Ph 2-OH-Phenyl2 CH2Ph 3-OH-Phenyl 656 2 CH2Ph 2-OH-Phenyl3 CH2Ph 3-OH-Phenyl 657 3 CH2Ph 2-OH-Phenyl1 COMe 3-OH-Phenyl 658 1 COMe 2-OH-Phenyl2 COMe 3-OH-Phenyl 659 2 COMe 2-OH-Phenyl3 COMe 3-OH-Phenyl 660 3 COMe 2-OH-Phenyl1 C02Me 3-OH-Phenyl 661 1 C02Me 2-OH-Phenyl2 C02Me 3-OH-Phenyl 662 2 C02Me 2-OH-Phenyl3 C02Me 3-OH-Phenyl 663 3 C02Me 2-OH-Phenyl1 C02tBu 3-OH-Phenyl 664 1 C02tBu 2-OH-Phenyl2 C02tBu 3-OH-Phenyl 665 2 C02tBu 2-OH-Phenyl3 C02tBu 3-OH-Phenyl 666 3 C02tBu 2-OH-Phenyl1 CONHMe 3-OH-Phenyl 667 1 CONHMe 2-OH-Phenyl2 CONHMe 3-OH-Phenyl 668 2 CONHMe 2-OH-Phenyl3 CONHMe 3-OH-Phenyl 669 3 CONHMe 2-OH-Phenyl1 S02Me 3-OH-Phenyl 670 1 S02Me 2-OH-Phenyl2 S02Me 3-OH-Phenyl 671 2 S02Me 2-OH-Phenyl3 S02Me 3-OH-Phenyl 672 3 S02Me 2-OH-Phenyl1 S02NH23-OH-Phenyl 673 1 S02NH22-OH-Phenyl2 S02NH23-OH-Phenyl 674 2 S02NH22-OH-Phenyl3 S02NH23-OH-Phenyl 675 3 S02NH22-OH-Phenyl1 H 4-N02-Phenyl 676 1 H 4-OMe-Phenyl2 H 4-N02-Phenyl 677 2 H 4-OMe-Phenyl3 H 4-N02-Phenyl 678 3 H 4-OMe-Phenyl1 Me 4-N02-Phenyl 679 1 Me 4-OMe-Phenyl2 Me 4-N02-Phenyl 680 2 Me 4-OMe-Phenyl3 Me 4-N02-Phenyl 681 3 Me 4-OMe-Phenyl1 CH2Ph 4-N02-Phenyl 682 1 CH2Ph 4-OMe-Phenyl2 CH2Ph 4-N02-Phenyl 683 2 CH2Ph 4-OMe-Phenyl3 CH2Ph 4-N02-Phenyl 684 3 CH2Ph 4-OMe-Phenyl1 COMe 4-N02-Phenyl 685 1 COMe 4-OMe-Phenyl2 COMe 4-N02-Phenyl 686 2 COMe 4-OMe-Phenyl3 COMe 4-N02-Phenyl 687 3 COMe 4-OMe-Phenyl1 C02Me 4-N02-Phenyl 688 1 C02Me 4-OMe-Phenyl2 C02Me 4-N02-Phenyl 689 2 C02Me 4-OMe-Phenyl3 C02Me 4-N02-Phenyl 690 3 C02Me 4-OMe-Phenyl1 C02tBu 4-N02-Phenyl 691 1 C02tBu 4-OMe-Phenyl2 C02tBu 4-N02-Phenyl 692 2 C02tBu 4-OMe-Phenyl3 C02tBu 4-N02-Phenyl 693 3 C02tBu 4-OMe-Phenyl1 CONHMe 4-N02-Phenyl 694 1 CONHMe 4-OMe-Phenyl2 CONHMe 4-N02-Phenyl 695 2 CONHMe 4-OMe-Phenyl3 CONHMe 4-N02-Phenyl 696 3 CONHMe 4-OMe-Phenyl1 S02Me 4-N02-Phenyl 697 1 S02Me 4-OMe-Phenyl2 S02Me 4-N02-Phenyl 698 2 S02Me 4-OMe-Phenyl3 S02Me 4-N02-Phenyl 699 3 S02Me 4-OMe-Phenyl1 S02NH24-N02-Phenyl 700 1 S02NH24-OMe-Phenyl2 S02NH24-N02-Phenyl 701 2 S02NH24-OMe-Phenyl3 S02NH24-N02-Phenyl 702 3 S02NH24-OMe-Phenyl1 H 3-OMe-Phenyl 703 1 H 2-OMe-Phenyl2 H 3-OMe-Phenyl 704 2 H 2-OMe-Phenyl3 H 3-OMe-Phenyl 705 3 H 2-OMe-Phenyl1 Me 3-OMe-Phenyl 706 1 Me 2-OMe-Phenyl2 Me 3-OMe-Phenyl 707 2 Me 2-OMe-Phenyl87 3 Me 3-OMe-Phenyl 708 3 Me 2-OMe-Phenyl88 1 CH2Ph 3-OMe-Phenyl 709 1 CH2Ph 2-OMe-Phenyl89 2 CH2Ph 3-OMe-Phenyl 710 2 CH2Ph 2-OMe-Phenyl90 3 CH2Ph 3-OMe-Phenyl 711 3 CH2Ph 2-OMe-Phenyl91 1 COMe 3-OMe-Phenyl 712 1 COMe 2-OMe-Phenyl92 2 COMe 3-OMe-Phenyl 713 2 COMe 2-OMe-Phenyl93 3 COMe 3-OMe-Phenyl 714 3 COMe 2-OMe-Phenyl94 1 C02Me 3-OMe-Phenyl 715 1 C02Me 2-OMe-Phenyl95 2 C02Me 3-OMe-Phenyl 716 2 C02Me 2-OMe-Phenyl96 3 C02Me 3-OMe-Phenyl 717 3 C02Me 2-OMe-Phenyl97 1 C02tBu 3-OMe-Phenyl 718 1 C02tBu 2-OMe-Phenyl98 2 C02tBu 3-OMe-Phenyl 719 2 C02tBu 2-OMe-Phenyl99 3 C02tBu 3-OMe-Phenyl 720 3 C02tBu 2-OMe-Phenyl100 1 CONHMe 3-OMe-Phenyl 721 1 CONHMe 2-OMe-Phenyl101 2 CONHMe 3-OMe-Phenyl 722 2 CONHMe 2-OMe-Phenyl102 3 CONHMe 3-OMe-Phenyl 723 3 CONHMe 2-OMe-Phenyl103 1 S02Me 3-OMe-Phenyl 724 1 S02Me 2-OMe-Phenyl104 2 S02Me 3-OMe-Phenyl 725 2 S02Me 2-OMe-Phenyl105 3 S02Me 3-OMe-Phenyl 726 3 S02Me 2-OMe-Phenyl106 1 S02NH23-OMe-Phenyl 727 1 S02NH22-OMe-Phenyl107 2 S02NH23-OMe-Phenyl 728 2 S02NH22-OMe-Phenyl108 3 S02NH23-OMe-Phenyl 729 3 S02NH22-OMe-Phenyl109 1 H 4-CN-Phenyl 730 1 H 3-CN-Phenyl110 2 H 4-CN-Phenyl 731 2 H 3-CN-Phenyl111 3 H 4-CN-Phenyl 732 3 H 3-CN-Phenyl112 1 Me 4-CN-Phenyl 733 1 Me 3-CN-Phenyl113 2 Me 4-CN-Phenyl 734 2 Me 3-CN-Phenyl114 3 Me 4-CN-Phenyl 735 3 Me 3-CN-Phenyl115 1 CH2Ph 4-CN-Phenyl 736 1 CH2Ph 3-CN-Phenyl116 2 CH2Ph 4-CN-Phenyl 737 2 CH2Ph 3-CN-Phenyl117 3 CH2Ph 4-CN-Phenyl 738 3 CH2Ph 3-CN-Phenyl118 1 COMe 4-CN-Phenyl 739 1 COMe 3-CN-Phenyl119 2 COMe 4-CN-Phenyl 740 2 COMe 3-CN-Phenyl120 3 COMe 4-CN-Phenyl 741 3 COMe 3-CN-Phenyl121 1 C02Me 4-CN-Phenyl 742 1 C02Me 3-CN-Phenyl122 2 C02Me 4-CN-Phenyl 743 2 C02Me 3-CN-Phenyl123 3 C02Me 4-CN-Phenyl 744 3 C02Me 3-CN-Phenyl124 1 C02tBu 4-CN-Phenyl 745 1 C02tBu 3-CN-Phenyl125 2 C02tBu 4-CN-Phenyl 746 2 C02tBu 3-CN-Phenyl126 3 C02tBu 4-CN-Phenyl 747 3 C02tBu 3-CN-Phenyl127 1 CONHMe 4-CN-Phenyl 748 1 CONHMe 3-CN-Phenyl128 2 CONHMe 4-CN-Phenyl 749 2 CONHMe 3-CN-Phenyl129 3 CONHMe 4-CN-Phenyl 750 3 CONHMe 3-CN-Phenyl130 1 S02Me 4-CN-Phenyl 751 1 S02Me 3-CN-Phenyl131 2 S02Me 4-CN-Phenyl 752 2 S02Me 3-CN-Phenyl132 3 S02Me 4-CN-Phenyl 753 3 S02Me 3-CN-Phenyl133 1 S02NH24-CN-Phenyl 754 1 S02NH23-CN-Phenyl134 2 S02NH24-CN-Phenyl 755 2 S02NH23-CN-Phenyl135 3 S02NH24-CN-Phenyl 756 3 S02NH23-CN-Phenyl136 1 H 2-CN-Phenyl 757 1 H 2-Me-Phenyl137 2 H 2-CN-Phenyl 758 2 H 2-Me-Phenyl138 3 H 2-CN-Phenyl 759 3 H 2-Me-Phenyl139 1 Me 2-CN-Phenyl 760 1 Me 2-Me-Phenyl140 2 Me 2-CN-Phenyl 761 2 Me 2-Me-Phenyl141 3 Me 2-CN-Phenyl 762 3 Me 2-Me-Phenyl142 1 CH2Ph 2-CN-Phenyl 763 1 CH2Ph 2-Me-Phenyl143 2 CH2Ph 2-CN-Phenyl 764 2 CH2Ph 2-Me-Phenyl144 3 CH2Ph 2-CN-Phenyl 765 3 CH2Ph 2-Me-Phenyl145 1 COMe 2-CN-Phenyl 766 1 COMe 2-Me-Phenyl146 2 COMe 2-CN-Phenyl 767 2 COMe 2-Me-Phenyl147 3 COMe 2-CN-Phenyl 768 3 COMe 2-Me-Phenyl148 1 C02Me 2-CN-Phenyl 769 1 C02Me 2-Me-Phenyl149 2 C02Me 2-CN-Phenyl 770 2 C02Me 2-Me-Phenyl150 3 C02Me 2-CN-Phenyl 771 3 C02Me 2-Me-Phenyl151 1 C02tBu 2-CN-Phenyl 772 1 C02tBu 2-Me-Phenyl152 2 C02tBu 2-CN-Phenyl 773 2 C02tBu 2-Me-Phenyl153 3 C02tBu 2-CN-Phenyl 774 3 C02tBu 2-Me-Phenyl154 1 CONHMe 2-CN-Phenyl 775 1 CONHMe 2-Me-Phenyl155 2 CONHMe 2-CN-Phenyl 776 2 CONHMe 2-Me-Phenyl156 3 CONHMe 2-CN-Phenyl 777 3 CONHMe 2-Me-Phenyl157 1 S02Me 2-CN-Phenyl 778 1 S02Me 2-Me-Phenyl158 2 S02Me 2-CN-Phenyl 779 2 S02Me 2-Me-Phenyl159 3 S02Me 2-CN-Phenyl 780 3 S02Me 2-Me-Phenyl160 1 S02NH22-CN-Phenyl 781 1 S02NH22-Me-Phenyl161 2 S02NH22-CN-Phenyl 782 2 S02NH22-Me-Phenyl162 3 S02NH22-CN-Phenyl 783 3 S02NH22-Me-Phenyl163 1 H 3-Me-Phenyl 784 1 H 4-Me-Phenyl164 2 H 3-Me-Phenyl 785 2 H 4-Me-Phenyl165 3 H 3-Me-Phenyl 786 3 H 4-Me-Phenyl166 1 Me 3-Me-Phenyl 787 1 Me 4-Me-Phenyl167 2 Me 3-Me-Phenyl 788 2 Me 4-Me-Phenyl168 3 Me 3-Me-Phenyl 789 3 Me 4-Me-Phenyl169 1 CH2Ph 3-Me-Phenyl 790 1 CH2Ph 4-Me-Phenyl170 2 CH2Ph 3-Me-Phenyl 791 2 CH2Ph 4-Me-Phenyl171 3 CH2Ph 3-Me-Phenyl 792 3 CH2Ph 4-Me-Phenyl172 1 COMe 3-Me-Phenyl 793 1 COMe 4-Me-Phenyl173 2 COMe 3-Me-Phenyl 794 2 COMe 4-Me-Phenyl174 3 COMe 3-Me-Phenyl 795 3 COMe 4-Me-Phenyl175 1 C02Me 3-Me-Phenyl 796 1 C02Me 4-Me-Phenyl176 2 C02Me 3-Me-Phenyl 797 2 C02Me 4-Me-Phenyl177 3 C02Me 3-Me-Phenyl 798 3 C02Me 4-Me-Phenyl178 1 C02tBu 3-Me-Phenyl 799 1 C02tBu 4-Me-Phenyl179 2 C02tBu 3-Me-Phenyl 800 2 C02tBu 4-Me-Phenyl180 3 C02tBu 3-Me-Phenyl 801 3 C02tBu 4-Me-Phenyl181 1 CONHMe 3-Me-Phenyl 802 1 CONHMe 4-Me-Phenyl182 2 CONHMe 3-Me-Phenyl 803 2 CONHMe 4-Me-Phenyl183 3 CONHMe 3-Me-Phenyl 804 3 CONHMe 4-Me-Phenyl184 1 S02Me 3-Me-Phenyl 805 1 S02Me 4-Me-Phenyl185 2 S02Me 3-Me-Phenyl 806 2 S02Me 4-Me-Phenyl186 3 S02Me 3-Me-Phenyl 807 3 S02Me 4-Me-Phenyl187 1 S02NH23-Me-Phenyl 808 1 S02NH24-Me-Phenyl188 2 S02NH23-Me-Phenyl 809 2 S02NH24-Me-Phenyl189 3 S02NH23-Me-Phenyl 810 3 S02NH24-Me-Phenyl190 1 H 2-F-Phenyl 811 1 H 3-F-Phenyl191 2 H 2-F-Phenyl 812 2 H 3-F-Phenyl192 3 H 2-F-Phenyl 813 3 H 3-F-Phenyl193 1 Me 2-F-Phenyl 814 1 Me 3-F-Phenyl194 2 Me 2-F-Phenyl 815 2 Me 3-F-Phenyl195 3 Me 2-F-Phenyl 816 3 Me 3-F-Phenyl196 1 CH2Ph 2-F-Phenyl 817 1 CH2Ph 3-F-Phenyl197 2 CH2Ph 2-F-Phenyl 818 2 CH2Ph 3-F-Phenyl198 3 CH2Ph 2-F-Phenyl 819 3 CH2Ph 3-F-Phenyl199 1 COMe 2-F-Phenyl 820 1 COMe 3-F-Phenyl200 2 COMe 2-F-Phenyl 821 2 COMe 3-F-Phenyl201 3 COMe 2-F-Phenyl 822 3 COMe 3-F-Phenyl202 1 C02Me 2-F-Phenyl 823 1 C02Me 3-F-Phenyl203 2 C02Me 2-F-Phenyl 824 2 C02Me 3-F-Phenyl204 3 C02Me 2-F-Phenyl 825 3 C02Me 3-F-Phenyl205 1 C02tBu 2-F-Phenyl 826 1 C02tBu 3-F-Phenyl206 2 C02tBu 2-F-Phenyl 827 2 C02tBu 3-F-Phenyl207 3 C02tBu 2-F-Phenyl 828 3 C02tBu 3-F-Phenyl208 1 CONHMe 2-F-Phenyl 829 1 CONHMe 3-F-Phenyl209 2 CONHMe 2-F-Phenyl 830 2 CONHMe 3-F-Phenyl210 3 CONHMe 2-F-Phenyl 831 3 CONHMe 3-F-Phenyl211 1 S02Me 2-F-Phenyl 832 1 S02Me 3-F-Phenyl212 2 S02Me 2-F-Phenyl 833 2 S02Me 3-F-Phenyl213 3 S02Me 2-F-Phenyl 834 3 S02Me 3-F-Phenyl214 1 S02NH22-F-Phenyl 835 1 S02NH23-F-Phenyl215 2 S02NH22-F-Phenyl 836 2 S02NH23-F-Phenyl216 3 S02NH22-F-Phenyl 837 3 S02NH23-F-Phenyl217 1 H 4-F-Phenyl 838 1 H 2-Cl-Phenyl218 2 H 4-F-Phenyl 839 2 H 2-Cl-Phenyl219 3 H 4-F-Phenyl 840 3 H 2-Cl-Phenyl220 1 Me 4-F-Phenyl 841 1 Me 2-Cl-Phenyl221 2 Me 4-F-Phenyl 842 2 Me 2-Cl-Phenyl222 3 Me 4-F-Phenyl 843 3 Me 2-Cl-Phenyl223 1 CH2Ph 4-F-Phenyl 844 1 CH2Ph 2-Cl-Phenyl224 2 CH2Ph 4-F-Phenyl 845 2 CH2Ph 2-Cl-Phenyl225 3 CH2Ph 4-F-Phenyl 846 3 CH2Ph 2-Cl-Phenyl226 1 COMe 4-F-Phenyl 847 1 COMe 2-Cl-Phenyl227 2 COMe 4-F-Phenyl 848 2 COMe 2-Cl-Phenyl228 3 COMe 4-F-Phenyl 849 3 COMe 2-Cl-Phenyl229 1 C02Me 4-F-Phenyl 850 1 C02Me 2-Cl-Phenyl230 2 C02Me 4-F-Phenyl 851 2 C02Me 2-Cl-Phenyl231 3 C02Me 4-F-Phenyl 852 3 C02Me 2-Cl-Phenyl232 1 C02tBu 4-F-Phenyl 853 1 C02tBu 2-Cl-Phenyl233 2 C02tBu 4-F-Phenyl 854 2 C02tBu 2-Cl-Phenyl234 3 C02tBu 4-F-Phenyl 855 3 C02tBu 2-Cl-Phenyl235 1 CONHMe 4-F-Phenyl 856 1 CONHMe 2-Cl-Phenyl236 2 CONHMe 4-F-Phenyl 857 2 CONHMe 2-Cl-Phenyl237 3 CONHMe 4-F-Phenyl 858 3 CONHMe 2-Cl-Phenyl238 1 S02Me 4-F-Phenyl 859 1 S02Me 2-Cl-Phenyl239 2 S02Me 4-F-Phenyl 860 2 S02Me 2-Cl-Phenyl240 3 S02Me 4-F-Phenyl 861 3 S02Me 2-Cl-Phenyl241 1 S02NH24-F-Phenyl 862 1 S02NH22-Cl-Phenyl242 2 S02NH24-F-Phenyl 863 2 S02NH22-Cl-Phenyl243 3 SO2NH2 4-F-Phenyl 864 3 S02NH22-Cl-Phenyl244 1 H 3-Cl-Phenyl 865 1 H 4-Cl-Phenyl245 2 H 3-Cl-Phenyl 866 2 H 4-Cl-Phenyl246 3 H 3-Cl-Phenyl 867 3 H 4-Cl-Phenyl247 1 Me 3-Cl-Phenyl 868 1 Me 4-Cl-Phenyl248 2 Me 3-Cl-Phenyl 869 2 Me 4-Cl-Phenyl249 3 Me 3-Cl-Phenyl 870 3 Me 4-Cl-Phenyl250 1 CH2Ph 3-Cl-Phenyl 871 1 CH2Ph 4-Cl-Phenyl251 2 CH2Ph 3-Cl-Phenyl 872 2 CH2Ph 4-Cl-Phenyl252 3 CH2Ph 3-Cl-Phenyl 873 3 CH2Ph 4-Cl-Phenyl253 1 COMe 3-Cl-Phenyl 874 1 COMe 4-Cl-Phenyl254 2 COMe 3-Cl-Phenyl 875 2 COMe 4-Cl-Phenyl255 3 COMe 3-Cl-Phenyl 876 3 COMe 4-Cl-Phenyl256 1 C02Me 3-Cl-Phenyl 877 1 C02Me 4-Cl-Phenyl257 2 C02Me 3-Cl-Phenyl 878 2 C02Me 4-Cl-Phenyl258 3 C02Me 3-Cl-Phenyl 879 3 C02Me 4-Cl-Phenyl259 1 C02tBu 3-Cl-Phenyl 880 1 C02tBu 4-Cl-Phenyl260 2 C02tBu 3-Cl-Phenyl 881 2 C02tBu 4-Cl-Phenyl261 3 C02tBu 3-Cl-Phenyl 882 3 C02tBu 4-Cl-Phenyl262 1 CONHMe 3-Cl-Phenyl 883 1 CONHMe 4-Cl-Phenyl263 2 CONHMe 3-Cl-Phenyl 884 2 CONHMe 4-Cl-Phenyl264 3 CONHMe 3-Cl-Phenyl 885 3 CONHMe 4-Cl-Phenyl265 1 S02Me 3-Cl-Phenyl 886 1 S02Me 4-Cl-Phenyl266 2 S02Me 3-Cl-Phenyl 887 2 S02Me 4-Cl-Phenyl267 3 S02Me 3-Cl-Phenyl 888 3 S02Me 4-Cl-Phenyl268 1 S02NH23-Cl-Phenyl 889 1 S02NH24-Cl-Phenyl269 2 SO2NH2 3-Cl-Phenyl 890 2 S02NH24-Cl-Phenyl270 3 SO2NH2 3-Cl-Phenyl 891 3 S02NH24-Cl-Phenyl271 1 H 2-Br-Phenyl 892 1 H 3-Br-Phenyl272 2 H 2-Br-Phenyl 893 2 H 3-Br-Phenyl273 3 H 2-Br-Phenyl 894 3 H 3-Br-Phenyl274 1 Me 2-Br-Phenyl 895 1 Me 3-Br-Phenyl275 2 Me 2-Br-Phenyl 896 2 Me 3-Br-Phenyl276 3 Me 2-Br-Phenyl 897 3 Me 3-Br-Phenyl277 1 CH2Ph 2-Br-Phenyl 898 1 CH2Ph 3-Br-Phenyl278 2 CH2Ph 2-Br-Phenyl 899 2 CH2Ph 3-Br-Phenyl279 3 CH2Ph 2-Br-Phenyl 900 3 CH2Ph 3-Br-Phenyl280 1 COMe 2-Br-Phenyl 901 1 COMe 3-Br-Phenyl281 2 COMe 2-Br-Phenyl 902 2 COMe 3-Br-Phenyl282 3 COMe 2-Br-Phenyl 903 3 COMe 3-Br-Phenyl283 1 C02Me 2-Br-Phenyl 904 1 C02Me 3-Br-Phenyl284 2 C02Me 2-Br-Phenyl 905 2 C02Me 3-Br-Phenyl285 3 C02Me 2-Br-Phenyl 906 3 C02Me 3-Br-Phenyl286 1 C02tBu 2-Br-Phenyl 907 1 C02tBu 3-Br-Phenyl287 2 C02tBu 2-Br-Phenyl 908 2 C02tBu 3-Br-Phenyl288 3 C02tBu 2-Br-Phenyl 909 3 C02tBu 3-Br-Phenyl289 1 CONHMe 2-Br-Phenyl 910 1 CONHMe 3-Br-Phenyl290 2 CONHMe 2-Br-Phenyl 911 2 CONHMe 3-Br-Phenyl291 3 CONHMe 2-Br-Phenyl 912 3 CONHMe 3-Br-Phenyl292 1 S02Me 2-Br-Phenyl 913 1 S02Me 3-Br-Phenyl293 2 S02Me 2-Br-Phenyl 914 2 S02Me 3-Br-Phenyl294 3 S02Me 2-Br-Phenyl 915 3 S02Me 3-Br-Phenyl295 1 SO2NH2 2-Br-Phenyl 916 1 S02NH23-Br-Phenyl296 2 SO2NH2 2-Br-Phenyl 917 2 S02NH23-Br-Phenyl297 3 SO2NH2 2-Br-Phenyl 918 3 S02NH23-Br-Phenyl298 1 H 4-Br-Phenyl 919 1 H 2-CF3-Phenyl299 2 H 4-Br-Phenyl 920 2 H 2-CF3-Phenyl300 3 H 4-Br-Phenyl 921 3 H 2-CF3-Phenyl301 1 Me 4-Br-Phenyl 922 1 Me 2-CF3-Phenyl302 2 Me 4-Br-Phenyl 923 2 Me 2-CF3-Phenyl303 3 Me 4-Br-Phenyl 924 3 Me 2-CF3-Phenyl304 1 CH2Ph 4-Br-Phenyl 925 1 CH2Ph 2-CF3-Phenyl305 2 CH2Ph 4-Br-Phenyl 926 2 CH2Ph 2-CF3-Phenyl306 3 CH2Ph 4-Br-Phenyl 927 3 CH2Ph 2-CF3-Phenyl307 1 COMe 4-Br-Phenyl 928 1 COMe 2-CF3-Phenyl308 2 COMe 4-Br-Phenyl 929 2 COMe 2-CF3-Phenyl309 3 COMe 4-Br-Phenyl 930 3 COMe 2-CF3-Phenyl310 1 C02Me 4-Br-Phenyl 931 1 C02Me 2-CF3-Phenyl311 2 C02Me 4-Br-Phenyl 932 2 C02Me 2-CF3-Phenyl312 3 C02Me 4-Br-Phenyl 933 3 C02Me 2-CF3-Phenyl313 1 C02tBu 4-Br-Phenyl 934 1 C02tBu 2-CF3-Phenyl314 2 C02tBu 4-Br-Phenyl 935 2 C02tBu 2-CF3-Phenyl315 3 C02tBu 4-Br-Phenyl 936 3 C02tBu 2-CF3-Phenyl316 1 CONHMe 4-Br-Phenyl 937 1 CONHMe 2-CF3-Phenyl317 2 CONHMe 4-Br-Phenyl 938 2 CONHMe 2-CF3-Phenyl318 3 CONHMe 4-Br-Phenyl 939 3 CONHMe 2-CF3-Phenyl319 1 S02Me 4-Br-Phenyl 940 1 S02Me 2-CF3-Phenyl320 2 S02Me 4-Br-Phenyl 941 2 S02Me 2-CF3-Phenyl321 3 S02Me 4-Br-Phenyl 942 3 S02Me 2-CF3-Phenyl322 1 SO2NH2 4-Br-Phenyl 943 1 S02NH22-CF3-Phenyl323 2 SO2NH2 4-Br-Phenyl 944 2 S02NH22-CF3-Phenyl324 3 SO2NH2 4-Br-Phenyl 945 3 S02NH22-CF3-Phenyl325 1 H 3-CF3-Phenyl 946 1 H 4-CF3-Phenyl326 2 H 3-CF3-Phenyl 947 2 H 4-CF3-Phenyl327 3 H 3-CF3-Phenyl 948 3 H 4-CF3-Phenyl328 1 Me 3-CF3-Phenyl 949 1 Me 4-CF3-Phenyl329 2 Me 3-CF3-Phenyl 950 2 Me 4-CF3-Phenyl330 3 Me 3-CF3-Phenyl 951 3 Me 4-CF3-Phenyl331 1 CH2Ph 3-CF3-Phenyl 952 1 CH2Ph 4-CF3-Phenyl332 2 CH2Ph 3-CF3-Phenyl 953 2 CH2Ph 4-CF3-Phenyl333 3 CH2Ph 3-CF3-Phenyl 954 3 CH2Ph 4-CF3-Phenyl334 1 COMe 3-CF3-Phenyl 955 1 COMe 4-CF3-Phenyl335 2 COMe 3-CF3-Phenyl 956 2 COMe 4-CF3-Phenyl336 3 COMe 3-CF3-Phenyl 957 3 COMe 4-CF3-Phenyl337 1 C02Me 3-CF3-Phenyl 958 1 C02Me 4-CF3-Phenyl338 2 C02Me 3-CF3-Phenyl 959 2 C02Me 4-CF3-Phenyl339 3 C02Me 3-CF3-Phenyl 960 3 C02Me 4-CF3-Phenyl340 1 C02tBu 3-CF3-Phenyl 961 1 C02tBu 4-CF3-Phenyl341 2 C02tBu 3-CF3-Phenyl 962 2 C02tBu 4-CF3-Phenyl342 3 C02tBu 3-CF3-Phenyl 963 3 C02tBu 4-CF3-Phenyl343 1 CONHMe 3-CF3-Phenyl 964 1 CONHMe 4-CF3-Phenyl344 2 CONHMe 3-CF3-Phenyl 965 2 CONHMe 4-CF3-Phenyl345 3 CONHMe 3-CF3-Phenyl 966 3 CONHMe 4-CF3-Phenyl346 1 S02Me 3-CF3-Phenyl 967 1 S02Me 4-CF3-Phenyl347 2 S02Me 3-CF3-Phenyl 968 2 S02Me 4-CF3-Phenyl348 3 S02Me 3-CF3-Phenyl 969 3 S02Me 4-CF3-Phenyl349 1 SO2NH2 3-CF3-Phenyl 970 1 S02NH24-CF3-Phenyl350 2 SO2NH2 3-CF3-Phenyl 971 2 S02NH24-CF3-Phenyl351 3 SO2NH2 3-CF3-Phenyl 972 3 S02NH24-CF3-Phenyl352 1 H 2-iPr-Phenyl 973 1 H 3-iPr-Phenyl353 2 H 2-iPr-Phenyl 974 2 H 3-iPr-Phenyl354 3 H 2-iPr-Phenyl 975 3 H 3-iPr-Phenyl355 1 Me 2-iPr-Phenyl 976 1 Me 3-iPr-Phenyl356 2 Me 2-iPr-Phenyl 977 2 Me 3-iPr-Phenyl357 3 Me 2-iPr-Phenyl 978 3 Me 3-iPr-Phenyl358 1 CH2Ph 2-iPr-Phenyl 979 1 CH2Ph 3-iPr-Phenyl359 2 CH2Ph 2-iPr-Phenyl 980 2 CH2Ph 3-iPr-Phenyl360 3 CH2Ph 2-iPr-Phenyl 981 3 CH2Ph 3-iPr-Phenyl361 1 COMe 2-iPr-Phenyl 982 1 COMe 3-iPr-Phenyl362 2 COMe 2-iPr-Phenyl 983 2 COMe 3-iPr-Phenyl363 3 COMe 2-iPr-Phenyl 984 3 COMe 3-iPr-Phenyl364 1 C02Me 2-iPr-Phenyl 985 1 C02Me 3-iPr-Phenyl365 2 C02Me 2-iPr-Phenyl 986 2 C02Me 3-iPr-Phenyl366 3 C02Me 2-iPr-Phenyl 987 3 C02Me 3-iPr-Phenyl367 1 C02tBu 2-iPr-Phenyl 988 1 C02tBu 3-iPr-Phenyl368 2 C02tBu 2-iPr-Phenyl 989 2 C02tBu 3-iPr-Phenyl369 3 C02tBu 2-iPr-Phenyl 990 3 C02tBu 3-iPr-Phenyl370 1 CONHMe 2-iPr-Phenyl 991 1 CONHMe 3-iPr-Phenyl371 2 CONHMe 2-iPr-Phenyl 992 2 CONHMe 3-iPr-Phenyl372 3 CONHMe 2-iPr-Phenyl 993 3 CONHMe 3-iPr-Phenyl373 1 S02Me 2-iPr-Phenyl 994 1 S02Me 3-iPr-Phenyl374 2 S02Me 2-iPr-Phenyl 995 2 S02Me 3-iPr-Phenyl375 3 S02Me 2-iPr-Phenyl 996 3 S02Me 3-iPr-Phenyl376 1 SO2NH2 2-iPr-Phenyl 997 1 S02NH23-iPr-Phenyl377 2 SO2NH2 2-iPr-Phenyl 998 2 S02NH23-iPr-Phenyl378 3 SO2NH2 2-iPr-Phenyl 999 3 S02NH23-iPr-Phenyl379 1 H 4-iPr-Phenyl 1000 1 H 4-NH2-Phenyl380 2 H 4-iPr-Phenyl 1001 2 H 4-NH2-Phenyl381 3 H 4-iPr-Phenyl 1002 3 H 4-NH2-Phenyl382 1 Me 4-iPr-Phenyl 1003 1 Me 4-NH2-Phenyl383 2 Me 4-iPr-Phenyl 1004 2 Me 4-NH2-Phenyl384 3 Me 4-iPr-Phenyl 1005 3 Me 4-NH2-Phenyl385 1 CH2Ph 4-iPr-Phenyl 1006 1 CH2Ph 4-NH2-Phenyl386 2 CH2Ph 4-iPr-Phenyl 1007 2 CH2Ph 4-NH2-Phenyl387 3 CH2Ph 4-iPr-Phenyl 1008 3 CH2Ph 4-NH2-Phenyl388 1 COMe 4-iPr-Phenyl 1009 1 COMe 4-NH2-Phenyl389 2 COMe 4-iPr-Phenyl 1010 2 COMe 4-NH2-Phenyl390 3 COMe 4-iPr-Phenyl 1011 3 COMe 4-NH2-Phenyl391 1 C02Me 4-iPr-Phenyl 1012 1 C02Me 4-NH2-Phenyl392 2 C02Me 4-iPr-Phenyl 1013 2 C02Me 4-NH2-Phenyl393 3 C02Me 4-iPr-Phenyl 1014 3 C02Me 4-NH2-Phenyl394 1 C02tBu 4-iPr-Phenyl 1015 1 C02tBu 4-NH2-Phenyl395 2 C02tBu 4-iPr-Phenyl 1016 2 C02tBu 4-NH2-Phenyl396 3 C02tBu 4-iPr-Phenyl 1017 3 C02tBu 4-NH2-Phenyl397 1 CONHMe 4-iPr-Phenyl 1018 1 CONHMe 4-NH2-Phenyl398 2 CONHMe 4-iPr-Phenyl 1019 2 CONHMe 4-NH2-Phenyl399 3 CONHMe 4-iPr-Phenyl 1020 3 CONHMe 4-NH2-Phenyl400 1 S02Me 4-iPr-Phenyl 1021 1 S02Me 4-NH2-Phenyl401 2 S02Me 4-iPr-Phenyl 1022 2 S02Me 4-NH2-Phenyl402 3 S02Me 4-iPr-Phenyl 1023 3 S02Me 4-NH2-Phenyl403 1 SO2NH2 4-iPr-Phenyl 1024 1 S02NH24-NH2-Phenyl404 2 SO2NH2 4-iPr-Phenyl 1025 2 S02NH24-NH2-Phenyl405 3 SO2NH2 4-iPr-Phenyl 1026 3 S02NH24-NH2-Phenyl406 1 H 3-NH2-Phenyl 1027 1 H 2-NH2-Phenyl407 2 H 3-NH2-Phenyl 1028 2 H 2-NH2-Phenyl408 3 H 3-NH2-Phenyl 1029 3 H 2-NH2-Phenyl409 1 Me 3-NH2-Phenyl 1030 1 Me 2-NH2-Phenyl410 2 Me 3-NH2-Phenyl 1031 2 Me 2-NH2-Phenyl411 3 Me 3-NH2-Phenyl 1032 3 Me 2-NH2-Phenyl412 1 CH2Ph 3-NH2-Phenyl 1033 1 CH2Ph 2-NH2-Phenyl413 2 CH2Ph 3-NH2-Phenyl 1034 2 CH2Ph 2-NH2-Phenyl414 3 CH2Ph 3-NH2-Phenyl 1035 3 CH2Ph 2-NH2-Phenyl415 1 COMe 3-NH2-Phenyl 1036 1 COMe 2-NH2-Phenyl416 2 COMe 3-NH2-Phenyl 1037 2 COMe 2-NH2-Phenyl417 3 COMe 3-NH2-Phenyl 1038 3 COMe 2-NH2-Phenyl418 1 C02Me 3-NH2-Phenyl 1039 1 C02Me 2-NH2-Phenyl419 2 C02Me 3-NH2-Phenyl 1040 2 C02Me 2-NH2-Phenyl420 3 C02Me 3-NH2-Phenyl 1041 3 C02Me 2-NH2-Phenyl421 1 C02tBu 3-NH2-Phenyl 1042 1 C02tBu 2-NH2-Phenyl422 2 C02tBu 3-NH2-Phenyl 1043 2 C02tBu 2-NH2-Phenyl423 3 C02tBu 3-NH2-Phenyl 1044 3 C02tBu 2-NH2-Phenyl424 1 CONHMe 3-NH2-Phenyl 1045 1 CONHMe 2-NH2-Phenyl425 2 CONHMe 3-NH2-Phenyl 1046 2 CONHMe 2-NH2-Phenyl426 3 CONHMe 3-NH2-Phenyl 1047 3 CONHMe 2-NH2-Phenyl427 1 S02Me 3-NH2-Phenyl 1048 1 S02Me 2-NH2-Phenyl428 2 S02Me 3-NH2-Phenyl 1049 2 S02Me 2-NH2-Phenyl429 3 S02Me 3-NH2-Phenyl 1050 3 S02Me 2-NH2-Phenyl430 1 SO2NH2 3-NH2-Phenyl 1051 1 S02NH22-NH2-Phenyl431 2 SO2NH2 3-NH2-Phenyl 1052 2 S02NH22-NH2-Phenyl432 3 SO2NH2 3-NH2-Phenyl 1053 3 S02NH22-NH2-Phenyl433 1 H 2,4-di-Me-Phenyl 1054 1 H 2,6-di-Me-Phenyl434 2 H 2,4-di-Me-Phenyl 1055 2 H 2,6-di-Me-Phenyl435 3 H 2,4-di-Me-Phenyl 1056 3 H 2,6-di-Me-Phenyl436 1 Me 2,4-di-Me-Phenyl 1057 1 Me 2,6-di-Me-Phenyl437 2 Me 2,4-di-Me-Phenyl 1058 2 Me 2,6-di-Me-Phenyl438 3 Me 2,4-di-Me-Phenyl 1059 3 Me 2,6-di-Me-Phenyl439 1 CH2Ph 2,4-di-Me-Phenyl 1060 1 CH2Ph 2,6-di-Me-Phenyl440 2 CH2Ph 2,4-di-Me-Phenyl 1061 2 CH2Ph 2,6-di-Me-Phenyl441 3 CH2Ph 2,4-di-Me-Phenyl 1062 3 CH2Ph 2,6-di-Me-Phenyl442 1 COMe 2,4-di-Me-Phenyl 1063 1 COMe 2,6-di-Me-Phenyl443 2 COMe 2,4-di-Me-Phenyl 1064 2 COMe 2,6-di-Me-Phenyl444 3 COMe 2,4-di-Me-Phenyl 1065 3 COMe 2,6-di-Me-Phenyl445 1 C02Me 2,4-di-Me-Phenyl 1066 1 C02Me 2,6-di-Me-Phenyl446 2 C02Me 2,4-di-Me-Phenyl 1067 2 C02Me 2,6-di-Me-Phenyl447 3 C02Me 2,4-di-Me-Phenyl 1068 3 C02Me 2,6-di-Me-Phenyl448 1 C02tBu 2,4-di-Me-Phenyl 1069 1 C02tBu 2,6-di-Me-Phenyl449 2 C02tBu 2,4-di-Me-Phenyl 1070 2 C02tBu 2,6-di-Me-Phenyl450 3 C02tBu 2,4-di-Me-Phenyl 1071 3 C02tBu 2,6-di-Me-Phenyl451 1 CONHMe 2,4-di-Me-Phenyl 1072 1 CONHMe 2,6-di-Me-Phenyl452 2 CONHMe 2,4-di-Me-Phenyl 1073 2 CONHMe 2,6-di-Me-Phenyl453 3 CONHMe 2,4-di-Me-Phenyl 1074 3 CONHMe 2,6-di-Me-Phenyl454 1 S02Me 2,4-di-Me-Phenyl 1075 1 S02Me 2,6-di-Me-Phenyl455 2 S02Me 2,4-di-Me-Phenyl 1076 2 S02Me 2,6-di-Me-Phenyl456 3 S02Me 2,4-di-Me-Phenyl 1077 3 S02Me 2,6-di-Me-Phenyl457 1 SO2NH2 2,4-di-Me-Phenyl 1078 1 S02NH22,6-di-Me-Phenyl458 2 SO2NH2 2,4-di-Me-Phenyl 1079 2 S02NH22,6-di-Me-Phenyl459 3 SO2NH2 2,4-di-Me-Phenyl 1080 3 S02NH22,6-di-Me-Phenyl460 1 H 2,6-di-iPr-Phenyl 1081 1 H 2-Ph-Phenyl461 2 H 2,6-di-iPr-Phenyl 1082 2 H 2-Ph-Phenyl462 3 H 2,6-di-iPr-Phenyl 1083 3 H 2-Ph-Phenyl463 1 Me 2,6-di-iPr-Phenyl 1084 1 Me 2-Ph-Phenyl464 2 Me 2,6-di-iPr-Phenyl 1085 2 Me 2-Ph-Phenyl465 3 Me 2,6-di-iPr-Phenyl 1086 3 Me 2-Ph-Phenyl466 1 CH2Ph 2,6-di-iPr-Phenyl 1087 1 CH2Ph 2-Ph-Phenyl467 2 CH2Ph 2,6-di-iPr-Phenyl 1088 2 CH2Ph 2-Ph-Phenyl468 3 CH2Ph 2,6-di-iPr-Phenyl 1089 3 CH2Ph 2-Ph-Phenyl469 1 COMe 2,6-di-iPr-Phenyl 1090 1 COMe 2-Ph-Phenyl470 2 COMe 2,6-di-iPr-Phenyl 1091 2 COMe 2-Ph-Phenyl471 3 COMe 2,6-di-iPr-Phenyl 1092 3 COMe 2-Ph-Phenyl472 1 C02Me 2,6-di-iPr-Phenyl 1093 1 C02Me 2-Ph-Phenyl473 2 C02Me 2,6-di-iPr-Phenyl 1094 2 C02Me 2-Ph-Phenyl474 3 C02Me 2,6-di-iPr-Phenyl 1095 3 C02Me 2-Ph-Phenyl475 1 C02tBu 2,6-di-iPr-Phenyl 1096 1 C02tBu 2-Ph-Phenyl476 2 C02tBu 2,6-di-iPr-Phenyl 1097 2 C02tBu 2-Ph-Phenyl477 3 C02tBu 2,6-di-iPr-Phenyl 1098 3 C02tBu 2-Ph-Phenyl478 1 CONHMe 2,6-di-iPr-Phenyl 1099 1 CONHMe 2-Ph-Phenyl479 2 CONHMe 2,6-di-iPr-Phenyl 1100 2 CONHMe 2-Ph-Phenyl480 3 CONHMe 2,6-di-iPr-Phenyl 1101 3 CONHMe 2-Ph-Phenyl481 1 S02Me 2,6-di-iPr-Phenyl 1102 1 S02Me 2-Ph-Phenyl482 2 S02Me 2,6-di-iPr-Phenyl 1103 2 S02Me 2-Ph-Phenyl483 3 S02Me 2,6-di-iPr-Phenyl 1104 3 S02Me 2-Ph-Phenyl484 1 S02NH22,6-di-iPr-Phenyl 1105 1 S02NH22-Ph-Phenyl485 2 S02NH22,6-di-iPr-Phenyl 1106 2 S02NH22-Ph-Phenyl486 3 S02NH22,6-di-iPr-Phenyl 1107 3 S02NH22-Ph-Phenyl487 1 H 3-Ph-Phenyl 1108 1 H 4-Ph-Phenyl488 2 H 3-Ph-Phenyl 1109 2 H 4-Ph-Phenyl489 3 H 3-Ph-Phenyl 1110 3 H 4-Ph-Phenyl490 1 Me 3-Ph-Phenyl 1111 1 Me 4-Ph-Phenyl491 2 Me 3-Ph-Phenyl 1112 2 Me 4-Ph-Phenyl492 3 Me 3-Ph-Phenyl 1113 3 Me 4-Ph-Phenyl493 1 CH2Ph 3-Ph-Phenyl 1114 1 CH2Ph 4-Ph-Phenyl494 2 CH2Ph 3-Ph-Phenyl 1115 2 CH2Ph 4-Ph-Phenyl495 3 CH2Ph 3-Ph-Phenyl 1116 3 CH2Ph 4-Ph-Phenyl496 1 COMe 3-Ph-Phenyl 1117 1 COMe 4-Ph-Phenyl497 2 COMe 3-Ph-Phenyl 1118 2 COMe 4-Ph-Phenyl498 3 COMe 3-Ph-Phenyl 1119 3 COMe 4-Ph-Phenyl499 1 C02Me 3-Ph-Phenyl 1120 1 C02Me 4-Ph-Phenyl500 2 C02Me 3-Ph-Phenyl 1121 2 C02Me 4-Ph-Phenyl501 3 C02Me 3-Ph-Phenyl 1122 3 C02Me 4-Ph-Phenyl502 1 C02tBu 3-Ph-Phenyl 1123 1 C02tBu 4-Ph-Phenyl503 2 C02tBu 3-Ph-Phenyl 1124 2 C02tBu 4-Ph-Phenyl504 3 C02tBu 3-Ph-Phenyl 1125 3 C02tBu 4-Ph-Phenyl505 1 CONHMe 3-Ph-Phenyl 1126 1 CONHMe 4-Ph-Phenyl506 2 CONHMe 3-Ph-Phenyl 1127 2 CONHMe 4-Ph-Phenyl507 3 CONHMe 3-Ph-Phenyl 1128 3 CONHMe 4-Ph-Phenyl508 1 S02Me 3-Ph-Phenyl 1129 1 S02Me 4-Ph-Phenyl509 2 S02Me 3-Ph-Phenyl 1130 2 S02Me 4-Ph-Phenyl510 3 S02Me 3-Ph-Phenyl 1131 3 S02Me 4-Ph-Phenyl511 1 S02NH23-Ph-Phenyl 1132 1 S02NH24-Ph-Phenyl512 2 S02NH23-Ph-Phenyl 1133 2 S02NH24-Ph-Phenyl513 3 S02NH23-Ph-Phenyl 1134 3 S02NH24-Ph-Phenyl514 1 H 2-morpholino-phenyl 1135 1 H 3 -morpholino -pheny 1515 2 H 2-morpholino-phenyl 1136 2 H 3 -moφholino -pheny 1516 3 H 2-morpholino-phenyl 1137 3 H 3 -morpholino -pheny 1517 1 Me 2 -morpholino-pheny 1 1138 1 Me 3 -morpholino -pheny 1518 2 Me 2 -morpholino-pheny 1 1139 2 Me 3 -morpholino -pheny 1519 3 Me 2 -morpholino-pheny 1 1140 3 Me 3 -morpholino -pheny 1520 1 CH2Ph 2-morpholino-phenyl 1141 1 CH2Ph 3 -morpholino -pheny 1521 2 CH2Ph 2-morpholino-phenyl 1142 2 CH2Ph 3 -morpholino -pheny 1522 3 CH2Ph 2-morpholino-phenyl 1143 3 CH2Ph 3 -morpholino -pheny 1523 1 COMe 2 -morpholino-pheny 1 1144 1 COMe 3-morpholino-phenyl524 2 COMe 2 -morpholino-pheny 1 1145 2 COMe 3-morpholino-phenyl525 3 COMe 2 -morpholino-pheny 1 1146 3 COMe 3-morpholino-phenyl526 1 C02Me 2 -morpholino-pheny 1 1147 1 C02Me 3-morpholino-phenyl527 2 C02Me 2 -morpholino-pheny 1 1148 2 C02Me 3-morpholino-phenyl528 3 C02Me 2 -morpholino-pheny 1 1149 3 C02Me 3-morpholino-phenyl529 1 C02tBu 2-morpholino-phenyl 1150 1 C02tBu 3 -morpholino -pheny 1530 2 C02tBu 2-morpholino-phenyl 1151 2 C02tBu 3 -morpholino -pheny 1531 3 C02tBu 2-morpholino-phenyl 1152 3 C02tBu 3 -morpholino -pheny 1532 1 CONHMe 2-morpholino-phenyl 1153 1 CONHMe 3 -morpholino-pheny 1533 2 CONHMe 2-morpholino-phenyl 1154 2 CONHMe 3 -morpholino-pheny 1534 3 CONHMe 2-morpholino-phenyl 1155 3 CONHMe 3 -morpholino-pheny 1535 1 S02Me 2 -morpholino-pheny 1 1156 1 S02Me 3 -morpholino-pheny 1536 2 S02Me 2 -morpholino-pheny 1 1157 2 S02Me 3 -morpholino -pheny 1537 3 S02Me 2 -morpholino-pheny 1 1158 3 S02Me 3 -morpholino -pheny 1538 1 S02NH22-morpholino-phenyl 1159 1 S02NH23 -morpholino -pheny 1539 2 S02NH22-morpholino-phenyl 1160 2 S02NH23 -morpholino -pheny 1540 3 S02NH22-morpholino-phenyl 1161 3 S02NH23 -morpholino -pheny 1541 1 H 4-morpholino-phenyl 1162 1 H 2-pyrazinyl542 2 H 4-morpholino-phenyl 1163 2 H 2-pyrazinyl543 3 H 4-morpholino-phenyl 1164 3 H 2-pyrazinyl544 1 Me 4 -morpholino-pheny 1 1165 1 Me 2-pyrazinyl545 2 Me 4 -morpholino-pheny 1 1166 2 Me 2-pyrazinyl546 3 Me 4 -morpholino-pheny 1 1167 3 Me 2-pyrazinyl547 1 CH2Ph 4-morpholino-phenyl 1168 1 CH2Ph 2-pyrazinyl548 2 CH2Ph 4-morpholino-phenyl 1169 2 CH2Ph 2-pyrazinyl549 3 CH2Ph 4-morpholino-phenyl 1170 3 CH2Ph 2-pyrazinyl550 1 COMe 4 -morpholino-pheny 1 1171 1 COMe 2-pyrazinyl551 2 COMe 4 -morpholino-pheny 1 1172 2 COMe 2-pyrazinyl552 3 COMe 4 -morpholino-pheny 1 1173 3 COMe 2-pyrazinyl553 1 C02Me 4 -morpholino-pheny 1 1174 1 C02Me 2-pyrazinyl554 2 C02Me 4 -morpholino-pheny 1 1175 2 C02Me 2-pyrazinyl555 3 C02Me 4 -morpholino-pheny 1 1176 3 C02Me 2-pyrazinyl556 1 C02tBu 4-morpholino-phenyl 1177 1 C02tBu 2-pyrazinyl557 2 C02tBu 4-morpholino-phenyl 1178 2 C02tBu 2-pyrazinyl558 3 C02tBu 4-morpholino-phenyl 1179 3 C02tBu 2-pyrazinyl559 1 CONHMe 4-morpholino-phenyl 1180 1 CONHMe 2-pyrazinyl560 2 CONHMe 4-morpholino-phenyl 1181 2 CONHMe 2-pyrazinyl561 3 CONHMe 4-morpholino-phenyl 1182 3 CONHMe 2-pyrazinyl562 1 S02Me 4 -morpholino-pheny 1 1183 1 S02Me 2-pyrazinyl563 2 S02Me 4 -morpholino-pheny 1 1184 2 S02Me 2-pyrazinyl564 3 S02Me 4 -morpholino-pheny 1 1185 3 S02Me 2-pyrazinyl565 1 S02NH24-morpholino-phenyl 1186 1 S02NH22-pyrazinyl566 2 S02NH24-morpholino-phenyl 1187 2 S02NH22-pyrazinyl567 3 S02NH24-morpholino-phenyl 1188 3 S02NH22-pyrazinyl568 1 H 2-pyrimidinyl 1189 1 H 5-indolyl569 2 H 2-pyrimidinyl 1190 2 H 5-indolyl570 3 H 2-pyrimidinyl 1191 3 H 5-indolyl571 1 Me 2-pyrimidinyl 1192 1 Me 5-indolyl572 2 Me 2-pyrimidinyl 1193 2 Me 5-indolyl573 3 Me 2-pyrimidinyl 1194 3 Me 5-indolyl574 1 CH2Ph 2-pyrimidinyl 1195 1 CH2Ph 5-indolyl575 2 CH2Ph 2-pyrimidinyl 1196 2 CH2Ph 5-indolyl576 3 CH2Ph 2-pyrimidinyl 1197 3 CH2Ph 5-indolyl577 1 COMe 2-pyrimidinyl 1198 1 COMe 5-indolyl578 2 COMe 2-pyrimidinyl 1199 2 COMe 5-indolyl579 3 COMe 2-pyrimidinyl 1200 3 COMe 5-indolyl580 1 C02Me 2-pyrimidinyl 1201 1 C02Me 5-indolyl581 2 C02Me 2-pyrimidinyl 1202 2 C02Me 5-indolyl582 3 C02Me 2-pyrimidinyl 1203 3 C02Me 5-indolyl583 1 C02tBu 2-pyrimidinyl 1204 1 C02tBu 5-indolyl584 2 C02tBu 2-pyrimidinyl 1205 2 C02tBu 5-indolyl585 3 C02tBu 2-pyrimidinyl 1206 3 C02tBu 5-indolyl586 1 CONHMe 2-pyrimidinyl 1207 1 CONHMe 5-indolyl587 2 CONHMe 2-pyrimidinyl 1208 2 CONHMe 5-indolyl588 3 CONHMe 2-pyrimidinyl 1209 3 CONHMe 5-indolyl589 1 S02Me 2-pyrimidinyl 1210 1 S02Me 5-indolyl590 2 S02Me 2-pyrimidinyl 1211 2 S02Me 5-indolyl591 3 S02Me 2-pyrimidinyl 1212 3 S02Me 5-indolyl592 1 S02NH22-pyrimidinyl 1213 1 S02NH25-indolyl593 2 S02NH22-pyrimidinyl 1214 2 S02NH25-indolyl594 3 S02NH22-pyrimidinyl 1215 3 S02NH25-indolyl595 1 H 2-methyl-lH- 1216 1 H 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl596 2 H 2-methyl-lH- 1217 2 H 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl597 3 H 2-methyl-lH- 1218 3 H 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl598 1 Me 2-methyl-lH- 1219 1 Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl599 2 Me 2-methyl-lH- 1220 2 Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl600 3 Me 2-methyl-lH- 1221 3 Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl601 1 CH2Ph 2-methyl-lH- 1222 1 CH2Ph 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl602 2 CH2Ph 2-methyl-lH- 1223 2 CH2Ph 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl603 3 CH2Ph 2-methyl-lH- 1224 3 CH2Ph 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl604 1 COMe 2-methyl-lH- 1225 1 COMe 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl605 2 COMe 2-methyl-lH- 1226 2 COMe 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl606 3 COMe 2-methyl-lH- 1227 3 COMe 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl607 1 C02Me 2-methyl-lH- 1228 1 C02Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl608 2 C02Me 2-methyl-lH- 1229 2 C02Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl609 3 C02Me 2-methyl-lH- 1230 3 C02Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl610 1 C02tBu 2-methyl-lH- 1231 1 C02tBu 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl611 2 C02tBu 2-methyl-lH- 1232 2 C02tBu 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl612 3 C02tBu 2-methyl-lH- 1233 3 C02tBu 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl613 1 CONHMe 2-methyl-lH- 1234 1 CONHMe 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl614 2 CONHMe 2-methyl-lH- 1235 2 CONHMe 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl615 3 CONHMe 2-methyl-lH- 1236 3 CONHMe 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl616 1 S02Me 2-methyl-lH- 1237 1 S02Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl617 2 S02Me 2-methyl-lH- 1238 2 S02Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl618 3 S02Me 2-methyl-lH- 1239 3 S02Me 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl619 1 S02NH22-methyl-lH- 1240 1 S02NH21 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl620 2 SO2NH2 2-methyl-lH- 1241 2 SO2NH2 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl621 3 SO2NH2 2-methyl-lH- 1242 3 SO2NH2 1 H-benzo [d] imidazol- benzo [d] imidazol-4-y 1 4-yl
[0328] Exemplary embodiments include compounds having the formula (XIX)or a pharmaceutically acceptable salt form thereof defined herein below in Table 3.Table 32 C02tBu H H H H3 C02tBu H H H H1 CONHMe H H H H2 CONHMe H H H H3 CONHMe H H H H1 S02Me H H H H2 S02Me H H H H3 S02Me H H H H1 S02NH2H H H H2 S02NH2H H H H3 S02NH2H H H H1 H H H OH H2 H H H OH H3 H H H OH H1 Me H H OH H2 Me H H OH H3 Me H H OH H1 CH2Ph H H OH H2 CH2Ph H H OH H3 CH2Ph H H OH H1 COMe H H OH H2 COMe H H OH H3 COMe H H OH H1 C02Me H H OH H2 C02Me H H OH H3 C02Me H H OH H1 C02tBu H H OH H2 C02tBu H H OH H3 C02tBu H H OH H1 CONHMe H H OH H2 CONHMe H H OH H3 CONHMe H H OH H1 S02Me H H OH H2 S02Me H H OH H3 S02Me H H OH H1 S02NH2H H OH H2 S02NH2H H OH H3 S02NH2H H OH H1 H H H OMe H2 H H H OMe H3 H H H OMe H1 Me H H OMe H2 Me H H OMe H3 Me H H OMe H1 CH2Ph H H OMe H2 CH2Ph H H OMe H3 CH2Ph H H OMe H1 COMe H H OMe H2 COMe H H OMe H3 COMe H H OMe H1 C02Me H H OMe H2 C02Me H H OMe H3 C02Me H H OMe H1 C02tBu H H OMe H2 C02tBu H H OMe H3 C02tBu H H OMe H1 CONHMe H H OMe H2 CONHMe H H OMe H3 CONHMe H H OMe H1 S02Me H H OMe H2 S02Me H H OMe H3 S02Me H H OMe H1 S02NH2H H OMe H2 S02NH2H H OMe H3 S02NH2H H OMe H1 H H H Me H2 H H H Me H3 H H H Me H1 Me H H Me H2 Me H H Me H3 Me H H Me H1 CH2Ph H H Me H2 CH2Ph H H Me H3 CH2Ph H H Me H1 COMe H H Me H2 COMe H H Me H3 COMe H H Me H1 C02Me H H Me H95 2 C02Me H H Me H96 3 C02Me H H Me H97 1 C02tBu H H Me H98 2 C02tBu H H Me H99 3 C02tBu H H Me H100 1 CONHMe H H Me H101 2 CONHMe H H Me H102 3 CONHMe H H Me H103 1 S02Me H H Me H104 2 S02Me H H Me H105 3 S02Me H H Me H106 1 S02NH2H H Me H107 2 S02NH2H H Me H108 3 S02NH2H H Me H109 1 H H H CF3H110 2 H H H CF3H111 3 H H H CF3H112 1 Me H H CF3H113 2 Me H H CF3H114 3 Me H H CF3H115 1 CH2Ph H H CF3H116 2 CH2Ph H H CF3H117 3 CH2Ph H H CF3H118 1 COMe H H CF3H119 2 COMe H H CF3H120 3 COMe H H CF3H121 1 C02Me H H CF3H122 2 C02Me H H CF3H123 3 C02Me H H CF3H124 1 C02tBu H H CF3H125 2 C02tBu H H CF3H126 3 C02tBu H H CF3H127 1 CONHMe H H CF3H128 2 CONHMe H H CF3H129 3 CONHMe H H CF3H130 1 S02Me H H CF3H131 2 S02Me H H CF3H132 3 S02Me H H CF3H133 1 S02NH2H H CF3H134 2 S02NH2H H CF3H135 3 S02NH2H H CF3H136 1 H H H F H137 2 H H H F H138 3 H H H F H139 1 Me H H F H140 2 Me H H F H141 3 Me H H F H142 1 CH2Ph H H F H143 2 CH2Ph H H F H144 3 CH2Ph H H F H145 1 COMe H H F H146 2 COMe H H F H147 3 COMe H H F H148 1 C02Me H H F H149 2 C02Me H H F H150 3 C02Me H H F H151 1 C02tBu H H F H152 2 C02tBu H H F H153 3 C02tBu H H F H154 1 CONHMe H H F H155 2 CONHMe H H F H156 3 CONHMe H H F H157 1 S02Me H H F H158 2 S02Me H H F H159 3 S02Me H H F H160 1 S02NH2H H F H161 2 S02NH2H H F H162 3 S02NH2H H F H163 1 H H H CI H164 2 H H H CI H165 3 H H H CI H166 1 Me H H CI H167 2 Me H H CI H168 3 Me H H CI H169 1 CH2Ph H H CI H170 2 CH2Ph H H CI H171 3 CH2Ph H H CI H172 1 COMe H H CI H173 2 COMe H H CI H174 3 COMe H H CI H175 1 C02Me H H CI H176 2 C02Me H H CI H177 3 C02Me H H CI H178 1 C02tBu H H CI H179 2 C02tBu H H CI H180 3 C02tBu H H CI H181 1 CONHMe H H CI H182 2 CONHMe H H CI H183 3 CONHMe H H CI H184 1 S02Me H H CI H185 2 S02Me H H CI H186 3 S02Me H H CI H187 1 S02NH2H H CI H188 2 S02NH2H H CI H189 3 S02NH2H H CI H190 1 H H H CN H191 2 H H H CN H192 3 H H H CN H193 1 Me H H CN H194 2 Me H H CN H195 3 Me H H CN H196 1 CH2Ph H H CN H197 2 CH2Ph H H CN H198 3 CH2Ph H H CN H199 1 COMe H H CN H200 2 COMe H H CN H201 3 COMe H H CN H202 1 C02Me H H CN H203 2 C02Me H H CN H204 3 C02Me H H CN H205 1 C02tBu H H CN H206 2 C02tBu H H CN H207 3 C02tBu H H CN H208 1 CONHMe H H CN H209 2 CONHMe H H CN H210 3 CONHMe H H CN H111 1 S02Me H H CN H212 2 S02Me H H CN H213 3 S02Me H H CN H214 1 S02NH2H H CN H215 2 S02NH2H H CN H216 3 S02NH2H H CN H217 1 H H OH H H218 2 H H OH H H219 3 H H OH H H220 1 Me H OH H H221 2 Me H OH H H222 3 Me H OH H H223 1 CH2Ph H OH H H224 2 CH2Ph H OH H H225 3 CH2Ph H OH H H226 1 COMe H OH H H227 2 COMe H OH H H228 3 COMe H OH H H229 1 C02Me H OH H H230 2 C02Me H OH H H231 3 C02Me H OH H H232 1 C02tBu H OH H H233 2 C02tBu H OH H H234 3 C02tBu H OH H H235 1 CONHMe H OH H H236 2 CONHMe H OH H H237 3 CONHMe H OH H H238 1 S02Me H OH H H239 2 S02Me H OH H H240 3 S02Me H OH H H241 1 S02NH2H OH H H242 2 S02NH2H OH H H243 3 S02NH2H OH H H244 1 H H OMe H H245 2 H H OMe H H246 3 H H OMe H H247 1 Me H OMe H H248 2 Me H OMe H H249 3 Me H OMe H H250 1 CH2Ph H OMe H H251 2 CH2Ph H OMe H H252 3 CH2Ph H OMe H H253 1 COMe H OMe H H254 2 COMe H OMe H H255 3 COMe H OMe H H256 1 C02Me H OMe H H257 2 C02Me H OMe H H258 3 C02Me H OMe H H259 1 C02tBu H OMe H H260 2 C02tBu H OMe H H261 3 C02tBu H OMe H H262 1 CONHMe H OMe H H263 2 CONHMe H OMe H H264 3 CONHMe H OMe H H265 1 S02Me H OMe H H266 2 S02Me H OMe H H267 3 S02Me H OMe H H268 1 S02NH2H OMe H H269 2 S02NH2H OMe H H270 3 S02NH2H OMe H H271 1 H H Me H H272 2 H H Me H H273 3 H H Me H H274 1 Me H Me H H275 2 Me H Me H H276 3 Me H Me H H277 1 CH2Ph H Me H H278 2 CH2Ph H Me H H279 3 CH2Ph H Me H H280 1 COMe H Me H H281 2 COMe H Me H H282 3 COMe H Me H H283 1 C02Me H Me H H284 2 C02Me H Me H H285 3 C02Me H Me H H286 1 C02tBu H Me H H287 2 C02tBu H Me H H288 3 C02tBu H Me H H289 1 CONHMe H Me H H290 2 CONHMe H Me H H291 3 CONHMe H Me H H292 1 S02Me H Me H H293 2 S02Me H Me H H294 3 S02Me H Me H H295 1 S02NH2H Me H H296 2 S02NH2H Me H H297 3 S02NH2H Me H H298 1 H H CF3H H299 2 H H CF3H H300 3 H H CF3H H301 1 Me H CF3H H302 2 Me H CF3H H303 3 Me H CF3H H304 1 CH2Ph H CF3H H305 2 CH2Ph H CF3H H306 3 CH2Ph H CF3H H307 1 COMe H CF3H H308 2 COMe H CF3H H309 3 COMe H CF3H H310 1 C02Me H CF3H H311 2 C02Me H CF3H H312 3 C02Me H CF3H H313 1 C02tBu H CF3H H314 2 C02tBu H CF3H H315 3 C02tBu H CF3H H316 1 CONHMe H CF3H H317 2 CONHMe H CF3H H318 3 CONHMe H CF3H H319 1 S02Me H CF3H H320 2 S02Me H CF3H H321 3 S02Me H CF3H H322 1 S02NH2H CF3H H323 2 S02NH2H CF3H H324 3 S02NH2H CF3H H325 1 H H F H H326 2 H H F H H327 3 H H F H H328 1 Me H F H H329 2 Me H F H H330 3 Me H F H H331 1 CH2Ph H F H H332 2 CH2Ph H F H H333 3 CH2Ph H F H H334 1 COMe H F H H335 2 COMe H F H H336 3 COMe H F H H337 1 C02Me H F H H338 2 C02Me H F H H339 3 C02Me H F H H340 1 C02tBu H F H H341 2 C02tBu H F H H342 3 C02tBu H F H H343 1 CONHMe H F H H344 2 CONHMe H F H H345 3 CONHMe H F H H346 1 S02Me H F H H347 2 S02Me H F H H348 3 S02Me H F H H349 1 S02NH2H F H H350 2 S02NH2H F H H351 3 S02NH2H F H H352 1 H H CI H H353 2 H H CI H H354 3 H H CI H H355 1 Me H CI H H356 2 Me H CI H H357 3 Me H CI H H358 1 CH2Ph H CI H H359 2 CH2Ph H CI H H360 3 CH2Ph H CI H H361 1 COMe H CI H H362 2 COMe H CI H H363 3 COMe H CI H H364 1 C02Me H CI H H365 2 C02Me H CI H H366 3 C02Me H CI H H367 1 C02tBu H CI H H368 2 C02tBu H CI H H369 3 C02tBu H CI H H370 1 CONHMe H CI H H371 2 CONHMe H CI H H372 3 CONHMe H CI H H373 1 S02Me H CI H H374 2 S02Me H CI H H375 3 S02Me H CI H H376 1 S02NH2H CI H H377 2 S02NH2H CI H H378 3 S02NH2H CI H H379 1 H H CN H H380 2 H H CN H H381 3 H H CN H H382 1 Me H CN H H383 2 Me H CN H H384 3 Me H CN H H385 1 CH2Ph H CN H H386 2 CH2Ph H CN H H387 3 CH2Ph H CN H H388 1 COMe H CN H H389 2 COMe H CN H H390 3 COMe H CN H H391 1 C02Me H CN H H392 2 C02Me H CN H H393 3 C02Me H CN H H394 1 C02tBu H CN H H395 2 C02tBu H CN H H396 3 C02tBu H CN H H397 1 CONHMe H CN H H398 2 CONHMe H CN H H399 3 CONHMe H CN H H400 1 S02Me H CN H H401 2 S02Me H CN H H402 3 S02Me H CN H H403 1 S02NH2H CN H H404 2 S02NH2H CN H H405 3 S02NH2H CN H H Exemplary embodiments include compounds having the formula (XX)or a pharmaceutically acceptable salt form thereof defined herein below in Table 4.Table 4126 3 C02tBu H H CF3H127 1 CONHMe H H CF3H128 2 CONHMe H H CF3H129 3 CONHMe H H CF3H130 1 S02Me H H CF3H131 2 S02Me H H CF3H132 3 S02Me H H CF3H133 1 S02NH2H H CF3H134 2 S02NH2H H CF3H135 3 S02NH2H H CF3H136 1 H H H F H137 2 H H H F H138 3 H H H F H139 1 Me H H F H140 2 Me H H F H141 3 Me H H F H142 1 CH2Ph H H F H143 2 CH2Ph H H F H144 3 CH2Ph H H F H145 1 COMe H H F H146 2 COMe H H F H147 3 COMe H H F H148 1 C02Me H H F H149 2 C02Me H H F H150 3 C02Me H H F H151 1 C02tBu H H F H152 2 C02tBu H H F H153 3 C02tBu H H F H154 1 CONHMe H H F H155 2 CONHMe H H F H156 3 CONHMe H H F H157 1 S02Me H H F H158 2 S02Me H H F H159 3 S02Me H H F H160 1 S02NH2H H F H161 2 S02NH2H H F H162 3 S02NH2H H F H163 1 H H H CI H164 2 H H H CI H165 3 H H H CI H166 1 Me H H CI H167 2 Me H H CI H168 3 Me H H CI H169 1 CH2Ph H H CI H170 2 CH2Ph H H CI H171 3 CH2Ph H H CI H172 1 COMe H H CI H173 2 COMe H H CI H174 3 COMe H H CI H175 1 C02Me H H CI H176 2 C02Me H H CI H177 3 C02Me H H CI H178 1 C02tBu H H CI H179 2 C02tBu H H CI H180 3 C02tBu H H CI H181 1 CONHMe H H CI H182 2 CONHMe H H CI H183 3 CONHMe H H CI H184 1 S02Me H H CI H185 2 S02Me H H CI H186 3 S02Me H H CI H187 1 S02NH2H H CI H188 2 S02NH2H H CI H189 3 S02NH2H H CI H190 1 H H H CN H191 2 H H H CN H192 3 H H H CN H193 1 Me H H CN H194 2 Me H H CN H195 3 Me H H CN H196 1 CH2Ph H H CN H197 2 CH2Ph H H CN H198 3 CH2Ph H H CN H199 1 COMe H H CN H200 2 COMe H H CN H201 3 COMe H H CN H202 1 C02Me H H CN H203 2 C02Me H H CN H204 3 C02Me H H CN H205 1 C02tBu H H CN H206 2 C02tBu H H CN H207 3 C02tBu H H CN H208 1 CONHMe H H CN H209 2 CONHMe H H CN H210 3 CONHMe H H CN H111 1 S02Me H H CN H212 2 S02Me H H CN H213 3 S02Me H H CN H214 1 S02NH2H H CN H215 2 S02NH2H H CN H216 3 S02NH2H H CN H217 1 H H OH H H218 2 H H OH H H219 3 H H OH H H220 1 Me H OH H H221 2 Me H OH H H222 3 Me H OH H H223 1 CH2Ph H OH H H224 2 CH2Ph H OH H H225 3 CH2Ph H OH H H226 1 COMe H OH H H227 2 COMe H OH H H228 3 COMe H OH H H229 1 C02Me H OH H H230 2 C02Me H OH H H231 3 C02Me H OH H H232 1 C02tBu H OH H H233 2 C02tBu H OH H H234 3 C02tBu H OH H H235 1 CONHMe H OH H H236 2 CONHMe H OH H H237 3 CONHMe H OH H H238 1 S02Me H OH H H239 2 S02Me H OH H H240 3 S02Me H OH H H241 1 S02NH2H OH H H242 2 S02NH2H OH H H243 3 S02NH2H OH H H244 1 H H OMe H H245 2 H H OMe H H246 3 H H OMe H H247 1 Me H OMe H H248 2 Me H OMe H H249 3 Me H OMe H H250 1 CH2Ph H OMe H H251 2 CH2Ph H OMe H H252 3 CH2Ph H OMe H H253 1 COMe H OMe H H254 2 COMe H OMe H H255 3 COMe H OMe H H256 1 C02Me H OMe H H257 2 C02Me H OMe H H258 3 C02Me H OMe H H259 1 C02tBu H OMe H H260 2 C02tBu H OMe H H261 3 C02tBu H OMe H H262 1 CONHMe H OMe H H263 2 CONHMe H OMe H H264 3 CONHMe H OMe H H265 1 S02Me H OMe H H266 2 S02Me H OMe H H267 3 S02Me H OMe H H268 1 S02NH2H OMe H H269 2 S02NH2H OMe H H270 3 S02NH2H OMe H H271 1 H H Me H H272 2 H H Me H H273 3 H H Me H H274 1 Me H Me H H275 2 Me H Me H H276 3 Me H Me H H277 1 CH2Ph H Me H H278 2 CH2Ph H Me H H279 3 CH2Ph H Me H H280 1 COMe H Me H H281 2 COMe H Me H H282 3 COMe H Me H H283 1 C02Me H Me H H284 2 C02Me H Me H H285 3 C02Me H Me H H286 1 C02tBu H Me H H287 2 C02tBu H Me H H288 3 C02tBu H Me H H289 1 CONHMe H Me H H290 2 CONHMe H Me H H291 3 CONHMe H Me H H292 1 S02Me H Me H H293 2 S02Me H Me H H294 3 S02Me H Me H H295 1 S02NH2H Me H H296 2 S02NH2H Me H H297 3 S02NH2H Me H H298 1 H H CF3H H299 2 H H CF3H H300 3 H H CF3H H301 1 Me H CF3H H302 2 Me H CF3H H303 3 Me H CF3H H304 1 CH2Ph H CF3H H305 2 CH2Ph H CF3H H306 3 CH2Ph H CF3H H307 1 COMe H CF3H H308 2 COMe H CF3H H309 3 COMe H CF3H H310 1 C02Me H CF3H H311 2 C02Me H CF3H H312 3 C02Me H CF3H H313 1 C02tBu H CF3H H314 2 C02tBu H CF3H H315 3 C02tBu H CF3H H316 1 CONHMe H CF3H H317 2 CONHMe H CF3H H318 3 CONHMe H CF3H H319 1 S02Me H CF3H H320 2 S02Me H CF3H H321 3 S02Me H CF3H H322 1 S02NH2H CF3H H323 2 S02NH2H CF3H H324 3 S02NH2H CF3H H325 1 H H F H H326 2 H H F H H327 3 H H F H H328 1 Me H F H H329 2 Me H F H H330 3 Me H F H H331 1 CH2Ph H F H H332 2 CH2Ph H F H H333 3 CH2Ph H F H H334 1 COMe H F H H335 2 COMe H F H H336 3 COMe H F H H337 1 C02Me H F H H338 2 C02Me H F H H339 3 C02Me H F H H340 1 C02tBu H F H H341 2 C02tBu H F H H342 3 C02tBu H F H H343 1 CONHMe H F H H344 2 CONHMe H F H H345 3 CONHMe H F H H346 1 S02Me H F H H347 2 S02Me H F H H348 3 S02Me H F H H349 1 S02NH2H F H H350 2 S02NH2H F H H351 3 S02NH2H F H H352 1 H H CI H H353 2 H H CI H H354 3 H H CI H H355 1 Me H CI H H356 2 Me H CI H H357 3 Me H CI H H358 1 CH2Ph H CI H H359 2 CH2Ph H CI H H360 3 CH2Ph H CI H H361 1 COMe H CI H H362 2 COMe H CI H H363 3 COMe H CI H H364 1 C02Me H CI H H365 2 C02Me H CI H H366 3 C02Me H CI H H367 1 C02tBu H CI H H368 2 C02tBu H CI H H369 3 C02tBu H CI H H370 1 CONHMe H CI H H371 2 CONHMe H CI H H372 3 CONHMe H CI H H373 1 S02Me H CI H H374 2 S02Me H CI H H375 3 S02Me H CI H H376 1 S02NH2H CI H H377 2 S02NH2H CI H H378 3 S02NH2H CI H H379 1 H H CN H H380 2 H H CN H H381 3 H H CN H H382 1 Me H CN H H383 2 Me H CN H H384 3 Me H CN H H385 1 CH2Ph H CN H H386 2 CH2Ph H CN H H387 3 CH2Ph H CN H H388 1 COMe H CN H H389 2 COMe H CN H H390 3 COMe H CN H H391 1 C02Me H CN H H392 2 C02Me H CN H H393 3 C02Me H CN H H394 1 C02tBu H CN H H395 2 C02tBu H CN H H396 3 C02tBu H CN H H397 1 CONHMe H CN H H398 2 CONHMe H CN H H399 3 CONHMe H CN H H400 1 S02Me H CN H H401 2 S02Me H CN H H402 3 S02Me H CN H H403 1 S02NH2H CN H H404 2 S02NH2H CN H H405 3 S02NH2H CN H H
[0330] Exemplary embodiments include compounds having the formula (XXI)or a pharmaceutically acceptable salt form thereof defined herein below in Table 5.Table 5
[0331] Exemplary embodiments include compounds having the formula (XXII)or a pharmaceutically acceptable salt form thereof defined herein below in Table 6.Table 618 3 C02tBu H H H H19 1 CONHMe H H H H20 2 CONHMe H H H H21 3 CONHMe H H H H22 1 S02Me H H H H23 2 S02Me H H H H24 3 S02Me H H H H25 1 S02NH2H H H H26 2 S02NH2H H H H27 3 S02NH2H H H H
[0332] Exemplary embodiments include compounds having the formula (XXIII)or a pharmaceutically acceptable salt form thereof defined herein below in Table 7.Table 71 S02Phenyl 286 1 S024-OH-Phenyl2 so2Phenyl 287 2 so24-OH-Phenyl3 so2Phenyl 288 3 so24-OH-Phenyl1 0 3-OH-Phenyl 289 1 0 2-OH-Phenyl2 0 3-OH-Phenyl 290 2 0 2-OH-Phenyl3 0 3-OH-Phenyl 291 3 0 2-OH-Phenyl1 s 3-OH-Phenyl 292 1 s 2-OH-Phenyl2 s 3-OH-Phenyl 293 2 s 2-OH-Phenyl3 s 3-OH-Phenyl 294 3 s 2-OH-Phenyl1 so 3-OH-Phenyl 295 1 so 2-OH-Phenyl2 so 3-OH-Phenyl 296 2 so 2-OH-Phenyl3 so 3-OH-Phenyl 297 3 so 2-OH-Phenyl1 so23-OH-Phenyl 298 1 so22-OH-Phenyl2 so23-OH-Phenyl 299 2 so22-OH-Phenyl3 so23-OH-Phenyl 300 3 so22-OH-Phenyl1 0 4-N02-Phenyl 301 1 0 4-OMe-Phenyl2 0 4-N02-Phenyl 302 2 0 4-OMe-Phenyl3 0 4-N02-Phenyl 303 3 0 4-OMe-Phenyl1 s 4-N02-Phenyl 304 1 s 4-OMe-Phenyl2 s 4-N02-Phenyl 305 2 s 4-OMe-Phenyl3 s 4-N02-Phenyl 306 3 s 4-OMe-Phenyl1 so 4-N02-Phenyl 307 1 so 4-OMe-Phenyl2 so 4-N02-Phenyl 308 2 so 4-OMe-Phenyl3 so 4-N02-Phenyl 309 3 so 4-OMe-Phenyl1 so24-N02-Phenyl 310 1 so24-OMe-Phenyl2 so24-N02-Phenyl 311 2 so24-OMe-Phenyl3 so24-N02-Phenyl 312 3 so24-OMe-Phenyl1 0 3-OMe-Phenyl 313 1 0 2-OMe-Phenyl2 0 3-OMe-Phenyl 314 2 0 2-OMe-Phenyl3 0 3-OMe-Phenyl 315 3 0 2-OMe-Phenyl1 s 3-OMe-Phenyl 316 1 s 2-OMe-Phenyl2 s 3-OMe-Phenyl 317 2 s 2-OMe-Phenyl3 s 3-OMe-Phenyl 318 3 s 2-OMe-Phenyl1 so 3-OMe-Phenyl 319 1 so 2-OMe-Phenyl2 so 3-OMe-Phenyl 320 2 so 2-OMe-Phenyl3 so 3-OMe-Phenyl 321 3 so 2-OMe-Phenyl1 so23-OMe-Phenyl 322 1 so22-OMe-Phenyl2 so23-OMe-Phenyl 323 2 so22-OMe-Phenyl3 so23-OMe-Phenyl 324 3 so22-OMe-Phenyl1 0 4-CN-Phenyl 325 1 0 3-CN-Phenyl2 0 4-CN-Phenyl 326 2 0 3-CN-Phenyl3 0 4-CN-Phenyl 327 3 0 3-CN-Phenyl1 s 4-CN-Phenyl 328 1 s 3-CN-Phenyl2 s 4-CN-Phenyl 329 2 s 3-CN-Phenyl3 s 4-CN-Phenyl 330 3 s 3-CN-Phenyl1 so 4-CN-Phenyl 331 1 so 3-CN-Phenyl2 so 4-CN-Phenyl 332 2 so 3-CN-Phenyl3 so 4-CN-Phenyl 333 3 so 3-CN-Phenyl1 so24-CN-Phenyl 334 1 so23-CN-Phenyl2 so24-CN-Phenyl 335 2 so23-CN-Phenyl3 so24-CN-Phenyl 336 3 so23-CN-Phenyl1 0 2-CN-Phenyl 337 1 0 2-Me-Phenyl2 0 2-CN-Phenyl 338 2 O 2-Me-Phenyl3 0 2-CN-Phenyl 339 3 O 2-Me-Phenyl1 s 2-CN-Phenyl 340 1 s 2-Me-Phenyl2 s 2-CN-Phenyl 341 2 s 2-Me-Phenyl3 s 2-CN-Phenyl 342 3 s 2-Me-Phenyl1 so 2-CN-Phenyl 343 1 so 2-Me-Phenyl2 so 2-CN-Phenyl 344 2 so 2-Me-Phenyl3 so 2-CN-Phenyl 345 3 so 2-Me-Phenyl1 so22-CN-Phenyl 346 1 so22-Me-Phenyl2 so22-CN-Phenyl 347 2 so22-Me-Phenyl3 so22-CN-Phenyl 348 3 so22-Me-Phenyl1 0 3-Me-Phenyl 349 1 0 4-Me-Phenyl2 0 3-Me-Phenyl 350 2 0 4-Me-Phenyl3 0 3-Me-Phenyl 351 3 0 4-Me-Phenyl1 s 3-Me-Phenyl 352 1 s 4-Me-Phenyl2 s 3-Me-Phenyl 353 2 s 4-Me-Phenyl3 s 3-Me-Phenyl 354 3 s 4-Me-Phenyl1 so 3-Me-Phenyl 355 1 so 4-Me-Phenyl2 so 3-Me-Phenyl 356 2 so 4-Me-Phenyl3 so 3-Me-Phenyl 357 3 so 4-Me-Phenyl1 so23-Me-Phenyl 358 1 so24-Me-Phenyl2 so23-Me-Phenyl 359 2 so24-Me-Phenyl3 so23-Me-Phenyl 360 3 so24-Me-Phenyl1 0 2-F-Phenyl 361 1 0 3-F-Phenyl2 0 2-F-Phenyl 362 2 0 3-F-Phenyl3 0 2-F-Phenyl 363 3 0 3-F-Phenyl88 1 S 2-F-Phenyl 364 1 S 3-F-Phenyl89 2 S 2-F-Phenyl 365 2 S 3-F-Phenyl90 3 s 2-F-Phenyl 366 3 s 3-F-Phenyl91 1 so 2-F-Phenyl 367 1 so 3-F-Phenyl92 2 so 2-F-Phenyl 368 2 so 3-F-Phenyl93 3 so 2-F-Phenyl 369 3 so 3-F-Phenyl94 1 so22-F-Phenyl 370 1 so23-F-Phenyl95 2 so22-F-Phenyl 371 2 so23-F-Phenyl96 3 so22-F-Phenyl 372 3 so23-F-Phenyl97 1 0 4-F-Phenyl 373 1 0 2-Cl-Phenyl98 2 0 4-F-Phenyl 374 2 0 2-Cl-Phenyl99 3 0 4-F-Phenyl 375 3 0 2-Cl-Phenyl100 1 s 4-F-Phenyl 376 1 s 2-Cl-Phenyl101 2 s 4-F-Phenyl 377 2 s 2-Cl-Phenyl102 3 s 4-F-Phenyl 378 3 s 2-Cl-Phenyl103 1 so 4-F-Phenyl 379 1 so 2-Cl-Phenyl104 2 so 4-F-Phenyl 380 2 so 2-Cl-Phenyl105 3 so 4-F-Phenyl 381 3 so 2-Cl-Phenyl106 1 so24-F-Phenyl 382 1 so22-Cl-Phenyl107 2 so24-F-Phenyl 383 2 so22-Cl-Phenyl108 3 so24-F-Phenyl 384 3 so22-Cl-Phenyl109 1 0 3-Cl-Phenyl 385 1 0 4-Cl-Phenyl110 2 0 3-Cl-Phenyl 386 2 0 4-Cl-Phenyl111 3 0 3-Cl-Phenyl 387 3 0 4-Cl-Phenyl112 1 s 3-Cl-Phenyl 388 1 s 4-Cl-Phenyl113 2 s 3-Cl-Phenyl 389 2 s 4-Cl-Phenyl114 3 S 3-Cl-Phenyl 390 3 S 4-Cl-Phenyl115 1 SO 3-Cl-Phenyl 391 1 SO 4-Cl-Phenyl116 2 so 3-Cl-Phenyl 392 2 so 4-Cl-Phenyl117 3 so 3-Cl-Phenyl 393 3 so 4-Cl-Phenyl118 1 so23-Cl-Phenyl 394 1 so24-Cl-Phenyl119 2 so23-Cl-Phenyl 395 2 so24-Cl-Phenyl120 3 so23-Cl-Phenyl 396 3 so24-Cl-Phenyl121 1 0 2-Br-Phenyl 397 1 0 3-Br-Phenyl122 2 0 2-Br-Phenyl 398 2 0 3-Br-Phenyl123 3 0 2-Br-Phenyl 399 3 0 3-Br-Phenyl124 1 s 2-Br-Phenyl 400 1 s 3-Br-Phenyl125 2 s 2-Br-Phenyl 401 2 s 3-Br-Phenyl126 3 s 2-Br-Phenyl 402 3 s 3-Br-Phenyl127 1 so 2-Br-Phenyl 403 1 so 3-Br-Phenyl128 2 so 2-Br-Phenyl 404 2 so 3-Br-Phenyl129 3 so 2-Br-Phenyl 405 3 so 3-Br-Phenyl130 1 so22-Br-Phenyl 406 1 so23-Br-Phenyl131 2 so22-Br-Phenyl 407 2 so23-Br-Phenyl132 3 so22-Br-Phenyl 408 3 so23-Br-Phenyl133 1 0 4-Br-Phenyl 409 1 0 2-CF3-Phenyl134 2 0 4-Br-Phenyl 410 2 0 2-CF3-Phenyl135 3 0 4-Br-Phenyl 411 3 0 2-CF3-Phenyl136 1 s 4-Br-Phenyl 412 1 s 2-CF3-Phenyl137 2 s 4-Br-Phenyl 413 2 s 2-CF3-Phenyl138 3 s 4-Br-Phenyl 414 3 s 2-CF3-Phenyl139 1 so 4-Br-Phenyl 415 1 so 2-CF3-Phenyl140 2 SO 4-Br-Phenyl 416 2 SO 2-CF3-Phenyl141 3 SO 4-Br-Phenyl 417 3 SO 2-CF3-Phenyl142 1 so24-Br-Phenyl 418 1 so22-CF3-Phenyl143 2 so24-Br-Phenyl 419 2 so22-CF3-Phenyl144 3 so24-Br-Phenyl 420 3 so22-CF3-Phenyl145 1 0 3-CF3-Phenyl 421 1 0 4-CF3-Phenyl146 2 0 3-CF3-Phenyl 422 2 0 4-CF3-Phenyl147 3 0 3-CF3-Phenyl 423 3 0 4-CF3-Phenyl148 1 s 3-CF3-Phenyl 424 1 s 4-CF3-Phenyl149 2 s 3-CF3-Phenyl 425 2 s 4-CF3-Phenyl150 3 s 3-CF3-Phenyl 426 3 s 4-CF3-Phenyl151 1 so 3-CF3-Phenyl 427 1 so 4-CF3-Phenyl152 2 so 3-CF3-Phenyl 428 2 so 4-CF3-Phenyl153 3 so 3-CF3-Phenyl 429 3 so 4-CF3-Phenyl154 1 so23-CF3-Phenyl 430 1 so24-CF3-Phenyl155 2 so23-CF3-Phenyl 431 2 so24-CF3-Phenyl156 3 so23-CF3-Phenyl 432 3 so24-CF3-Phenyl157 1 0 2-iPr-Phenyl 433 1 0 3-iPr-Phenyl158 2 0 2-iPr-Phenyl 434 2 0 3-iPr-Phenyl159 3 0 2-iPr-Phenyl 435 3 0 3-iPr-Phenyl160 1 s 2-iPr-Phenyl 436 1 s 3-iPr-Phenyl161 2 s 2-iPr-Phenyl 437 2 s 3-iPr-Phenyl162 3 s 2-iPr-Phenyl 438 3 s 3-iPr-Phenyl163 1 so 2-iPr-Phenyl 439 1 so 3-iPr-Phenyl164 2 so 2-iPr-Phenyl 440 2 so 3-iPr-Phenyl165 3 so 2-iPr-Phenyl 441 3 so 3-iPr-Phenyl166 1 S022-iPr-Phenyl 442 1 S023-iPr-Phenyl167 2 so22-iPr-Phenyl 443 2 so23-iPr-Phenyl168 3 so22-iPr-Phenyl 444 3 so23-iPr-Phenyl169 1 0 4-iPr-Phenyl 445 1 0 4-NH2-Phenyl170 2 0 4-iPr-Phenyl 446 2 0 4-NH2-Phenyl171 3 0 4-iPr-Phenyl 447 3 0 4-NH2-Phenyl172 1 s 4-iPr-Phenyl 448 1 s 4-NH2-Phenyl173 2 s 4-iPr-Phenyl 449 2 s 4-NH2-Phenyl174 3 s 4-iPr-Phenyl 450 3 s 4-NH2-Phenyl175 1 so 4-iPr-Phenyl 451 1 so 4-NH2-Phenyl176 2 so 4-iPr-Phenyl 452 2 so 4-NH2-Phenyl177 3 so 4-iPr-Phenyl 453 3 so 4-NH2-Phenyl178 1 so24-iPr-Phenyl 454 1 so24-NH2-Phenyl179 2 so24-iPr-Phenyl 455 2 so24-NH2-Phenyl180 3 so24-iPr-Phenyl 456 3 so24-NH2-Phenyl181 1 0 3-NH2-Phenyl 457 1 0 2-NH2-Phenyl182 2 0 3-NH2-Phenyl 458 2 0 2-NH2-Phenyl183 3 0 3-NH2-Phenyl 459 3 0 2-NH2-Phenyl184 1 s 3-NH2-Phenyl 460 1 s 2-NH2-Phenyl185 2 s 3-NH2-Phenyl 461 2 s 2-NH2-Phenyl186 3 s 3-NH2-Phenyl 462 3 s 2-NH2-Phenyl187 1 so 3-NH2-Phenyl 463 1 so 2-NH2-Phenyl188 2 so 3-NH2-Phenyl 464 2 so 2-NH2-Phenyl189 3 so 3-NH2-Phenyl 465 3 so 2-NH2-Phenyl190 1 so23-NH2-Phenyl 466 1 so22-NH2-Phenyl191 2 so23-NH2-Phenyl 467 2 so22-NH2-Phenyl192 3 so23-NH2-Phenyl 468 3 so22-NH2-Phenyl193 1 0 2,4-di-Me-Phenyl 469 1 0 2,6-di-Me-Phenyl194 2 0 2,4-di-Me-Phenyl 470 2 0 2,6-di-Me-Phenyl195 3 0 2,4-di-Me-Phenyl 471 3 0 2,6-di-Me-Phenyl196 1 s 2,4-di-Me-Phenyl 472 1 s 2,6-di-Me-Phenyl197 2 s 2,4-di-Me-Phenyl 473 2 s 2,6-di-Me-Phenyl198 3 s 2,4-di-Me-Phenyl 474 3 s 2,6-di-Me-Phenyl199 1 so 2,4-di-Me-Phenyl 475 1 so 2,6-di-Me-Phenyl200 2 so 2,4-di-Me-Phenyl 476 2 so 2,6-di-Me-Phenyl201 3 so 2,4-di-Me-Phenyl 477 3 so 2,6-di-Me-Phenyl202 1 so22,4-di-Me-Phenyl 478 1 so22,6-di-Me-Phenyl203 2 so22,4-di-Me-Phenyl 479 2 so22,6-di-Me-Phenyl204 3 so22,4-di-Me-Phenyl 480 3 so22,6-di-Me-Phenyl205 1 0 2,6-di-iPr-Phenyl 481 1 0 2-Ph-Phenyl206 2 0 2,6-di-iPr-Phenyl 482 2 0 2-Ph-Phenyl207 3 0 2,6-di-iPr-Phenyl 483 3 0 2-Ph-Phenyl208 1 s 2,6-di-iPr-Phenyl 484 1 s 2-Ph-Phenyl209 2 s 2,6-di-iPr-Phenyl 485 2 s 2-Ph-Phenyl210 3 s 2,6-di-iPr-Phenyl 486 3 s 2-Ph-Phenyl211 1 so 2,6-di-iPr-Phenyl 487 1 so 2-Ph-Phenyl212 2 so 2,6-di-iPr-Phenyl 488 2 so 2-Ph-Phenyl213 3 so 2,6-di-iPr-Phenyl 489 3 so 2-Ph-Phenyl214 1 so22,6-di-iPr-Phenyl 490 1 so22-Ph-Phenyl215 2 so22,6-di-iPr-Phenyl 491 2 so22-Ph-Phenyl216 3 so22,6-di-iPr-Phenyl 492 3 so22-Ph-Phenyl217 1 0 3-Ph-Phenyl 493 1 0 4-Ph-Phenyl218 2 0 3-Ph-Phenyl 494 2 O 4-Ph-Phenyl219 3 0 3-Ph-Phenyl 495 3 O 4-Ph-Phenyl220 1 s 3-Ph-Phenyl 496 1 s 4-Ph-Phenyl221 2 s 3-Ph-Phenyl 497 2 s 4-Ph-Phenyl222 3 s 3-Ph-Phenyl 498 3 s 4-Ph-Phenyl223 1 so 3-Ph-Phenyl 499 1 so 4-Ph-Phenyl224 2 so 3-Ph-Phenyl 500 2 so 4-Ph-Phenyl225 3 so 3-Ph-Phenyl 501 3 so 4-Ph-Phenyl226 1 so23-Ph-Phenyl 502 1 so24-Ph-Phenyl227 2 so23-Ph-Phenyl 503 2 so24-Ph-Phenyl228 3 so23-Ph-Phenyl 504 3 so24-Ph-Phenyl229 1 0 2-morpholino-phenyl 505 1 0 3 -morpholino-pheny 1230 2 0 2-morpholino-phenyl 506 2 0 3 -morpholino-pheny 1231 3 0 2-morpholino-phenyl 507 3 0 3 -morpholino-pheny 1232 1 s 2 -morpholino -pheny 1 508 1 s 3 -morpholino-pheny 1233 2 s 2 -morpholino -pheny 1 509 2 s 3 -morpholino-pheny 1234 3 s 2 -morpholino -pheny 1 510 3 s 3 -morpholino-pheny 1235 1 so 2 -morpholino -pheny 1 511 1 so 3 -morpholino -pheny 1236 2 so 2 -morpholino -pheny 1 512 2 so 3 -morpholino-pheny 1237 3 so 2 -morpholino -pheny 1 513 3 so 3 -morpholino-pheny 1238 1 so22 -morpholino -pheny 1 514 1 so23 -morpholino-pheny 1239 2 so22 -morpholino -pheny 1 515 2 so23 -morpholino-pheny 1240 3 so22 -morpholino -pheny 1 516 3 so23 -morpholino-pheny 1241 1 0 4-morpholino-phenyl 517 1 0 2-pyrazinyl242 2 0 4-morpholino-phenyl 518 2 0 2-pyrazinyl243 3 0 4-morpholino-phenyl 519 3 0 2-pyrazinyl244 1 S 4 -morpholino -pheny 1 520 1 S 2-pyrazinyl245 2 s 4 -morpholino -pheny 1 521 2 s 2-pyrazinyl246 3 s 4 -morpholino -pheny 1 522 3 s 2-pyrazinyl247 1 so 4-morpholino-phenyl 523 1 so 2-pyrazinyl248 2 so 4 -morpholino -pheny 1 524 2 so 2-pyrazinyl249 3 so 4 -morpholino -pheny 1 525 3 so 2-pyrazinyl250 1 so24 -morpholino -pheny 1 526 1 so22-pyrazinyl251 2 so24 -morpholino -pheny 1 527 2 so22-pyrazinyl252 3 so24 -morpholino -pheny 1 528 3 so22-pyrazinyl253 1 0 2-pyrimidinyl 529 1 0 5-indolyl254 2 0 2-pyrimidinyl 530 2 0 5-indolyl255 3 0 2-pyrimidinyl 531 3 0 5-indolyl256 1 s 2-pyrimidinyl 532 1 s 5-indolyl257 2 s 2-pyrimidinyl 533 2 s 5-indolyl258 3 s 2-pyrimidinyl 534 3 s 5-indolyl259 1 so 2-pyrimidinyl 535 1 so 5-indolyl260 2 so 2-pyrimidinyl 536 2 so 5-indolyl261 3 so 2-pyrimidinyl 537 3 so 5-indolyl262 1 so22-pyrimidinyl 538 1 so25-indolyl263 2 so22-pyrimidinyl 539 2 so25-indolyl264 3 so22-pyrimidinyl 540 3 so25-indolyl265 1 0 2-methyl-lH- 541 1 0 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl266 2 0 2-methyl-lH- 542 2 0 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl267 3 0 2-methyl-lH- 543 3 0 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl268 1 s 2-methyl-lH- 544 1 s 1 H-benzo [d] imidazol-benzo[d]imidazol-4-yl 4-yl269 2 S 2-methyl-lH- 545 2 S 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl270 3 S 2-methyl-lH- 546 3 S 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl271 1 SO 2-methyl-lH- 547 1 SO 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl272 2 so 2-methyl-lH- 548 2 so 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl273 3 so 2-methyl-lH- 549 3 so 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl274 1 so22-methyl-lH- 550 1 so21 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl275 2 so22-methyl-lH- 551 2 so21 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl276 3 so22-methyl-lH- 552 3 so21 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl
[0333] Exemplary embodiments include compounds having the formula (XXIV)or a pharmaceutically acceptable salt form thereof defined herein below in Table 8.Table 81 SO Phenyl 283 1 SO 4-OH-Phenyl2 SO Phenyl 284 2 SO 4-OH-Phenyl3 so Phenyl 285 3 so 4-OH-Phenyl1 so2Phenyl 286 1 so24-OH-Phenyl2 so2Phenyl 287 2 so24-OH-Phenyl3 so2Phenyl 288 3 so24-OH-Phenyl1 0 3-OH-Phenyl 289 1 0 2-OH-Phenyl2 0 3-OH-Phenyl 290 2 0 2-OH-Phenyl3 0 3-OH-Phenyl 291 3 0 2-OH-Phenyl1 s 3-OH-Phenyl 292 1 s 2-OH-Phenyl2 s 3-OH-Phenyl 293 2 s 2-OH-Phenyl3 s 3-OH-Phenyl 294 3 s 2-OH-Phenyl1 so 3-OH-Phenyl 295 1 so 2-OH-Phenyl2 so 3-OH-Phenyl 296 2 so 2-OH-Phenyl3 so 3-OH-Phenyl 297 3 so 2-OH-Phenyl1 so23-OH-Phenyl 298 1 so22-OH-Phenyl2 so23-OH-Phenyl 299 2 so22-OH-Phenyl3 so23-OH-Phenyl 300 3 so22-OH-Phenyl1 0 4-N02-Phenyl 301 1 0 4-OMe-Phenyl2 0 4-N02-Phenyl 302 2 0 4-OMe-Phenyl3 0 4-N02-Phenyl 303 3 0 4-OMe-Phenyl1 s 4-N02-Phenyl 304 1 s 4-OMe-Phenyl2 s 4-N02-Phenyl 305 2 s 4-OMe-Phenyl3 s 4-N02-Phenyl 306 3 s 4-OMe-Phenyl1 so 4-N02-Phenyl 307 1 so 4-OMe-Phenyl2 so 4-N02-Phenyl 308 2 so 4-OMe-Phenyl3 SO 4-N02-Phenyl 309 3 SO 4-OMe-Phenyl1 so24-N02-Phenyl 310 1 so24-OMe-Phenyl2 so24-N02-Phenyl 311 2 so24-OMe-Phenyl3 so24-N02-Phenyl 312 3 so24-OMe-Phenyl1 0 3-OMe-Phenyl 313 1 0 2-OMe-Phenyl2 0 3-OMe-Phenyl 314 2 0 2-OMe-Phenyl3 0 3-OMe-Phenyl 315 3 0 2-OMe-Phenyl1 s 3-OMe-Phenyl 316 1 s 2-OMe-Phenyl2 s 3-OMe-Phenyl 317 2 s 2-OMe-Phenyl3 s 3-OMe-Phenyl 318 3 s 2-OMe-Phenyl1 so 3-OMe-Phenyl 319 1 so 2-OMe-Phenyl2 so 3-OMe-Phenyl 320 2 so 2-OMe-Phenyl3 so 3-OMe-Phenyl 321 3 so 2-OMe-Phenyl1 so23-OMe-Phenyl 322 1 so22-OMe-Phenyl2 so23-OMe-Phenyl 323 2 so22-OMe-Phenyl3 so23-OMe-Phenyl 324 3 so22-OMe-Phenyl1 0 4-CN-Phenyl 325 1 0 3-CN-Phenyl2 0 4-CN-Phenyl 326 2 0 3-CN-Phenyl3 0 4-CN-Phenyl 327 3 0 3-CN-Phenyl1 s 4-CN-Phenyl 328 1 s 3-CN-Phenyl2 s 4-CN-Phenyl 329 2 s 3-CN-Phenyl3 s 4-CN-Phenyl 330 3 s 3-CN-Phenyl1 so 4-CN-Phenyl 331 1 so 3-CN-Phenyl2 so 4-CN-Phenyl 332 2 so 3-CN-Phenyl3 so 4-CN-Phenyl 333 3 so 3-CN-Phenyl1 so24-CN-Phenyl 334 1 so23-CN-Phenyl2 S024-CN-Phenyl 335 2 S023-CN-Phenyl3 so24-CN-Phenyl 336 3 so23-CN-Phenyl1 0 2-CN-Phenyl 337 1 0 2-Me-Phenyl2 0 2-CN-Phenyl 338 2 0 2-Me-Phenyl3 0 2-CN-Phenyl 339 3 0 2-Me-Phenyl1 s 2-CN-Phenyl 340 1 s 2-Me-Phenyl2 s 2-CN-Phenyl 341 2 s 2-Me-Phenyl3 s 2-CN-Phenyl 342 3 s 2-Me-Phenyl1 so 2-CN-Phenyl 343 1 so 2-Me-Phenyl2 so 2-CN-Phenyl 344 2 so 2-Me-Phenyl3 so 2-CN-Phenyl 345 3 so 2-Me-Phenyl1 so22-CN-Phenyl 346 1 so22-Me-Phenyl2 so22-CN-Phenyl 347 2 so22-Me-Phenyl3 so22-CN-Phenyl 348 3 so22-Me-Phenyl1 0 3-Me-Phenyl 349 1 0 4-Me-Phenyl2 0 3-Me-Phenyl 350 2 0 4-Me-Phenyl3 0 3-Me-Phenyl 351 3 0 4-Me-Phenyl1 s 3-Me-Phenyl 352 1 s 4-Me-Phenyl2 s 3-Me-Phenyl 353 2 s 4-Me-Phenyl3 s 3-Me-Phenyl 354 3 s 4-Me-Phenyl1 so 3-Me-Phenyl 355 1 so 4-Me-Phenyl2 so 3-Me-Phenyl 356 2 so 4-Me-Phenyl3 so 3-Me-Phenyl 357 3 so 4-Me-Phenyl1 so23-Me-Phenyl 358 1 so24-Me-Phenyl2 so23-Me-Phenyl 359 2 so24-Me-Phenyl3 so23-Me-Phenyl 360 3 so24-Me-Phenyl85 1 0 2-F-Phenyl 361 1 O 3-F-Phenyl86 2 0 2-F-Phenyl 362 2 O 3-F-Phenyl87 3 0 2-F-Phenyl 363 3 0 3-F-Phenyl88 1 s 2-F-Phenyl 364 1 s 3-F-Phenyl89 2 s 2-F-Phenyl 365 2 s 3-F-Phenyl90 3 s 2-F-Phenyl 366 3 s 3-F-Phenyl91 1 so 2-F-Phenyl 367 1 so 3-F-Phenyl92 2 so 2-F-Phenyl 368 2 so 3-F-Phenyl93 3 so 2-F-Phenyl 369 3 so 3-F-Phenyl94 1 so22-F-Phenyl 370 1 so23-F-Phenyl95 2 so22-F-Phenyl 371 2 so23-F-Phenyl96 3 so22-F-Phenyl 372 3 so23-F-Phenyl97 1 0 4-F-Phenyl 373 1 0 2-Cl-Phenyl98 2 0 4-F-Phenyl 374 2 0 2-Cl-Phenyl99 3 0 4-F-Phenyl 375 3 0 2-Cl-Phenyl100 1 s 4-F-Phenyl 376 1 s 2-Cl-Phenyl101 2 s 4-F-Phenyl 377 2 s 2-Cl-Phenyl102 3 s 4-F-Phenyl 378 3 s 2-Cl-Phenyl103 1 so 4-F-Phenyl 379 1 so 2-Cl-Phenyl104 2 so 4-F-Phenyl 380 2 so 2-Cl-Phenyl105 3 so 4-F-Phenyl 381 3 so 2-Cl-Phenyl106 1 so24-F-Phenyl 382 1 so22-Cl-Phenyl107 2 so24-F-Phenyl 383 2 so22-Cl-Phenyl108 3 so24-F-Phenyl 384 3 so22-Cl-Phenyl109 1 0 3-Cl-Phenyl 385 1 0 4-Cl-Phenyl110 2 0 3-Cl-Phenyl 386 2 0 4-Cl-Phenyl111 3 0 3-Cl-Phenyl 387 3 0 4-Cl-Phenyl112 1 s 3-Cl-Phenyl 388 1 s 4-Cl-Phenyl113 2 s 3-Cl-Phenyl 389 2 s 4-Cl-Phenyl114 3 s 3-Cl-Phenyl 390 3 s 4-Cl-Phenyl115 1 so 3-Cl-Phenyl 391 1 so 4-Cl-Phenyl116 2 so 3-Cl-Phenyl 392 2 so 4-Cl-Phenyl117 3 so 3-Cl-Phenyl 393 3 so 4-Cl-Phenyl118 1 so23-Cl-Phenyl 394 1 so24-Cl-Phenyl119 2 so23-Cl-Phenyl 395 2 so24-Cl-Phenyl120 3 so23-Cl-Phenyl 396 3 so24-Cl-Phenyl121 1 0 2-Br-Phenyl 397 1 0 3-Br-Phenyl122 2 0 2-Br-Phenyl 398 2 0 3-Br-Phenyl123 3 0 2-Br-Phenyl 399 3 0 3-Br-Phenyl124 1 s 2-Br-Phenyl 400 1 s 3-Br-Phenyl125 2 s 2-Br-Phenyl 401 2 s 3-Br-Phenyl126 3 s 2-Br-Phenyl 402 3 s 3-Br-Phenyl127 1 so 2-Br-Phenyl 403 1 so 3-Br-Phenyl128 2 so 2-Br-Phenyl 404 2 so 3-Br-Phenyl129 3 so 2-Br-Phenyl 405 3 so 3-Br-Phenyl130 1 so22-Br-Phenyl 406 1 so23-Br-Phenyl131 2 so22-Br-Phenyl 407 2 so23-Br-Phenyl132 3 so22-Br-Phenyl 408 3 so23-Br-Phenyl133 1 0 4-Br-Phenyl 409 1 0 2-CF3-Phenyl134 2 0 4-Br-Phenyl 410 2 0 2-CF3-Phenyl135 3 0 4-Br-Phenyl 411 3 0 2-CF3-Phenyl136 1 s 4-Br-Phenyl 412 1 s 2-CF3-Phenyl137 2 S 4-Br-Phenyl 413 2 S 2-CF3-Phenyl138 3 S 4-Br-Phenyl 414 3 S 2-CF3-Phenyl139 1 SO 4-Br-Phenyl 415 1 SO 2-CF3-Phenyl140 2 so 4-Br-Phenyl 416 2 so 2-CF3-Phenyl141 3 so 4-Br-Phenyl 417 3 so 2-CF3-Phenyl142 1 so24-Br-Phenyl 418 1 so22-CF3-Phenyl143 2 so24-Br-Phenyl 419 2 so22-CF3-Phenyl144 3 so24-Br-Phenyl 420 3 so22-CF3-Phenyl145 1 0 3-CF3-Phenyl 421 1 0 4-CF3-Phenyl146 2 0 3-CF3-Phenyl 422 2 0 4-CF3-Phenyl147 3 0 3-CF3-Phenyl 423 3 0 4-CF3-Phenyl148 1 s 3-CF3-Phenyl 424 1 s 4-CF3-Phenyl149 2 s 3-CF3-Phenyl 425 2 s 4-CF3-Phenyl150 3 s 3-CF3-Phenyl 426 3 s 4-CF3-Phenyl151 1 so 3-CF3-Phenyl 427 1 so 4-CF3-Phenyl152 2 so 3-CF3-Phenyl 428 2 so 4-CF3-Phenyl153 3 so 3-CF3-Phenyl 429 3 so 4-CF3-Phenyl154 1 so23-CF3-Phenyl 430 1 so24-CF3-Phenyl155 2 so23-CF3-Phenyl 431 2 so24-CF3-Phenyl156 3 so23-CF3-Phenyl 432 3 so24-CF3-Phenyl157 1 0 2-iPr-Phenyl 433 1 0 3-iPr-Phenyl158 2 0 2-iPr-Phenyl 434 2 0 3-iPr-Phenyl159 3 0 2-iPr-Phenyl 435 3 0 3-iPr-Phenyl160 1 s 2-iPr-Phenyl 436 1 s 3-iPr-Phenyl161 2 s 2-iPr-Phenyl 437 2 s 3-iPr-Phenyl162 3 s 2-iPr-Phenyl 438 3 s 3-iPr-Phenyl163 1 SO 2-iPr-Phenyl 439 1 SO 3-iPr-Phenyl164 2 SO 2-iPr-Phenyl 440 2 SO 3-iPr-Phenyl165 3 so 2-iPr-Phenyl 441 3 so 3-iPr-Phenyl166 1 so22-iPr-Phenyl 442 1 so23-iPr-Phenyl167 2 so22-iPr-Phenyl 443 2 so23-iPr-Phenyl168 3 so22-iPr-Phenyl 444 3 so23-iPr-Phenyl169 1 0 4-iPr-Phenyl 445 1 0 4-NH2-Phenyl170 2 0 4-iPr-Phenyl 446 2 0 4-NH2-Phenyl171 3 0 4-iPr-Phenyl 447 3 0 4-NH2-Phenyl172 1 s 4-iPr-Phenyl 448 1 s 4-NH2-Phenyl173 2 s 4-iPr-Phenyl 449 2 s 4-NH2-Phenyl174 3 s 4-iPr-Phenyl 450 3 s 4-NH2-Phenyl175 1 so 4-iPr-Phenyl 451 1 so 4-NH2-Phenyl176 2 so 4-iPr-Phenyl 452 2 so 4-NH2-Phenyl177 3 so 4-iPr-Phenyl 453 3 so 4-NH2-Phenyl178 1 so24-iPr-Phenyl 454 1 so24-NH2-Phenyl179 2 so24-iPr-Phenyl 455 2 so24-NH2-Phenyl180 3 so24-iPr-Phenyl 456 3 so24-NH2-Phenyl181 1 0 3-NH2-Phenyl 457 1 0 2-NH2-Phenyl182 2 0 3-NH2-Phenyl 458 2 0 2-NH2-Phenyl183 3 0 3-NH2-Phenyl 459 3 0 2-NH2-Phenyl184 1 s 3-NH2-Phenyl 460 1 s 2-NH2-Phenyl185 2 s 3-NH2-Phenyl 461 2 s 2-NH2-Phenyl186 3 s 3-NH2-Phenyl 462 3 s 2-NH2-Phenyl187 1 so 3-NH2-Phenyl 463 1 so 2-NH2-Phenyl188 2 so 3-NH2-Phenyl 464 2 so 2-NH2-Phenyl189 3 SO 3-NH2-Phenyl 465 3 SO 2-NH2-Phenyl190 1 so23-NH2-Phenyl 466 1 so22-NH2-Phenyl191 2 so23-NH2-Phenyl 467 2 so22-NH2-Phenyl192 3 so23-NH2-Phenyl 468 3 so22-NH2-Phenyl193 1 0 2,4-di-Me-Phenyl 469 1 0 2,6-di-Me-Phenyl194 2 0 2,4-di-Me-Phenyl 470 2 0 2,6-di-Me-Phenyl195 3 0 2,4-di-Me-Phenyl 471 3 0 2,6-di-Me-Phenyl196 1 s 2,4-di-Me-Phenyl 472 1 s 2,6-di-Me-Phenyl197 2 s 2,4-di-Me-Phenyl 473 2 s 2,6-di-Me-Phenyl198 3 s 2,4-di-Me-Phenyl 474 3 s 2,6-di-Me-Phenyl199 1 so 2,4-di-Me-Phenyl 475 1 so 2,6-di-Me-Phenyl200 2 so 2,4-di-Me-Phenyl 476 2 so 2,6-di-Me-Phenyl201 3 so 2,4-di-Me-Phenyl 477 3 so 2,6-di-Me-Phenyl202 1 so22,4-di-Me-Phenyl 478 1 so22,6-di-Me-Phenyl203 2 so22,4-di-Me-Phenyl 479 2 so22,6-di-Me-Phenyl204 3 so22,4-di-Me-Phenyl 480 3 so22,6-di-Me-Phenyl205 1 0 2,6-di-iPr-Phenyl 481 1 0 2-Ph-Phenyl206 2 0 2,6-di-iPr-Phenyl 482 2 0 2-Ph-Phenyl207 3 0 2,6-di-iPr-Phenyl 483 3 0 2-Ph-Phenyl208 1 s 2,6-di-iPr-Phenyl 484 1 s 2-Ph-Phenyl209 2 s 2,6-di-iPr-Phenyl 485 2 s 2-Ph-Phenyl210 3 s 2,6-di-iPr-Phenyl 486 3 s 2-Ph-Phenyl211 1 so 2,6-di-iPr-Phenyl 487 1 so 2-Ph-Phenyl212 2 so 2,6-di-iPr-Phenyl 488 2 so 2-Ph-Phenyl213 3 so 2,6-di-iPr-Phenyl 489 3 so 2-Ph-Phenyl214 1 so22,6-di-iPr-Phenyl 490 1 so22-Ph-Phenyl215 2 S022,6-di-iPr-Phenyl 491 2 S022-Ph-Phenyl216 3 so22,6-di-iPr-Phenyl 492 3 so22-Ph-Phenyl217 1 0 3-Ph-Phenyl 493 1 0 4-Ph-Phenyl218 2 0 3-Ph-Phenyl 494 2 0 4-Ph-Phenyl219 3 0 3-Ph-Phenyl 495 3 0 4-Ph-Phenyl220 1 s 3-Ph-Phenyl 496 1 s 4-Ph-Phenyl221 2 s 3-Ph-Phenyl 497 2 s 4-Ph-Phenyl222 3 s 3-Ph-Phenyl 498 3 s 4-Ph-Phenyl223 1 so 3-Ph-Phenyl 499 1 so 4-Ph-Phenyl224 2 so 3-Ph-Phenyl 500 2 so 4-Ph-Phenyl225 3 so 3-Ph-Phenyl 501 3 so 4-Ph-Phenyl226 1 so23-Ph-Phenyl 502 1 so24-Ph-Phenyl227 2 so23-Ph-Phenyl 503 2 so24-Ph-Phenyl228 3 so23-Ph-Phenyl 504 3 so24-Ph-Phenyl229 1 0 2-morpholino-phenyl 505 1 0 3 -morpholino-pheny 1230 2 0 2-morpholino-phenyl 506 2 0 3 -morpholino-pheny 1231 3 0 2-morpholino-phenyl 507 3 0 3 -morpholino-pheny 1232 1 s 2 -morpholino -pheny 1 508 1 s 3 -morpholino-pheny 1233 2 s 2 -morpholino -pheny 1 509 2 s 3 -morpholino-pheny 1234 3 s 2 -morpholino -pheny 1 510 3 s 3 -morpholino-pheny 1235 1 so 2 -morpholino -pheny 1 511 1 so 3 -morpholino -pheny 1236 2 so 2 -morpholino -pheny 1 512 2 so 3 -morpholino-pheny 1237 3 so 2 -morpholino -pheny 1 513 3 so 3 -morpholino-pheny 1238 1 so22 -morpholino -pheny 1 514 1 so23 -morpholino-pheny 1239 2 so22 -morpholino -pheny 1 515 2 so23 -morpholino-pheny 1240 3 so22 -morpholino -pheny 1 516 3 so23 -morpholino-pheny 1241 1 0 4-morpholino-phenyl 517 1 O 2-pyrazinyl242 2 0 4-morpholino-phenyl 518 2 O 2-pyrazinyl243 3 0 4-morpholino-phenyl 519 3 0 2-pyrazinyl244 1 s 4 -morpholino -pheny 1 520 1 s 2-pyrazinyl245 2 s 4 -morpholino -pheny 1 521 2 s 2-pyrazinyl246 3 s 4 -morpholino -pheny 1 522 3 s 2-pyrazinyl247 1 so 4-morpholino-phenyl 523 1 so 2-pyrazinyl248 2 so 4 -morpholino -pheny 1 524 2 so 2-pyrazinyl249 3 so 4 -morpholino -pheny 1 525 3 so 2-pyrazinyl250 1 so24 -morpholino -pheny 1 526 1 so22-pyrazinyl251 2 so24 -morpholino -pheny 1 527 2 so22-pyrazinyl252 3 so24 -morpholino -pheny 1 528 3 so22-pyrazinyl253 1 0 2-pyrimidinyl 529 1 0 5-indolyl254 2 0 2-pyrimidinyl 530 2 0 5-indolyl255 3 0 2-pyrimidinyl 531 3 0 5-indolyl256 1 s 2-pyrimidinyl 532 1 s 5-indolyl257 2 s 2-pyrimidinyl 533 2 s 5-indolyl258 3 s 2-pyrimidinyl 534 3 s 5-indolyl259 1 so 2-pyrimidinyl 535 1 so 5-indolyl260 2 so 2-pyrimidinyl 536 2 so 5-indolyl261 3 so 2-pyrimidinyl 537 3 so 5-indolyl262 1 so22-pyrimidinyl 538 1 so25-indolyl263 2 so22-pyrimidinyl 539 2 so25-indolyl264 3 so22-pyrimidinyl 540 3 so25-indolyl265 1 0 2-methyl-lH- 541 1 0 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl266 2 0 2-methyl-lH- 542 2 0 1 H-benzo [d] imidazol-benzo[d]imidazol-4-yl 4-yl267 3 0 2-methyl-lH- 543 3 0 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl268 1 s 2-methyl-lH- 544 1 s 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl269 2 s 2-methyl-lH- 545 2 s 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl270 3 s 2-methyl-lH- 546 3 s 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl271 1 so 2-methyl-lH- 547 1 so 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl272 2 so 2-methyl-lH- 548 2 so 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl273 3 so 2-methyl-lH- 549 3 so 1 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl274 1 so22-methyl-lH- 550 1 so21 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl275 2 so22-methyl-lH- 551 2 so21 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl276 3 so22-methyl-lH- 552 3 so21 H-benzo [d] imidazol- benzo[d]imidazol-4-yl 4-yl
[0334] Exemplary embodiments include compounds having the formula (XXV)or a pharmaceutically acceptable salt form thereof defined herein below in Table 9Table 9-CH2CF34-CH3-phenyl 261 -CH2CF32-CH3-phenyl-CH2CH2CF34-CH3-phenyl 262 -CH2CH2CF32-CH3-phenyl cyclopropyl 4-CH3-phenyl 263 cyclopropyl 2-CH3-phenylCyclobutyl 4-CH3-phenyl 264 Cyclobutyl 2-CH3-phenyl cyclopentyl 4-CH3-phenyl 265 cyclopentyl 2-CH3-phenyl cyclohexyl 4-CH3-phenyl 266 cyclohexyl 2-CH3-phenyl3-pyridyl 4-CH3-phenyl 267 3-pyridyl 2-CH3-phenyl1-methyl-lH- 4-CH3-phenyl 1 -methyl- 1H- 2-CH3-phenyl268pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 4-CH3-phenyl 269 lH-imidazol-4-yl 2-CH3-phenyl2-furanyl 4-CH3-phenyl 270 2-furanyl 2-CH3-phenyl ethyl 3-CH3-phenyl 271 ethyl 4-OH-Phenyl n-propyl 3-CH3-phenyl 272 n-propyl 4-OH-Phenyl isopropyl 3-CH3-phenyl 273 isopropyl 4-OH-Phenyl-CH2CH(CH3)23-CH3-phenyl 274 -CH2CH(CH3)24-OH-Phenyl-CF33-CH3-phenyl 275 -CF34-OH-Phenyl-CH2CF3 3-CH3-phenyl 276 -CH2CF34-OH-Phenyl-CH2CH2CF33-CH3-phenyl 277 -CH2CH2CF34-OH-Phenyl cyclopropyl 3-CH3-phenyl 278 cyclopropyl 4-OH-PhenylCyclobutyl 3-CH3-phenyl 279 Cyclobutyl 4-OH-Phenyl cyclopentyl 3-CH3-phenyl 280 cyclopentyl 4-OH-Phenyl cyclohexyl 3-CH3-phenyl 281 cyclohexyl 4-OH-Phenyl3-pyridyl 3-CH3-phenyl 282 3-pyridyl 4-OH-Phenyl1-methyl-lH- 3-CH3-phenyl 1 -methyl- 1H- 4-OH-Phenyl283pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 3-CH3-phenyl 284 lH-imidazol-4-yl 4-OH-Phenyl2-furanyl 3-CH3-phenyl 285 2-furanyl 4-OH-Phenyl ethyl 3-OH-Phenyl 286 ethyl 2-OH-Phenyl n-propyl 3-OH-Phenyl 287 n-propyl 2-OH-Phenyl isopropyl 3-OH-Phenyl 288 isopropyl 2-OH-Phenyl-CH2CH(CH3)23-OH-Phenyl 289 -CH2CH(CH3)22-OH-Phenyl-CF33-OH-Phenyl 290 -CF32-OH-Phenyl-CH2CF3 3-OH-Phenyl 291 -CH2CF32-OH-Phenyl-CH2CH2CF33-OH-Phenyl 292 -CH2CH2CF32-OH-Phenylcyclopropyl 3-OH-Phenyl 293 cyclopropyl 2-OH-PhenylCyclobutyl 3-OH-Phenyl 294 Cyclobutyl 2-OH-Phenyl cyclopentyl 3-OH-Phenyl 295 cyclopentyl 2-OH-Phenyl cyclohexyl 3-OH-Phenyl 296 cyclohexyl 2-OH-Phenyl3-pyridyl 3-OH-Phenyl 297 3-pyridyl 2-OH-Phenyl1-methyl-lH- 3-OH-Phenyl 1-methyl-lH- 2-OH-Phenyl298pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 3-OH-Phenyl 299 lH-imidazol-4-yl 2-OH-Phenyl2-furanyl 3-OH-Phenyl 300 2-furanyl 2-OH-Phenyl ethyl 4-OMe-Phenyl 301 ethyl 3-OMe-Phenyl n-propyl 4-OMe-Phenyl 302 n-propyl 3-OMe-Phenyl isopropyl 4-OMe-Phenyl 303 isopropyl 3-OMe-Phenyl-CH2CH(CH3)24-OMe-Phenyl 304 -CH2CH(CH3)2 3-OMe-Phenyl-CF34-OMe-Phenyl 305 -CF33-OMe-Phenyl-CH2CF3 4-OMe-Phenyl 306 -CH2CF33-OMe-Phenyl-CH2CH2CF34-OMe-Phenyl 307 -CH2CH2CF33-OMe-Phenyl cyclopropyl 4-OMe-Phenyl 308 cyclopropyl 3-OMe-PhenylCyclobutyl 4-OMe-Phenyl 309 Cyclobutyl 3-OMe-Phenyl cyclopentyl 4-OMe-Phenyl 310 cyclopentyl 3-OMe-Phenyl cyclohexyl 4-OMe-Phenyl 311 cyclohexyl 3-OMe-Phenyl3-pyridyl 4-OMe-Phenyl 312 3-pyridyl 3-OMe-Phenyl1-methyl-lH- 1-methyl-lH-4-OMe-Phenyl 313 3-OMe-Phenyl pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 4-OMe-Phenyl 314 lH-imidazol-4-yl 3-OMe-Phenyl2-furanyl 4-OMe-Phenyl 315 2-furanyl 3-OMe-Phenyl ethyl 2-OMe-Phenyl 316 ethyl 4-CN-Phenyl n-propyl 2-OMe-Phenyl 317 n-propyl 4-CN-Phenyl isopropyl 2-OMe-Phenyl 318 isopropyl 4-CN-Phenyl-CH2CH(CH3)22-OMe-Phenyl 319 -CH2CH(CH3)24-CN-Phenyl-CF32-OMe-Phenyl 320 -CF34-CN-Phenyl-CH2CF3 2-OMe-Phenyl 321 -CH2CF34-CN-Phenyl-CH2CH2CF32-OMe-Phenyl 322 -CH2CH2CF34-CN-Phenyl cyclopropyl 2-OMe-Phenyl 323 cyclopropyl 4-CN-PhenylCyclobutyl 2-OMe-Phenyl 324 Cyclobutyl 4-CN-Phenylcyclopentyl 2-OMe-Phenyl 325 cyclopentyl 4-CN-Phenyl cyclohexyl 2-OMe-Phenyl 326 cyclohexyl 4-CN-Phenyl3-pyridyl 2-OMe-Phenyl 327 3-pyridyl 4-CN-Phenyl1-methyl-lH- 1-methyl-lH-2-OMe-Phenyl 328 4-CN-Phenyl pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 2-OMe-Phenyl 329 lH-imidazol-4-yl 4-CN-Phenyl2-furanyl 2-OMe-Phenyl 330 2-furanyl 4-CN-Phenyl ethyl 3-CN-Phenyl 331 ethyl 2-CN-Phenyl n-propyl 3-CN-Phenyl 332 n-propyl 2-CN-Phenyl isopropyl 3-CN-Phenyl 333 isopropyl 2-CN-Phenyl-CH2CH(CH3)23-CN-Phenyl 334 -CH2CH(CH3)2 2-CN-Phenyl-CF33-CN-Phenyl 335 -CF32-CN-Phenyl-CH2CF3 3-CN-Phenyl 336 -CH2CF32-CN-Phenyl-CH2CH2CF33-CN-Phenyl 337 -CH2CH2CF32-CN-Phenyl cyclopropyl 3-CN-Phenyl 338 cyclopropyl 2-CN-PhenylCyclobutyl 3-CN-Phenyl 339 Cyclobutyl 2-CN-Phenyl cyclopentyl 3-CN-Phenyl 340 cyclopentyl 2-CN-Phenyl cyclohexyl 3-CN-Phenyl 341 cyclohexyl 2-CN-Phenyl3-pyridyl 3-CN-Phenyl 342 3-pyridyl 2-CN-Phenyl1-methyl-lH- 1-methyl-lH-3-CN-Phenyl 343 2-CN-Phenyl pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 3-CN-Phenyl 344 lH-imidazol-4-yl 2-CN-Phenyl2-furanyl 3-CN-Phenyl 345 2-furanyl 2-CN-Phenyl ethyl 2-F-Phenyl 346 ethyl 3-F-Phenyl n-propyl 2-F-Phenyl 347 n-propyl 3-F-Phenyl isopropyl 2-F-Phenyl 348 isopropyl 3-F-Phenyl-CH2CH(CH3)22-F-Phenyl 349 -CH2CH(CH3)23-F-Phenyl-CF32-F-Phenyl 350 -CF33-F-Phenyl-CH2CF3 2-F-Phenyl 351 -CH2CF33-F-Phenyl-CH2CH2CF32-F-Phenyl 352 -CH2CH2CF33-F-Phenyl cyclopropyl 2-F-Phenyl 353 cyclopropyl 3-F-PhenylCyclobutyl 2-F-Phenyl 354 Cyclobutyl 3-F-Phenyl cyclopentyl 2-F-Phenyl 355 cyclopentyl 3-F-Phenyl cyclohexyl 2-F-Phenyl 356 cyclohexyl 3-F-Phenyl102 3-pyridyl 2-F-Phenyl 357 3-pyridyl 3-F-Phenyl1-methyl-lH- 1-methyl-lH-103 2-F-Phenyl 358 3-F-Phenyl pyrazol-4-yl pyrazol-4-yl104 lH-imidazol-4-yl 2-F-Phenyl 359 lH-imidazol-4-yl 3-F-Phenyl105 2-furanyl 2-F-Phenyl 360 2-furanyl 3-F-Phenyl106 ethyl 4-F-Phenyl 361 ethyl 2-Cl-Phenyl107 n-propyl 4-F-Phenyl 362 n-propyl 2-Cl-Phenyl108 isopropyl 4-F-Phenyl 363 isopropyl 2-Cl-Phenyl109 -CH2CH(CH3)24-F-Phenyl 364 -CH2CH(CH3)2 2-Cl-Phenyl110 -CF34-F-Phenyl 365 -CF32-Cl-Phenyl111 -CH2CF3 4-F-Phenyl 366 -CH2CF32-Cl-Phenyl112 -CH2CH2CF34-F-Phenyl 367 -CH2CH2CF32-Cl-Phenyl113 cyclopropyl 4-F-Phenyl 368 cyclopropyl 2-Cl-Phenyl114 Cyclobutyl 4-F-Phenyl 369 Cyclobutyl 2-Cl-Phenyl115 cyclopentyl 4-F-Phenyl 370 cyclopentyl 2-Cl-Phenyl116 cyclohexyl 4-F-Phenyl 371 cyclohexyl 2-Cl-Phenyl117 3-pyridyl 4-F-Phenyl 372 3-pyridyl 2-Cl-Phenyl1-methyl-lH- 1-methyl-lH-118 4-F-Phenyl 373 2-Cl-Phenyl pyrazol-4-yl pyrazol-4-yl119 lH-imidazol-4-yl 4-F-Phenyl 374 lH-imidazol-4-yl 2-Cl-Phenyl120 2-furanyl 4-F-Phenyl 375 2-furanyl 2-Cl-Phenyl121 ethyl 3-Cl-Phenyl 376 ethyl 4-Cl-Phenyl122 n-propyl 3-Cl-Phenyl 377 n-propyl 4-Cl-Phenyl123 isopropyl 3-Cl-Phenyl 378 isopropyl 4-Cl-Phenyl124 -CH2CH(CH3)23-Cl-Phenyl 379 -CH2CH(CH3)24-Cl-Phenyl125 -CF33-Cl-Phenyl 380 -CF34-Cl-Phenyl126 -CH2CF3 3-Cl-Phenyl 381 -CH2CF34-Cl-Phenyl127 -CH2CH2CF33-Cl-Phenyl 382 -CH2CH2CF34-Cl-Phenyl128 cyclopropyl 3-Cl-Phenyl 383 cyclopropyl 4-Cl-Phenyl129 Cyclobutyl 3-Cl-Phenyl 384 Cyclobutyl 4-Cl-Phenyl130 cyclopentyl 3-Cl-Phenyl 385 cyclopentyl 4-Cl-Phenyl131 cyclohexyl 3-Cl-Phenyl 386 cyclohexyl 4-Cl-Phenyl132 3-pyridyl 3-Cl-Phenyl 387 3-pyridyl 4-Cl-Phenyl133 1 -methyl- 1H- 3-Cl-Phenyl 388 1-methyl-lH- 4-Cl-Phenylpyrazol-4-yl pyrazol-4-yl134 lH-imidazol-4-yl 3-Cl-Phenyl 389 lH-imidazol-4-yl 4-Cl-Phenyl135 2-furanyl 3-Cl-Phenyl 390 2-furanyl 4-Cl-Phenyl136 ethyl 2-Br-Phenyl 391 ethyl 3-Br-Phenyl137 n-propyl 2-Br-Phenyl 392 n-propyl 3-Br-Phenyl138 isopropyl 2-Br-Phenyl 393 isopropyl 3-Br-Phenyl139 -CH2CH(CH3)22-Br-Phenyl 394 -CH2CH(CH3)2 3-Br-Phenyl140 -CF32-Br-Phenyl 395 -CF33-Br-Phenyl141 -CH2CF3 2-Br-Phenyl 396 -CH2CF33-Br-Phenyl142 -CH2CH2CF32-Br-Phenyl 397 -CH2CH2CF33-Br-Phenyl143 cyclopropyl 2-Br-Phenyl 398 cyclopropyl 3-Br-Phenyl144 Cyclobutyl 2-Br-Phenyl 399 Cyclobutyl 3-Br-Phenyl145 cyclopentyl 2-Br-Phenyl 400 cyclopentyl 3-Br-Phenyl146 cyclohexyl 2-Br-Phenyl 401 cyclohexyl 3-Br-Phenyl147 3-pyridyl 2-Br-Phenyl 402 3-pyridyl 3-Br-Phenyl1-methyl-lH- 1-methyl-lH- 3-Br-Phenyl148 2-Br-Phenyl 403pyrazol-4-yl pyrazol-4-yl149 lH-imidazol-4-yl 2-Br-Phenyl 404 lH-imidazol-4-yl 3-Br-Phenyl150 2-furanyl 2-Br-Phenyl 405 2-furanyl 3-Br-Phenyl151 ethyl 4-Br-Phenyl 406 ethyl 2-CF3-Phenyl152 n-propyl 4-Br-Phenyl 407 n-propyl 2-CF3-Phenyl153 isopropyl 4-Br-Phenyl 408 isopropyl 2-CF3-Phenyl154 -CH2CH(CH3)24-Br-Phenyl 409 -CH2CH(CH3)22-CF3-Phenyl155 -CF34-Br-Phenyl 410 -CF32-CF3-Phenyl156 -CH2CF3 4-Br-Phenyl 411 -CH2CF32-CF3-Phenyl157 -CH2CH2CF34-Br-Phenyl 412 -CH2CH2CF32-CF3-Phenyl158 cyclopropyl 4-Br-Phenyl 413 cyclopropyl 2-CF3-Phenyl159 Cyclobutyl 4-Br-Phenyl 414 Cyclobutyl 2-CF3-Phenyl160 cyclopentyl 4-Br-Phenyl 415 cyclopentyl 2-CF3-Phenyl161 cyclohexyl 4-Br-Phenyl 416 cyclohexyl 2-CF3-Phenyl162 3-pyridyl 4-Br-Phenyl 417 3-pyridyl 2-CF3-Phenyl1-methyl-lH- 4-Br-Phenyl 1-methyl-lH-163 418 2-CF3-Phenyl pyrazol-4-yl pyrazol-4-yl164 lH-imidazol-4-yl 4-Br-Phenyl 419 lH-imidazol-4-yl 2-CF3-Phenyl165 2-furanyl 4-Br-Phenyl 420 2-furanyl 2-CF3-Phenyl166 ethyl 3-CF3-Phenyl 421 ethyl 4-CF3-Phenyl167 n-propyl 3-CF3-Phenyl 422 n-propyl 4-CF3-Phenyl168 isopropyl 3-CF3-Phenyl 423 isopropyl 4-CF3-Phenyl169 -CH2CH(CH3)23-CF3-Phenyl 424 -CH2CH(CH3)24-CF3-Phenyl170 -CF33-CF3-Phenyl 425 -CF34-CF3-Phenyl171 -CH2CF3 3-CF3-Phenyl 426 -CH2CF34-CF3-Phenyl172 -CH2CH2CF33-CF3-Phenyl 427 -CH2CH2CF34-CF3-Phenyl173 cyclopropyl 3-CF3-Phenyl 428 cyclopropyl 4-CF3-Phenyl174 Cyclobutyl 3-CF3-Phenyl 429 Cyclobutyl 4-CF3-Phenyl175 cyclopentyl 3-CF3-Phenyl 430 cyclopentyl 4-CF3-Phenyl176 cyclohexyl 3-CF3-Phenyl 431 cyclohexyl 4-CF3-Phenyl177 3-pyridyl 3-CF3-Phenyl 432 3-pyridyl 4-CF3-Phenyl1-methyl-lH- 1-methyl-lH-178 3-CF3-Phenyl 433 4-CF3-Phenyl pyrazol-4-yl pyrazol-4-yl179 lH-imidazol-4-yl 3-CF3-Phenyl 434 lH-imidazol-4-yl 4-CF3-Phenyl180 2-furanyl 3-CF3-Phenyl 435 2-furanyl 4-CF3-Phenyl181 ethyl 2-iPr-Phenyl 436 ethyl 3-iPr-Phenyl182 n-propyl 2-iPr-Phenyl 437 n-propyl 3-iPr-Phenyl183 isopropyl 2-iPr-Phenyl 438 isopropyl 3-iPr-Phenyl184 -CH2CH(CH3)22-iPr-Phenyl 439 -CH2CH(CH3)23-iPr-Phenyl185 -CF32-iPr-Phenyl 440 -CF33-iPr-Phenyl186 -CH2CF3 2-iPr-Phenyl 441 -CH2CF33-iPr-Phenyl187 -CH2CH2CF32-iPr-Phenyl 442 -CH2CH2CF33-iPr-Phenyl188 cyclopropyl 2-iPr-Phenyl 443 cyclopropyl 3-iPr-Phenyl189 Cyclobutyl 2-iPr-Phenyl 444 Cyclobutyl 3-iPr-Phenyl190 cyclopentyl 2-iPr-Phenyl 445 cyclopentyl 3-iPr-Phenyl191 cyclohexyl 2-iPr-Phenyl 446 cyclohexyl 3-iPr-Phenyl192 3-pyridyl 2-iPr-Phenyl 447 3-pyridyl 3-iPr-Phenyl1-methyl-lH- 1-methyl-lH-193 2-iPr-Phenyl 448 3-iPr-Phenyl pyrazol-4-yl pyrazol-4-yl194 lH-imidazol-4-yl 2-iPr-Phenyl 449 lH-imidazol-4-yl 3-iPr-Phenyl195 2-furanyl 2-iPr-Phenyl 450 2-furanyl 3-iPr-Phenyl196 ethyl 4-iPr-Phenyl 451 ethyl 2-moφholino-phenyl n-propyl n-propyl 2-morpholino-197 4-iPr-Phenyl 452phenyl isopropyl isopropyl 2-morpholino-198 4-iPr-Phenyl 453phenyl-CH2CH(CH3)2-CH2CH(CH3)22-morpholino-199 4-iPr-Phenyl 454phenyl-CF3-CF32-morpholino-200 4-iPr-Phenyl 455phenyl-CH2CF3 -CH2CF3 2-ιηοφ1ιο1ίηο-201 4-iPr-Phenyl 456phenyl-CH2CH2CF3-CH2CH2CF32-morpholino-202 4-iPr-Phenyl 457phenyl cyclopropyl cyclopropyl 2-ιηοφ1ιο1ίηο-203 4-iPr-Phenyl 458phenylCyclobutyl Cyclobutyl 2-morpholino-204 4-iPr-Phenyl 459phenyl cyclopentyl cyclopentyl 2-ηιοφηο1ίηο-205 4-iPr-Phenyl 460phenyl cyclohexyl cyclohexyl 2-ιηοφ1ιο1ίηο-206 4-iPr-Phenyl 461phenyl3-pyridyl 3-pyridyl 2-morpholino-207 4-iPr-Phenyl 462phenyl1-methyl-lH- 1-methyl-lH- 2-ιηοφ1ιο1ίηο-208 4-iPr-Phenyl 463pyrazol-4-yl pyrazol-4-yl phenyl lH-imidazol-4-yl lH-imidazol-4-yl 2-ιηοφ1ιο1ίηο-209 4-iPr-Phenyl 464phenyl2-furanyl 2-furanyl 2-ηιοφηο1ίηο-210 4-iPr-Phenyl 465phenyl ethyl ethyl 4-morpholino-211 3 -ιηοφΐιοΐίηο -pheny 1 466phenyl n-propyl n-propyl 4-ηιοφηο1ίηο-212 3 -morpholino -pheny 1 467phenyl213 isopropyl 3 -morpholino -pheny 1 468 isopropyl 4-moφholino-phenyl-CH2CH(CH3)2-CH2CH(CH3)24-morpholino-214 3 -moφholino -pheny 1 469phenyl-CF3-CF34-morpholino-215 3 -morpholino -pheny 1 470phenyl-CH2CF3 -CH2CF34-morpholino-216 3 -morpholino -pheny 1 471phenyl-CH2CH2CF3-CH2CH2CF34-morpholino-217 3 -morpholino -pheny 1 472phenyl cyclopropyl cyclopropyl 4-morpholino-218 3 -morpholino -pheny 1 473phenylCyclobutyl Cyclobutyl 4-morpholino-219 3 -morpholino -pheny 1 474phenyl cyclopentyl cyclopentyl 4-morpholino-220 3 -morpholino -pheny 1 475phenyl cyclohexyl cyclohexyl 4-morpholino-221 3 -morpholino -pheny 1 476phenyl3-pyridyl 3-pyridyl 4-morpholino-222 3 -morpholino -pheny 1 477phenyl1-methyl-lH- 1-methyl-lH- 4-ιηοφ1ιο1ίηο-223 3 -morpholino -pheny 1 478pyrazol-4-yl pyrazol-4-yl phenyl lH-imidazol-4-yl lH-imidazol-4-yl 4-morpholino-224 3 -morpholino -pheny 1 479phenyl2-furanyl 2-furanyl 4-ιηοφ1ιο1ίηο-225 3 -morpholino -pheny 1 480phenyl ethyl 4-cyano-2-morpholino- ethyl 4-methyl-2-226 481phenyl morpholino -pheny 1 n-propyl 4-cyano-2-morpholino- n-propyl 4-methyl-2-227 482phenyl morpholino -pheny 1 isopropyl 4-cyano-2-morpholino- isopropyl 4-methyl-2-228 483phenyl morpholino -pheny 1-CH2CH(CH3)24-cyano-2-morpholino- -CH2CH(CH3)24-methyl-2-229 484phenyl morpholino -pheny 1230 -CF34-cyano-2-morpholino- 485 -CF34-methyl-2-phenyl morpholino -pheny 1-CH2CF3 4^3ηο-2-ηιοφ1ιο1ίηο- -CH2CF3 4-methyl-2-231 486phenyl morpholino -pheny 1-CH2CH2CF34-cyano-2-morpholino- -CH2CH2CF34-methyl-2-232 487phenyl morpholino -pheny 1 cyclopropyl 4-cyano-2-morpholino- cyclopropyl 4-methyl-2-233 488phenyl morpholino -pheny 1Cyclobutyl 4-cyano-2-morpholino- Cyclobutyl 4-methyl-2-234 489phenyl morpholino -pheny 1 cyclopentyl 4-cyano-2-morpholino- cyclopentyl 4-methyl-2-235 490phenyl morpholino -pheny 1 cyclohexyl 4-cyano-2-morpholino- cyclohexyl 4-methyl-2-236 491phenyl morpholino -pheny 13-pyridyl 4-cyano-2-morpholino- 3-pyridyl 4-methyl-2-237 492phenyl morpholino -pheny 11-methyl-lH- 4^3ηο-2-ηιοφ1ιο1ίηο- 1-methyl-lH- 4-methyl-2-238 493pyrazol-4-yl phenyl pyrazol-4-yl morpholino -pheny 1 lH-imidazol-4-yl 4-cyano-2-morpholino- lH-imidazol-4-yl 4-methyl-2-239 494phenyl morpholino -pheny 12-furanyl 4-cyano-2-morpholino- 2-furanyl 4-methyl-2-240 495phenyl morpholino -pheny 1 ethyl 4-hydroxy-2-241morpholino -pheny 1n-propyl 4-hydroxy-2-242moφholino -pheny 1isopropyl 4-hydroxy-2-243ηιοφΐιοΐίηο -pheny 1-CH2CH(CH3)24-hydroxy-2-244ηιοφΐιοΐίηο -pheny 1-CF34-hydroxy-2-245ηιοφΐιοΐίηο -pheny 1-CH2CF3 4-hydroxy-2-246ηιοφηοϋηο -pheny 1247 -CH2CH2CF34-hydroxy-2-morpholino -pheny 1cyclopropyl 4-hydroxy-2-248moφholino -pheny 1Cyclobutyl 4-hydroxy-2-249ιηοφΐιοΐίηο -pheny 1cyclopentyl 4-hydroxy-2-250ιηοφΐιοΐίηο -pheny 1cyclohexyl 4-hydroxy-2-251ιηοφΐιοΐίηο -pheny 13-pyridyl 4-hydroxy-2-252ηιοφηοϋηο -pheny 11-methyl-lH- 4-hydroxy-2-253pyrazol-4-yl ιηοφΐιοΐίηο -pheny 1lH-imidazol-4-yl 4-hydroxy-2-254ιηοφΐιοΐίηο -pheny 12-furanyl 4-hydroxy-2-255ιηοφΐιοΐίηο -pheny 1
[0335] Exemplary e la (XXVI)or a pharmaceutically acceptable salt form thereof defined herein below in Table 10.Table 10cyclopentyl 4-CH3-phenyl 265 cyclopentyl 2-CH3-phenyl cyclohexyl 4-CH3-phenyl 266 cyclohexyl 2-CH3-phenyl3-pyridyl 4-CH3-phenyl 267 3-pyridyl 2-CH3-phenyl1-methyl-lH- 4-CH3-phenyl 1-methyl-lH- 2-CH3-phenyl268pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 4-CH3-phenyl 269 lH-imidazol-4-yl 2-CH3-phenyl2-furanyl 4-CH3-phenyl 270 2-furanyl 2-CH3-phenyl ethyl 3-CH3-phenyl 271 ethyl 4-OH-Phenyl n-propyl 3-CH3-phenyl 272 n-propyl 4-OH-Phenyl isopropyl 3-CH3-phenyl 273 isopropyl 4-OH-Phenyl-CH2CH(CH3)23-CH3-phenyl 274 -CH2CH(CH3)24-OH-Phenyl-CF33-CH3-phenyl 275 -CF34-OH-Phenyl-CH2CF3 3-CH3-phenyl 276 -CH2CF34-OH-Phenyl-CH2CH2CF33-CH3-phenyl 277 -CH2CH2CF34-OH-Phenyl cyclopropyl 3-CH3-phenyl 278 cyclopropyl 4-OH-PhenylCyclobutyl 3-CH3-phenyl 279 Cyclobutyl 4-OH-Phenyl cyclopentyl 3-CH3-phenyl 280 cyclopentyl 4-OH-Phenyl cyclohexyl 3-CH3-phenyl 281 cyclohexyl 4-OH-Phenyl3-pyridyl 3-CH3-phenyl 282 3-pyridyl 4-OH-Phenyl1-methyl-lH- 3-CH3-phenyl 1-methyl-lH- 4-OH-Phenyl283pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 3-CH3-phenyl 284 lH-imidazol-4-yl 4-OH-Phenyl2-furanyl 3-CH3-phenyl 285 2-furanyl 4-OH-Phenyl ethyl 3-OH-Phenyl 286 ethyl 2-OH-Phenyl n-propyl 3-OH-Phenyl 287 n-propyl 2-OH-Phenyl isopropyl 3-OH-Phenyl 288 isopropyl 2-OH-Phenyl-CH2CH(CH3)23-OH-Phenyl 289 -CH2CH(CH3)22-OH-Phenyl-CF33-OH-Phenyl 290 -CF32-OH-Phenyl-CH2CF3 3-OH-Phenyl 291 -CH2CF32-OH-Phenyl-CH2CH2CF33-OH-Phenyl 292 -CH2CH2CF32-OH-Phenyl cyclopropyl 3-OH-Phenyl 293 cyclopropyl 2-OH-PhenylCyclobutyl 3-OH-Phenyl 294 Cyclobutyl 2-OH-Phenyl cyclopentyl 3-OH-Phenyl 295 cyclopentyl 2-OH-Phenyl cyclohexyl 3-OH-Phenyl 296 cyclohexyl 2-OH-Phenyl3-pyridyl 3-OH-Phenyl 297 3-pyridyl 2-OH-Phenyl1-methyl-lH- 3-OH-Phenyl 1-methyl-lH- 2-OH-Phenyl298pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 3-OH-Phenyl 299 lH-imidazol-4-yl 2-OH-Phenyl2-furanyl 3-OH-Phenyl 300 2-furanyl 2-OH-Phenyl ethyl 4-OMe-Phenyl 301 ethyl 3-OMe-Phenyl n-propyl 4-OMe-Phenyl 302 n-propyl 3-OMe-Phenyl isopropyl 4-OMe-Phenyl 303 isopropyl 3-OMe-Phenyl-CH2CH(CH3)24-OMe-Phenyl 304 -CH2CH(CH3)2 3-OMe-Phenyl-CF34-OMe-Phenyl 305 -CF33-OMe-Phenyl-CH2CF3 4-OMe-Phenyl 306 -CH2CF33-OMe-Phenyl-CH2CH2CF34-OMe-Phenyl 307 -CH2CH2CF33-OMe-Phenyl cyclopropyl 4-OMe-Phenyl 308 cyclopropyl 3-OMe-PhenylCyclobutyl 4-OMe-Phenyl 309 Cyclobutyl 3-OMe-Phenyl cyclopentyl 4-OMe-Phenyl 310 cyclopentyl 3-OMe-Phenyl cyclohexyl 4-OMe-Phenyl 311 cyclohexyl 3-OMe-Phenyl3-pyridyl 4-OMe-Phenyl 312 3-pyridyl 3-OMe-Phenyl1-methyl-lH- 1-methyl-lH-4-OMe-Phenyl 313 3-OMe-Phenyl pyrazol-4-yl pyrazol-4-yllH-imidazol-4-yl 4-OMe-Phenyl 314 lH-imidazol-4-yl 3-OMe-Phenyl2-furanyl 4-OMe-Phenyl 315 2-furanyl 3-OMe-Phenyl ethyl 2-OMe-Phenyl 316 ethyl 4-CN-Phenyl n-propyl 2-OMe-Phenyl 317 n-propyl 4-CN-Phenyl isopropyl 2-OMe-Phenyl 318 isopropyl 4-CN-Phenyl-CH2CH(CH3)22-OMe-Phenyl 319 -CH2CH(CH3)24-CN-Phenyl-CF32-OMe-Phenyl 320 -CF34-CN-Phenyl-CH2CF3 2-OMe-Phenyl 321 -CH2CF34-CN-Phenyl-CH2CH2CF32-OMe-Phenyl 322 -CH2CH2CF34-CN-Phenyl cyclopropyl 2-OMe-Phenyl 323 cyclopropyl 4-CN-PhenylCyclobutyl 2-OMe-Phenyl 324 Cyclobutyl 4-CN-Phenyl cyclopentyl 2-OMe-Phenyl 325 cyclopentyl 4-CN-Phenyl cyclohexyl 2-OMe-Phenyl 326 cyclohexyl 4-CN-Phenyl3-pyridyl 2-OMe-Phenyl 327 3-pyridyl 4-CN-Phenyl1-methyl-lH- 2-OMe-Phenyl 328 1 -methyl- 1H- 4-CN-Phenylpyrazol-4-yl pyrazol-4-yl74 lH-imidazol-4-yl 2-OMe-Phenyl 329 lH-imidazol-4-yl 4-CN-Phenyl75 2-furanyl 2-OMe-Phenyl 330 2-furanyl 4-CN-Phenyl76 ethyl 3-CN-Phenyl 331 ethyl 2-CN-Phenyl77 n-propyl 3-CN-Phenyl 332 n-propyl 2-CN-Phenyl78 isopropyl 3-CN-Phenyl 333 isopropyl 2-CN-Phenyl79 -CH2CH(CH3)23-CN-Phenyl 334 -CH2CH(CH3)2 2-CN-Phenyl80 -CF33-CN-Phenyl 335 -CF32-CN-Phenyl81 -CH2CF3 3-CN-Phenyl 336 -CH2CF32-CN-Phenyl82 -CH2CH2CF33-CN-Phenyl 337 -CH2CH2CF32-CN-Phenyl83 cyclopropyl 3-CN-Phenyl 338 cyclopropyl 2-CN-Phenyl84 Cyclobutyl 3-CN-Phenyl 339 Cyclobutyl 2-CN-Phenyl85 cyclopentyl 3-CN-Phenyl 340 cyclopentyl 2-CN-Phenyl86 cyclohexyl 3-CN-Phenyl 341 cyclohexyl 2-CN-Phenyl87 3-pyridyl 3-CN-Phenyl 342 3-pyridyl 2-CN-Phenyl1-methyl-lH- 1-methyl-lH-88 3-CN-Phenyl 343 2-CN-Phenyl pyrazol-4-yl pyrazol-4-yl89 lH-imidazol-4-yl 3-CN-Phenyl 344 lH-imidazol-4-yl 2-CN-Phenyl90 2-furanyl 3-CN-Phenyl 345 2-furanyl 2-CN-Phenyl91 ethyl 2-F-Phenyl 346 ethyl 3-F-Phenyl92 n-propyl 2-F-Phenyl 347 n-propyl 3-F-Phenyl93 isopropyl 2-F-Phenyl 348 isopropyl 3-F-Phenyl94 -CH2CH(CH3)22-F-Phenyl 349 -CH2CH(CH3)23-F-Phenyl95 -CF32-F-Phenyl 350 -CF33-F-Phenyl96 -CH2CF3 2-F-Phenyl 351 -CH2CF33-F-Phenyl97 -CH2CH2CF32-F-Phenyl 352 -CH2CH2CF33-F-Phenyl98 cyclopropyl 2-F-Phenyl 353 cyclopropyl 3-F-Phenyl99 Cyclobutyl 2-F-Phenyl 354 Cyclobutyl 3-F-Phenyl100 cyclopentyl 2-F-Phenyl 355 cyclopentyl 3-F-Phenyl101 cyclohexyl 2-F-Phenyl 356 cyclohexyl 3-F-Phenyl102 3-pyridyl 2-F-Phenyl 357 3-pyridyl 3-F-Phenyl1-methyl-lH- 1-methyl-lH-103 2-F-Phenyl 358 3-F-Phenyl pyrazol-4-yl pyrazol-4-yl104 lH-imidazol-4-yl 2-F-Phenyl 359 lH-imidazol-4-yl 3-F-Phenyl105 2-furanyl 2-F-Phenyl 360 2-furanyl 3-F-Phenyl106 ethyl 4-F-Phenyl 361 ethyl 2-Cl-Phenyl107 n-propyl 4-F-Phenyl 362 n-propyl 2-Cl-Phenyl108 isopropyl 4-F-Phenyl 363 isopropyl 2-Cl-Phenyl109 -CH2CH(CH3)24-F-Phenyl 364 -CH2CH(CH3)2 2-Cl-Phenyl110 -CF34-F-Phenyl 365 -CF32-Cl-Phenyl111 -CH2CF3 4-F-Phenyl 366 -CH2CF32-Cl-Phenyl112 -CH2CH2CF34-F-Phenyl 367 -CH2CFi2CF32-Cl-Phenyl113 cyclopropyl 4-F-Phenyl 368 cyclopropyl 2-Cl-Phenyl114 Cyclobutyl 4-F-Phenyl 369 Cyclobutyl 2-Cl-Phenyl115 cyclopentyl 4-F-Phenyl 370 cyclopentyl 2-Cl-Phenyl116 cyclohexyl 4-F-Phenyl 371 cyclohexyl 2-Cl-Phenyl117 3-pyridyl 4-F-Phenyl 372 3-pyridyl 2-Cl-Phenyl1-methyl-lH- 1-methyl-lH-118 4-F-Phenyl 373 2-Cl-Phenyl pyrazol-4-yl pyrazol-4-yl119 lH-imidazol-4-yl 4-F-Phenyl 374 lH-imidazol-4-yl 2-Cl-Phenyl120 2-furanyl 4-F-Phenyl 375 2-furanyl 2-Cl-Phenyl121 ethyl 3-Cl-Phenyl 376 ethyl 4-Cl-Phenyl122 n-propyl 3-Cl-Phenyl 377 n-propyl 4-Cl-Phenyl123 isopropyl 3-Cl-Phenyl 378 isopropyl 4-Cl-Phenyl124 -CH2CH(CH3)23-Cl-Phenyl 379 -CH2CH(CH3)24-Cl-Phenyl125 -CF33-Cl-Phenyl 380 -CF34-Cl-Phenyl126 -CH2CF3 3-Cl-Phenyl 381 -CH2CF34-Cl-Phenyl127 -CH2CH2CF33-Cl-Phenyl 382 -CH2CH2CF34-Cl-Phenyl128 cyclopropyl 3-Cl-Phenyl 383 cyclopropyl 4-Cl-Phenyl129 Cyclobutyl 3-Cl-Phenyl 384 Cyclobutyl 4-Cl-Phenyl130 cyclopentyl 3-Cl-Phenyl 385 cyclopentyl 4-Cl-Phenyl131 cyclohexyl 3-Cl-Phenyl 386 cyclohexyl 4-Cl-Phenyl132 3-pyridyl 3-Cl-Phenyl 387 3-pyridyl 4-Cl-Phenyl1-methyl-lH- 1-methyl-lH-133 3-Cl-Phenyl 388 4-Cl-Phenyl pyrazol-4-yl pyrazol-4-yl134 lH-imidazol-4-yl 3-Cl-Phenyl 389 lH-imidazol-4-yl 4-Cl-Phenyl135 2-furanyl 3-Cl-Phenyl 390 2-furanyl 4-Cl-Phenyl136 ethyl 2-Br-Phenyl 391 ethyl 3-Br-Phenyl137 n-propyl 2-Br-Phenyl 392 n-propyl 3-Br-Phenyl138 isopropyl 2-Br-Phenyl 393 isopropyl 3-Br-Phenyl139 -CH2CH(CH3)22-Br-Phenyl 394 -CH2CH(CH3)23-Br-Phenyl140 -CF32-Br-Phenyl 395 -CF33-Br-Phenyl141 -CH2CF3 2-Br-Phenyl 396 -CH2CF33-Br-Phenyl142 -CH2CH2CF32-Br-Phenyl 397 -CH2CH2CF33-Br-Phenyl143 cyclopropyl 2-Br-Phenyl 398 cyclopropyl 3-Br-Phenyl144 Cyclobutyl 2-Br-Phenyl 399 Cyclobutyl 3-Br-Phenyl145 cyclopentyl 2-Br-Phenyl 400 cyclopentyl 3-Br-Phenyl146 cyclohexyl 2-Br-Phenyl 401 cyclohexyl 3-Br-Phenyl147 3-pyridyl 2-Br-Phenyl 402 3-pyridyl 3-Br-Phenyl1-methyl-lH- 1-methyl-lH- 3-Br-Phenyl148 2-Br-Phenyl 403pyrazol-4-yl pyrazol-4-yl149 lH-imidazol-4-yl 2-Br-Phenyl 404 lH-imidazol-4-yl 3-Br-Phenyl150 2-furanyl 2-Br-Phenyl 405 2-furanyl 3-Br-Phenyl151 ethyl 4-Br-Phenyl 406 ethyl 2-CF3-Phenyl152 n-propyl 4-Br-Phenyl 407 n-propyl 2-CF3-Phenyl153 isopropyl 4-Br-Phenyl 408 isopropyl 2-CF3-Phenyl154 -CH2CH(CH3)24-Br-Phenyl 409 -CH2CH(CH3)22-CF3-Phenyl155 -CF34-Br-Phenyl 410 -CF32-CF3-Phenyl156 -CH2CF3 4-Br-Phenyl 411 -CH2CF32-CF3-Phenyl157 -CH2CH2CF34-Br-Phenyl 412 -CH2CH2CF32-CF3-Phenyl158 cyclopropyl 4-Br-Phenyl 413 cyclopropyl 2-CF3-Phenyl159 Cyclobutyl 4-Br-Phenyl 414 Cyclobutyl 2-CF3-Phenyl160 cyclopentyl 4-Br-Phenyl 415 cyclopentyl 2-CF3-Phenyl161 cyclohexyl 4-Br-Phenyl 416 cyclohexyl 2-CF3-Phenyl162 3-pyridyl 4-Br-Phenyl 417 3-pyridyl 2-CF3-Phenyl1-methyl-lH- 4-Br-Phenyl 1-methyl-lH-163 418 2-CF3-Phenyl pyrazol-4-yl pyrazol-4-yl164 lH-imidazol-4-yl 4-Br-Phenyl 419 lH-imidazol-4-yl 2-CF3-Phenyl165 2-furanyl 4-Br-Phenyl 420 2-furanyl 2-CF3-Phenyl166 ethyl 3-CF3-Phenyl 421 ethyl 4-CF3-Phenyl167 n-propyl 3-CF3-Phenyl 422 n-propyl 4-CF3-Phenyl168 isopropyl 3-CF3-Phenyl 423 isopropyl 4-CF3-Phenyl169 -CH2CH(CH3)23-CF3-Phenyl 424 -CH2CH(CH3)24-CF3-Phenyl170 -CF33-CF3-Phenyl 425 -CF34-CF3-Phenyl171 -CH2CF3 3-CF3-Phenyl 426 -CH2CF34-CF3-Phenyl172 -CH2CH2CF33-CF3-Phenyl 427 -CH2CH2CF34-CF3-Phenyl173 cyclopropyl 3-CF3-Phenyl 428 cyclopropyl 4-CF3-Phenyl174 Cyclobutyl 3-CF3-Phenyl 429 Cyclobutyl 4-CF3-Phenyl175 cyclopentyl 3-CF3-Phenyl 430 cyclopentyl 4-CF3-Phenyl176 cyclohexyl 3-CF3-Phenyl 431 cyclohexyl 4-CF3-Phenyl177 3-pyridyl 3-CF3-Phenyl 432 3-pyridyl 4-CF3-Phenyl1-methyl-lH- 1-methyl-lH-178 3-CF3-Phenyl 433 4-CF3-Phenyl pyrazol-4-yl pyrazol-4-yl179 lH-imidazol-4-yl 3-CF3-Phenyl 434 lH-imidazol-4-yl 4-CF3-Phenyl180 2-furanyl 3-CF3-Phenyl 435 2-furanyl 4-CF3-Phenyl181 ethyl 2-iPr-Phenyl 436 ethyl 3-iPr-Phenyl182 n-propyl 2-iPr-Phenyl 437 n-propyl 3-iPr-Phenyl183 isopropyl 2-iPr-Phenyl 438 isopropyl 3-iPr-Phenyl184 -CH2CH(CH3)22-iPr-Phenyl 439 -CH2CH(CH3)23-iPr-Phenyl185 -CF32-iPr-Phenyl 440 -CF33-iPr-Phenyl186 -CH2CF3 2-iPr-Phenyl 441 -CH2CF33-iPr-Phenyl187 -CH2CH2CF32-iPr-Phenyl 442 -CH2CH2CF33-iPr-Phenyl188 cyclopropyl 2-iPr-Phenyl 443 cyclopropyl 3-iPr-Phenyl189 Cyclobutyl 2-iPr-Phenyl 444 Cyclobutyl 3-iPr-Phenyl190 cyclopentyl 2-iPr-Phenyl 445 cyclopentyl 3-iPr-Phenyl191 cyclohexyl 2-iPr-Phenyl 446 cyclohexyl 3-iPr-Phenyl192 3-pyridyl 2-iPr-Phenyl 447 3-pyridyl 3-iPr-Phenyl1-methyl-lH- 1-methyl-lH-193 2-iPr-Phenyl 448 3-iPr-Phenyl pyrazol-4-yl pyrazol-4-yl194 lH-imidazol-4-yl 2-iPr-Phenyl 449 lH-imidazol-4-yl 3-iPr-Phenyl195 2-furanyl 2-iPr-Phenyl 450 2-furanyl 3-iPr-Phenyl ethyl ethyl 2-morpholino-196 4-iPr-Phenyl 451phenyl n-propyl n-propyl 2-morpholino-197 4-iPr-Phenyl 452phenyl198 isopropyl 4-iPr-Phenyl 453 isopropyl 2-moφholino-phenyl-CH2CH(CH3)2-CH2CH(CH3)22-ηιοφηο1ίηο-199 4-iPr-Phenyl 454phenyl-CF3-CF32-ηιοφ1ιο1ίηο-200 4-iPr-Phenyl 455phenyl-CH2CF3 -CH2CF32-ηιοφ1ιο1ίηο-201 4-iPr-Phenyl 456phenyl-CH2CH2CF3-CH2CH2CF32-ηιοφηο1ίηο-202 4-iPr-Phenyl 457phenyl cyclopropyl cyclopropyl 2-ηιοφ1ιο1ίηο-203 4-iPr-Phenyl 458phenylCyclobutyl Cyclobutyl 2-morpholino-204 4-iPr-Phenyl 459phenyl cyclopentyl cyclopentyl 2-ηιοφ1ιο1ίηο-205 4-iPr-Phenyl 460phenyl cyclohexyl cyclohexyl 2-ηιοφ1ιο1ίηο-206 4-iPr-Phenyl 461phenyl3-pyridyl 3-pyridyl 2-morpholino-207 4-iPr-Phenyl 462phenyl1-methyl-lH- 1-methyl-lH- 2-ηιοφ1ιο1ίηο-208 4-iPr-Phenyl 463pyrazol-4-yl pyrazol-4-yl phenyl lH-imidazol-4-yl lH-imidazol-4-yl 2-ηιοφηο1ίηο-209 4-iPr-Phenyl 464phenyl2-furanyl 2-furanyl 2-moφholino-210 4-iPr-Phenyl 465phenyl ethyl 3-morpholino- ethyl 4-morpholino-211 466phenyl phenyl n-propyl 3-ηιοφ1ιο1ίηο- n-propyl 4-ηιοφηο1ίηο-212 467phenyl phenyl isopropyl 3-ηιοφ1ιο1ίηο- isopropyl 4-morpholino-213 468phenyl phenyl-CH2CH(CH3)23-morpholino- -CH2CH(CH3)24-ηιοφηο1ίηο-214 469phenyl phenyl215 -CF33-ηιοφ1ιο1ίηο- 470 -CF34-moφholino-232 -CH2CH2CF34-cyano-2- 487 -CH2CH2CF34-methyl-2-249 Cyclobutyl 4-hydroxy-2-moφholino-phenylcyclopentyl 4-hydroxy-2-250moφholino-phenylcy clone xyl 4-hydroxy-2-251morpholino-phenyl3-pyridyl 4-hydroxy-2-252moφholino-phenyl1-methyl-lH- 4-hydroxy-2-253pyrazol-4-yl moφholino-phenyllH-imidazol-4-yl 4-hydroxy-2-254moφholino-phenyl2-furanyl 4-hydroxy-2-255moφholino-phenyl
[0336] For the pvuposes of demonstrating the manner in which the compounds of the present invention are named and referred to herein, the compound having the formula:has the chemical name 8-(methylsulfonyl)-3-(2-(4-phenylpiperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] decan- 1 -one .
[0337] For the ρυφθβεβ of demonstrating the manner in which the compounds of the present invention are named and referred to herein, the compound having the formula:has the chemical name 8-(methylsulfonyl)-3-(2-(5-phenylhexahydropyrrolo[3,4-c]pyrrol-2(lH)- y l)ethy l)-2-oxa-8-azaspiro [4.5] decan- 1 -one.
[0338] For the ρυφοβεβ of the present invention, a compound depicted by the racemic formula, for example:will stand equally well for either of the two enantiomers having the formula:or the formula:or mixtures thereof, or in the case where a second chiral center is present, all diastereomers.
[0339] In all of the embodiments provided herein, examples of suitable optional substituents are not intended to limit the scope of the claimed invention. The compounds of the invention may contain any of the substituents, or combinations of substituents, provided herein.Process for preparing the 5-hydroxytryptamine receptor 7 activity modulators of the invention
[0340] The present invention further relates to a process for preparing the 5- hydroxytryptamine receptor 7 activity modulators of the present invention.
[0341] Compounds of the present teachings can be prepared in accordance with the procedures outlined herein, from commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unlessotherwise stated. Optimum reaction conditions can vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented can be varied for the purpose of optimizing the formation of the compounds described herein.
[0342] The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ¾ or13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatography such as high pressure liquid chromatograpy (HPLC), gas chromatography (GC), gel-permeation chromatography (GPC), or thin layer chromatography (TLC).
[0343] Preparation of the compounds can involve protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene et al., Protective Groups in Organic Synthesis, 2d. Ed. (Wiley & Sons, 1991), the entire disclosure of which is incorporated by reference herein for all purposes.
[0344] The reactions or the processes described herein can be carried out in suitable solvents which can be readily selected by one skilled in the art of organic synthesis. Suitable solvents typically are substantially nonreactive with the reactants, intermediates, and / or products at the temperatures at which the reactions are carried out, i.e., temperatures that can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.
[0345] The compounds of these teachings can be prepared by methods known in the art of organic chemistry. The reagents used in the preparation of the compounds of these teachings can be either commercially obtained or can be prepared by standard procedures described in the literature. For example, compounds of the present invention can be prepared according to the method illustrated in the General Synthetic Schemes:General Synthetic Schemes for Preparation of Compounds
[0346] The reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. In accordance with this invention, compounds in the genus may be produced by one of the following reaction schemes.
[0347] Compounds of the disclosure may be prepared according to the process outlined in Scheme 1-x.
[0348] A suitably substituted compound of formula (1), a known compound or compound prepared by known methods wherein X1is an Ci-s alkyl, is reacted with benzyl bromide in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like in the presence of a solvent such as ethanol, methanol, isopropanol, tetrahydrofuran, 1,4-dioxane, methylene chloride, Ν,Ν-dimethyl formamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (2). A compound of the formula (2) is reacted with a compound of the formula (3), a known compound or a compound prepared by known methods in which LG is a leaving group such as chlorine, bromine, iodine, mesylate, tosylate, and the like, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, and the like in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxy ethane, dimethylformamide, dimethylacetamide, and the like, to provide a compound of the formula (4). A compound of the formula (4) is then treated with paraformaldehyde in the presence of an acid such as sulfuric acid, hydrochloric acid, and the like, in an the presence of acetic acid, and optionally in an organic solvent such as methanol, ethanol, tetrahydrofuran, 1,4- dioxane, 1,2-dimethoxy ethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (5). A compound of the formula (5) is then treated with a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in an solvent such as water, methanol, ethanol, isopropanol, and the like, optionally with heating, and then treated with an acid such as sulfuric acid, hydrochloric acid, and the like, in a solvent such as water, methanol, ethanol, isopropanol, and the like, to provide a compound of the formula (6). A compound of the formula (6) is reacted with tert- butyldimethylchlorosilane in the presence of imidazole, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxy ethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, and the like, optionally with heating, optionally withmicrowave irradiation to provide a compoimd of the formula (7). Alternatively, a compound of the formula (6) is reacted with tert-butyldimethylsilyl trifluoromethane sulfonate in the presence of a base such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (7).
[0349] A compound of the formula (7) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, Ν,Ν-dimethylformamide, and the like, to provide a compound of the formula (8). A compound of the formula (8) is reacted with Di-tert-butyl dicarbonate in the presence of a base such as such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (9). A compound of the formula (9) is reacted with Tetra-n-butylammonium fluoride in the presence of solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (10).
[0350] A compound of the formula (10) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (11). A compound of the formula (11) is reacted with a compound of the formula (12), a known compound or a compound prepared by known methods, in the presence of a base such as sodiumcarbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (13). A compound of the formula (13) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (14).
[0351] A compound of the formula (14) is reacted with a compound of the formula (15), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (16).
[0352] A compound of the formula (14) is reacted with a compound of the formula (17), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (18).
[0353] A compound of the formula (14) is reacted with a compound of the formula (19), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (20).
[0354] A compound of the formula (14) is reacted with a compound of the formula (21), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (22).
[0355] A compound of the formula (14) is reacted with a compound of the formula (23), a known compound or a compound prepared by known methods, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (24).
[0356] A compound of the formula (14) is reacted with a compound of the formula (25), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (26).1) Base, solvent2) Acid, solvent
[0357] A suitably substituted compound of formula (27), a known compound or compound prepared by known methods wherein X1is an Ci-e alkyl, is reacted with a compound of the formula (28), a known compound or a compound prepared by known methods in which LG is a leaving group such as chlorine, bromine, iodine, mesylate, tosylate, and the like, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, and the like in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, to provide a compound of the formula (29). A compound of the formula (29) is then treated with paraformaldehyde in the presence of an acid such as sulfuric acid, hydrochloric acid, and the like, in an the presence of acetic acid, and optionally in an organic solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (30). A compound of the formula (30) is then treated with a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in an solvent such as water, methanol, ethanol, isopropanol, and the like, optionally with heating, and then treated with an acid such as sulfuric acid, hydrochloric acid, and the like, in a solvent such aswater, methanol, ethanol, isopropanol, and the like, to provide a compound of the formula (31). A compound of the formula (31) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4- dioxane, 1,2-dimethoxy ethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (32). A compound of the formula (32) is reacted with a compound of the formula (33), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (34).
[0358] A compound of the formula (29) is then reacted with iodine in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, and the like to provide a compound of the formula (35). A compound of the formula (35) is reacted with a compound of the formula (36), a known compound or compound prepared by known methods, in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6 lutidine, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (37).
[0359] A compound of the formula (4) is then reacted with iodine in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, and the like toprovide a compound of the formula (38). A compound of the formula (38) is reacted with a compound of the formula (39), a known compound or compound prepared by known methods, in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxy ethane, dimethylformamide, dimethylacetamide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6 lutidine, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (40). A compound of the formula (40) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N- dimethylformamide, and the like, to provide a compound of the formula (41).
[0360] A compound of the formula (41) is reacted with a compound of the formula (42), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (43).
[0361] A compound of the formula (41) is reacted with a compound of the formula (44), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N -dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (45).
[0362] A compound of the formula (41) is reacted with a compound of the formula (46), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (47).
[0363] A compound of the formula (41) is reacted with a compound of the formula (48), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (49).
[0364] A compound of the formula (41) is reacted with a compound of the formula (50), a known compound or a compound prepared by known methods, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (51).
[0365] A compound of the formula (41) is reacted with a compound of the formula (52), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (53).
[0366] A compound of the formula (4) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (54). A compound of the formula (54) is reacted with a compound of the formula (55), a known compound or compound prepared by known methods, wherein X2is a halogen, in the presence of a solvent such as ethyl ether, tetrahydrofuran, 1,4-dioxane and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (56). A compound of the formula (56) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (57). A compound of the formula (57) is reacted with a reducing agent such as lithium borohydride, sodium borohydride, sodium cyanoborohydride and the like, in a solvent such as methanol, ethanol, isopropanol, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (58). A compound of the formula (58) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4- dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula(59). A compound of the formula (59) is reacted with a compound of the formula (60), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (61).
[0367] A compound of the formula (62) is then converted to a compound of the formula (63), wherein LG is a mesylate, tosylate, nosylate, and the like, using methods that are known to one skilled in the art. Thus, a compound of the formula (62) is treated with a sulfonyl chloride such as methanesulfonyl chloride, toluenesulfonyl chloride p-nitrophenyl sulfonyl chloride, and the like, in the presence of a base such as triethylamine, diisopropyl amine, pyridine, 2,6-lutidine, and the like, in an organic solvent such as methylene chloride, dichloroethane, tetrahydrofuran, 1,4-dioxane, N, N- dimethylformamide, tetrahydrofuran, 1,4-dioxane and the like to provide a compound of the formula (63). A compound of the formula (63) is reacted with a compound of the formula (64), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (65).
[0368] A compound of the formula (4) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (66). A compound of the formula (66) is reacted with a compound of the formula (67), a known compound or compound prepared by known methods, wherein X2is a halogen, in the presence of a solvent such as ethyl ether, tetrahydrofuran, 1,4-dioxane and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (68). A compound of the formula (68) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (69). A compound of the formula (69) is reacted with a reducing agent such as lithium borohydride, sodium borohydride, sodium cyanoborohydride and the like, in a solvent such as methanol, ethanol, isopropanol, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (70). A compound of the formula (70) is reacted with tert-butyldimethylchlorosilane in the presence of imidazole, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxy ethane, Ν,Ν-dimethylformamide, N,N- dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (71). Alternatively, a compound of the formula (70) is reacted with tert-butyldimethylsilyl trifluoromethane sulfonate in the presence of a base such as pyridine, 2,6- lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (71).
[0369] A compound of the formula (71) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, Ν,Ν-dimethylformamide, and the like, to provide a compound of the formula (72). A compound of the formula (72) is reacted with Di-tert-butyl dicarbonate in the presence of a base such as such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such asmethylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compoimd of the formula (73). A compound of the formula (73) is reacted with Tetra-n-butylammonium fluoride in the presence of solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (74).
[0370] A compound of the formula (74) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (75). A compound of the formula (75) is reacted with a compound of the formula (76), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (77). A compound of the formula (77) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (78).
[0371] A compound of the formula (78) is reacted with a compound of the formula (79), a known compound or a compound prepared by known methods, in the presence of a base such astriethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (80).
[0372] A compound of the formula (78) is reacted with a compound of the formula (81), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (82).
[0373] A compound of the formula (78) is reacted with a compound of the formula (83), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (84).
[0374] A compound of the formula (78) is reacted with a compound of the formula (85), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride,1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (86).
[0375] A compound of the formula (78) is reacted with a compound of the formula (87), a known compound or a compound prepared by known methods, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N- dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (88).
[0376] A compound of the formula (78) is reacted with a compound of the formula (89), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (90).H
[0377] Diethanolamine (91) is reacted with 4-nitrobenzenesulfonyl chloride (NosCI) in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride and the like to provide a compound of the formula (92). A compound of the formula (92) is then reacted with a compound of the formula (93), a known compound or one prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine,2,6-lutidine, and the like, in a solvent such as acetonitrile, methanol, ethanol, dimethyl formamide, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (94). A compound of the formula (94) is reacted with a thiophenol in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, acetonitrile and the like, optionally in the presence of dimethylsulfoxide, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (95).R3X3Boc-r / YlH *►(96)
[0378] A compound of the formula (96), a known compound or a compound prepared by known methods, is reacted with a compound of the formula (97), a known compound or a compound prepared by known methods in which X3is selected from the group consisting of chlorine, bromine, iodine, and methanetrif uorosulfonate, in the presence of a base such as sodium tert-butoxide, lithium tert-butoxide, potassium tert-butoxide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethyl amine, pyridine, 2,6-lutidine, and the like, in the presence of a palladium catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), tris(dibenzylideneacetone)dipalladium(0), and the like, in the presence of a solvent such as toluene, benzene, methylene chloride, 1,2-dichloroethae, tetrahydrofuran, 1,4-dioxane, Ν,Ν-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (98). A compound of the formula (98) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (99).Λ - (101 ) Λγ , Λ - ,Boc-N NH *► Boc-N N-R3Boc-N N-R3^- ^-(100) (102)(1 03)
[0379] A compound of the formula (100), a known compound or a compound prepared by known methods, is reacted with a compound of the formula (101), a known compound or a compound prepared by known methods in which X3is selected from the group consisting of chlorine, bromine, iodine, and methanetrifluorosulfonate, in the presence of a base such as sodium tert-butoxide, lithium tert-butoxide, potassium tert-butoxide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethyl amine, pyridine, 2,6-lutidine, and the like, in the presence of a palladium catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), tris(dibenzylideneacetone)dipalladium(0), and the like, in the presence of a solvent such as toluene, benzene, methylene chloride, 1,2-dichloroethae, tetrahydrofuran, 1,4-dioxane, Ν,Ν-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (102). A compound of the formula (102) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (103).
[0380] A compound of the formula (104), a known compound or a compound prepared by known methods in which X4is an Ci-s alkyl, is reacted with di-tert-butyl dicarbonate in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like, in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, 1,4-dioxane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (105). A compound of the formula (105) is reacted with a compound of the formula (106), a known compound or a compound prepared by known methods where in LG1is a leaving group such as chlorine, bromine, iodine, mesylate, tosylate, and the like, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, and the like in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, to provide a compound of the formula (107).
[0381] A compound of the formula (107) is reacted with a base such as sodium hydroxide, lithium hydroxide, potassium hydroxide, sodium carbonate, lithium carbonate, potassium carbonate, and the like in a solvent such as methanol, ethanol, isopropanol, tetrahydrofuran, 1,4-dioxane, N,N- dimethylformamide, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (108). A compound of the formula (108) is then reacted with iodine in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, and the like to provide a compound of the formula (109).
[0382] A compound of the formula (109) is reacted with a compound of the formula (110), a known compound or compound prepared by known methods, in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxy ethane, dimethylformamide, dimethylacetamide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6 lutidine, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (111). A compound of the formula (111) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane, N,N-dimethylformamide, Ν,Ν-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (112).
[0383] A compound of the formula (113) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (114). A compound of the formula (114) is reacted with a compound of the formula (115), a known compound or compound prepared by known methods, wherein X5is a halogen, in the presence of a solvent such as ethyl ether, tetrahydrofuran, 1,4-dioxane and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (116). A compound of the formula (116) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (117). A compound of the formula (117) is reacted with a reducing agent such as lithium borohydride, sodium borohydride, sodium cyanoborohydride and the like, in a solvent such as methanol, ethanol, isopropanol, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (118).
[0384] A compound of the formula (7) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol,ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, Ν,Ν-dimethylformamide, and the like, to provide a compound of the formula (119). A compound of the formula (119) is reacted with a compound of the formula (15), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (120). A compound of the formula (120) is reacted with tetra-n-butylammonium fluoride in the presence of solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4- dioxane, 1,2-dimethoxyethane, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (121). A compound of the formula (121) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2- dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, Ν,Ν-dimethylformamide, N,N- dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (122). A compound of the formula (122) is reacted with a compound of the formula (12), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, Ν,Ν-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (123).
[0385] The Examples provided below provide representative methods for preparing exemplary compounds of the present invention. The skilled practitioner will know how to substitute the appropriate reagents, starting materials and purification methods known to those skilled in the art, in order to prepare the compounds of the present invention.EXAMPLES
[0386] The practice of the invention is illustrated by the following non-limiting examples. The Examples provided below provide representative methods for preparing exemplary compounds of the present invention. The skilled practitioner will know how to substitute the appropriate reagents, starting materials and purification methods known to those skilled in the art, in order to prepare the compounds of the present invention.
[0387] In the examples that follow, ¾-NMR spectra were obtained on a Varian Mercury 300-MHz NMR. Purity (%) and mass spectral data were determined with a Waters Alliance 2695 HPLC / MS (Waters Symmetry C18, 4.6 x 75 mm, 3.5 μιη) with a 2996 diode array detector from 210- 400 nm.
[0388] Example 1 : Preparation of ethyl l-benzylpiperidine-4-carboxylate: To a solution of ethyl piperidine-4-carboxylate (5.0 g, 31.8 mmol, 1.0 eq) and ethanol (15.0 mL), benzyl bromide (7.07 g, mmol, 1.3 eq) was added dropwise at 0 °C. Following, triethylamine (1.06 g, 10.5 mmol, 1.5 eq) was added in one portion while at 0 °C. The resulting mixture was allowed to warm to RT and stir overnight. The reaction was concentrated in vacuo to remove the presence of ethanol. The resulting residue was suspended in a mixture of ethyl acetate: D.I. water (20 mL:20 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined extract was dried over Na2S04, then filtered through a plug of silica gel and washed with ethyl acetate. The filtrated was concentrated in vacuo to give product that was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 7.41-7.20 (m, 5H), 4.14 (q, J = 7.2 Hz, 2H), 3.51 (s, 2H), 2.87 (dt, J = 3.5, 11.8 Hz, 2H), 2.29 (m, 1H), 2.04 (td, J= 2.5, 11.4 Hz, 2H), 1.95-1.85 (m, 2H), 1.85- 1.70 (m, 2H), 1.26 (t, J= 7.1 Hz, 3H).
[0389] Example 2: Preparation of methyl 4-allyltetrahydro-2H-pyran-4-carboxylate: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. To a solution of lithium diisopropylamide (1M, 1.20 equiv) in dry tetrahydrofuran (4.16 mL), methyl tetrahydro-2H-pyran-4- carboxylate (0.5 g, 3.47 mmol, 1.0 equiv), in 5 mL dry THF, was added dropwise during 0.5 hours at - 78 °C. The mixture was allowed to stir at this temperature for 1 hr followed by the addition of allyl bromide (0.457 g, 3.78 mmol, 1.1 eq) dropwise. The reaction mixture was allowed to warm to RT over a 1 hr period. The reaction was quenched with 10% HC1 (while cooling in ice bath) until acidic (pH = 2). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The extract was dried over Na2S04 and then concentrated in vacuo to give product that was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 5.68-5.52 (m, 1H), 5.03-4.91 (m, 2H), 3.75 (dt, J= 3.7, 11.8 Hz, 2H), 3.63 (s, 3H), 3.37 (td, J= 2.1, 11.6 Hz, 2H), 2.21 (d, J= 7.4 Hz, 2H), 2.03-1.95 (m, 2H), 1.53-1.40 (m, 2H).
[0390] Example 3: Preparation of ethyl 4-allyl-l-benzylpiperidine-4-carboxylate: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. To a solution of ethyl l-benzylpiperidine-4-carboxylate (6.24 g, 26.7 mmol, 1.0 eq) and dry THF (50 mL), lithium diisopropylamide (1M, 1.10 equiv) in dry tetrahydrofuran (29.3 mL) was added dropwise during 0.5 hours at -78 °C. The mixture was allowed to stir at this temperature for 1 hr followed by the addition of allyl iodine (6.73 g, 3.78 mmol, 1.5 eq) dropwise. The reaction mixture was allowed to warm to RT and stir for 2 hr. The reaction was quenched with sat. aq. NH4C1 until neutral pH (while cooling in ice bath). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined extract was dried over Na2S04, then filtered through a plug of silica gel and washed with ethyl acetate. The filtrated was concentrated in vacuo to give product that was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 7.37-7.20 (m, 5H), 5.78-5.62 (m, 1H), 5.10-4.97 (m, 2H), 4.17 (q, J= 7.1 Hz, 2H), 3.47 (s, 2H), 2.78-2.64 (m, 2H), 2.28 (d, J= 7.4 Hz, 2H), 2.18-2.03 (m, 4H), 1.61-1.46 (m, 2H), 1.26 (t, J= 7.1 Hz, 3H).
[0391] Example 4: Preparation of 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5]decan-l-one: A mixture of glacial acetic acid (10.9 g, 180 mmol, 53.6 eq), paraformaldehyde (0.309 g, 10.3 mmol, 3.0 eq) and H2S04(0.191 g, 1.95 mmol, 0.57 eq) was stirred for 30min at 70 °C before methyl 4- allyltetrahydro-2H-pyran-4-carboxylate (0.632 g, 3.43 mmol, 1.0 equiv) was added dropwise during 10 min. The reaction mixture was then maintained at 70-80 °C and allowed to stir overnight. Acetic acid was removed under reduced pressure and the reaction was quenched with 10% NaHCC solution. The mixture was then extracted with ethyl acetate (3 x 10 mL) and the combined organic phase was concentrated in vacuo to give a crude oil. The crude oil was used for next step without further purification.
[0392] A mixture of the crude oil (715 mg) and 30% NaOH (2.86 g NaOH, 4x crude oil) aqueous solution was refluxed for 2 hours. The mixture was cooled in an ice bath and excess 30% H2SO4 was added until acidic (pH < 2). The resulting mixture was extracted with ethyl acetate (3 x 25 mL), the combined organic phase was washed with 10% NaHCC , (50 mL), brine (50mL), dried over Na2S04 and concentrated in vacuo to give a crude product which was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 4.57 (m, 1H), 3.91 (dt, J= 4.5, 11.8 Hz, 1H), 3.79 (dt, J= 4.5, 12.0 Hz, 1H), 3.66 (t, J= 6.0 Hz, 2H), 3.54-3.44 (m, 1H), 3.43-3.34 (m, 1H), 3.13 (b, 1H),2.41 (dd, J= 6.1, 13.2 Hz, 1H), 2.01-1.91 (m, 1H), 1.89-1.64 (m, 4H), 1.54-1.44 (m, 1H), 1.42-1.33 (m, 1H).
[0393] Example 5: Preparation of 8-benzyl-3-(2-hydroxyethyl)-2-oxa-8-azaspiro[4.5]decan- 1-one: A mixture of glacial acetic acid (78.1 g, 1.3 mol, 53.6 eq), paraformaldehyde (2.21 g, 73.5 mmol, 3.0 eq) and H2SO4 (3.63 g, 37 mmol, 1.5 eq) was stirred for 30 min at 70 °C before ethyl 4- allyl-l-benzylpiperidine-4-carboxylate (7.03 g, 24.5 mmol, 1.0 equiv) was added dropwise during 10 min. The reaction mixture was then maintained at 70-80 °C and allowed to stir overnight. Acetic acid was removed under reduced pressure and the reaction was quenched with 10% NaHCC solution. The mixture was then extracted with ethyl acetate (3 x 40 mL) and the combined organic phase was concentrated in vacuo to give a crude oil. The crude oil was used for next step without further purification.
[0394] A mixture of the crude oil (7.07 mg) and 30% NaOH (28 g NaOH, 4x crude oil) aqueous solution was refluxed for 2 hours. The mixture was cooled in an ice bath and excess 30% H2SO4 was added until acidic (pH < 2). The resulting mixture was the neutralized (pH= 8-9) with sat. aq. NaHCC solution and then extracted with ethyl acetate (3 x 100 mL), the combined organic phase was dried over Na2S04 and concentrated in vacuo to give a crude product which was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 7.39-7.22 (m, 5H), 4.65 (m, 1H), 3.83 (t, J= 5.6 Hz, 2H), 3.54 (s, 2H), 2.95-2.84 (m, 1H), 2.83-2.73 (m, 1H), 2.42 (dd, J= 6.1, 13.0 Hz, 1H), 2.30-2.07 (m, 4H), 2.00-1.84 (m, 3H), 1.75-1.59 (m, 2H), 1.58-1.48 (m, 1H).
[0395] Example 6: Preparation of 8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxa- 8-azaspiro[4.5]decan-l-one: To a solution of 8-benzyl-3-(2-hydroxyethyl)-2-oxa-8- azaspiro[4.5]decan-l-one (10.0 g, 34.6 mmol, 1.0 eq.), imidazole (2.47 g, 36.3 mmol, 1.05 eq.) and dichloromethane (70 mL), was added a solution of tert-Butyldimethylsilyl chloride (1M, 5.47 g, 36.3 mmol, 1.05 eq.) in dichloromethane (36.3 mL). The reaction was allowed to stir at RT for 2 hr, before being quenched with D.I. water (50 mL). The organic layer was separated and the aqueous layer was extracted with dichloromethane (2 x 50 mL). The combined organic phase was dried over Na2S04 and concentrated in vacuo to give a crude product which was further purified by column chromatography (Ethyl acetate / Hexanes, 0% - 20%). ¾ NMR (400 MHz, CDC13) δ 7.32-7.11 (m, 5H), 4.52 (m, 1H), 3.73-3.65 (m, 2H), 3.46 (s, 2H), 2.87-2.76 (m, 1H), 2.72 (dt, J= 4.5, 11.8 Hz, 1H), 2.31 (dd, J= 6.2,12.9 Hz, 1H), 2.22-2.08 (m, 1H), 2.08-1.97 (m, 2H), 1.91-1.70 (m, 3H), 1.62 (dd, J= 9.8, 12.8 Hz, 1H), 1.59-1.50 (m, 1H), 1.49-1.38 (m, 1H), 0.83 (s, 9H), 0.00 (s, 6H).
[0396] Example 7: Preparation of tert-butyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-l-oxo- 2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A mixture of 8-benzyl-3-(2-((tert- butyldimethylsilyl)oxy)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one (4.77 g, 11.8 mmol, 1 eq.), Pd / C (954 mg, 20% wt) and MeOH (79 mL) was stirred at RT under 1 atm of ¾ (filled balloon) overnight. The mixture was filtered through a plug of Celite, washed with MeOH (50 mL) and concentrated in vacuo to give a crude oil. The crude oil (3.78 g) was dissolved in dichloromethane (79 mL) and cooled to 0 °C before the addition of Di-¾rt-butyl decarbonate (2.83 g, 13.0 mmol, 3. 3 eq ) and trimethylamine (1.8 g, 17.7 mmol, 1.5 eq.). The reaction was allowed to warm to RT and stir for 45 nun. At this point the reaction was diluted with sat. aq. NaHCC solution and then extracted with ethyl acetate (3 x 50 mL), the combined organic phase was dried over Na2S04 and concentrated in vacuo to give a crude product which was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 4.57 (m, 1H), 3.91 (b, 1H), 3.77 (b, 1H), 3.73-3.66 (m, 2H), 3.17-3.05 (m, 1H), 3.04-2.93 (m, 1H), 2.31 (dd, J= 6.2, 13.0 Hz, 1H), 1.96-1.81 (m, 2H), 1.81-1.64 (m, 3H), 1.59-1.48 (m, 1H), 1.48-1.32 (m, 10H), 0.83 (s, 9H), 0.00 (s, 6H).
[0397] Example 8: Preparation of tert-butyl 3-(2-hydroxyethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate: To a solution of tert-butyl 3-(2-((tert- butyldimethylsilyl)oxy)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (4.88 g, 11.8 mmol, 1 eq.) and THF (70 mL) was added ietra-n-buiylammonium fluoride (3.24 g, 12.4 mmol, 1.05 eq.); using THF (10 mL) to complete transfer. The resulting solution was allowed to stir at RT for 30 min before being concentrated in vacuo to give a crude product which was further purified by column chromatography (MeOH / DCM, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 4.67 (m, 1H), 3.95 (dt, J= 5.0, 13.6 Hz, 1H), 3.87-3.73 (m, 3H), 3.23-3.10 (m, 1H), 3.09-2.98 (m, 1H), 2.39 (dd, J= 6.0, 13.0 Hz, 1H), 1.99-1.84 (m, 4H), 1.83-1.68 (m, 2H), 1.63-1.53 (m, 1H), 1.53-1.36 (m, 10H).
[0398] Example 9: Preparation of 3-(2-bromoethyl)-2,8-dioxaspiro[4.5]decan-l-one: A solution of 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5]decan-l-one (0.320 g, 1.60 mmol, 1 eq.) and THF (15 mL) was cooled to 0 °C before triphenylphosphine (0.630 g. 2.4 mmol, 1.5 eq.) and carbon tetrabromide (0.795 g, 2.4 mmol, 1.5 eq.) were sequentially added to the solution. The reaction solution was allowed to warm to RT and stir overnight. The resulting mixture was then filtered and concentrated in vacuo to give a crude mixture. This mixture was suspended in diethyl ether (50 mL) and filtered 2x using diethyl ether to wash the filter cakes. The final filtrate was loaded onto Celite in vacuo and further purified by column chromatography (ethyl acetate / hexanes, 0% ~ 40%). ¾ NMR(400 MHz, CDC13) δ 4.67 (m, 1H), 4.04 (dt, J= 4.6, 11.8 Hz, 1H), 3.91 (dt, J= 4.6, 12.1 Hz, 1H), 3.60 (m, 1H), 3.56-3.45 (m, 3H), 2.50 (dd, J= 6.1, 12.9 Hz, 1H), 2.30-2.02 (m, 3H), 1.91 (m, 1H), 1.76 (dd, J= 9.8, 13.0 Hz, 1H), 1.64-1.55 (m, 1H), 1.52-1.44 (m, 1H).
[0399] Example 10: Preparation of tert-butyl 3-(2-bromoethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for 3-(2-bromoethyl)-2,8-dioxaspiro[4.5]decan-l-one, except tert-butyl 3-(2-hydroxyethyl)-l-oxo-2-oxa- 8-azaspiro[4.5]decane-8-carboxylate was substituted for 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5] decan-l-one: ¾ NMR (400 MHz, CDC13) δ 4.68 (m, 1H), 3.97 (dt, J= 5.0, 13.5 Hz, 1H), 3.83 (dt, J= 5.0, 13.7 Hz, 1H), 3.54 (dd, J= 5.3, 7.5 Hz, 2H), 3.27-3.14 (m, 1H), 3.13-3.01 (m, 1H), 2.42 (dd, J= 6.0, 13.0 Hz, 1H), 2.31-2.20 (m, 1H), 2.20-2.09 (m, 1H), 2.01-1.90 (m, 1H), 1.89-1.78 (m, 1H), 1.74 (dd, J= 9.8, 12.8 Hz, 1H), 1.66-1.56 (m, 1H), 1.54-1.36 (m, 10H).
[0400] Example 11 : Preparation of 8-benzyl-3-(2-bromoethyl)-2-oxa-8-azaspiro[4.5]decan- 1-one formate: A solution of 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5]decan-l-one (2.07 g, 7.16 mmol, 1 eq.) and THF (70 mL) was cooled to 0 °C before triphenylphosphine (2.83 g. 10.8 mmol, 1.5 eq.) and carbon tetrabromide (3.58 g, 10.8 mmol, 1.5 eq.) were sequentially added to the solution. The reaction solution was allowed to warm to RT and stir overnight. The resulting mixture was then filtered and concentrated in vacuo to give a crude mixture. This mixture was suspended in diethyl ether (50 mL) and filtered 2x using diethyl ether to wash the filter cakes. The final filtrate was loaded onto Celite in vacuo and further purified by column chromatography on a C 18 column. (ACN / H20, 0% ~ 100%, w / 0.1% formic acid). ¾ NMR (400 MHz, MeOD) δ 7.53 (b, 2H), 7.47 (b, 3H), 4.75 (m,1H), 4.27 (s, 2H), 3.64-3.47 (m, 3H), 3.34 (m, 1H), 3.19 (b, 1H), 3.08 (b, 1H), 2.52 (m, 1H), 2.35-2.15 (m, 3H), 2.15-1.97 (m, 2H), 1.96-1.
[0401] Example 12: Preparation of 3-(2-(4-phenylpiperazin-l-yl)ethyl)-2,8- dioxaspiro[4.5]decan-l-one: A solution of 3-(2-bromoethyl)-2,8-dioxaspiro[4.5]decan-l-one (0.050 g, 0.190 mmol, 1 eq.) , THF (4 mL) and 1-phenylpiperazine (0.065 g, 0.399 mmol, 2.1 eq.) was heated and stirred at 60 °C for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was further purified by column chromatography (methanol / dichloromethane, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 7.27 (m, 2H), 6.93 (d, J= 8.3 Hz, 2H), 6.86 (t, J= 7.3 Hz, 1H), 4.58 (m, 1H), 4.06 (dt, J= 4.6, 11.9 Hz, 1H), 3.93 (dt, J= 4.6, 12.0 Hz, 1H), 3.61 (m, 1H), 3.51 (m, 1H), 3.21 (t, J= 5.0 Hz, 4H), 2.70-2.52 (m, 6H), 2.47 (dd, J= 6.0, 12.8 Hz, 1H), 2.11 (m, 1H), 2.01-1.83 (m, 3H), 1.79 (dd, J= 9.7, 13.1 Hz, 1H), 1.65-1.54 (m, 1H), 1.54-1.45 (m, 1H); MS (LC / MS, M+H ): 344.8.
[0402] Example 13: Preparation of 3-(2-(4-(4-hydroxyphenyl)piperazin-l-yl)ethyl)-2,8- dioxaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 3-(2-(4- phenylpiperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one, except 4-(piperazin-l-yl)phenol was substituted for 1-phenylpiperazine: ¾ NMR (400 MHz, CDC13) δ 6.74 (d, J= 8.9 Hz, 2H), 6.63 (d, J= 8.9 Hz, 2H), 4.45 (m, 1H), 3.97 (dt, J= 4.6, 11.8 Hz, 1H), 3.83 (dt, J= 4.5, 12.3 Hz, 1H), 3.51 (m, 1H), 3.42 (m, 1H), 3.00 (t, J= 4.7 Hz, 4H), 2.67-2.42 (m, 6H), 2.35 (dd, J= 6.1, 12.1 Hz, 1H), 2.00 (m, 1H), 1.92-1.74 (m, 3H), 1.67 (dd, J= 9.6, 12.9 Hz, 1H), 1.52-1.43 (m, 1H), 1.43-1.34 (m, 1H); MS (LC / MS, M+H+): 360.8.
[0403] Example 14: Preparation of 8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one: A solution of 8-benzyl-3-(2-bromoethyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate (0.545 g, 1.37 mmol, 1 eq.) , THF (13.7 mL), l-(p-tolyl)piperazine (0.507 g, 2.88 mmol, 2.1 eq.) and triethylamine (0.107 g, 1.5 mmol, 1.1 eq.) was heated and stirred at 60 °C for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was furtherpurified by column chromatography (methanol / dichloromethane, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 7.39-7.23 (m, 5H), 7.10 (d, J= 8.3 Hz, 2H), 6.87 (d, J= 8.6 Hz, 2H), 4.53 (m, 1H), 3.54 (s, 2H), 3.17 (t, J= 5.0 Hz, 4H), 2.95-2.85 (m, 1H), 2.84-2.75 (m, 1H), 2.70-2.49 (m, 6H), 2.40 (dd, J= 6.2, 12.8 Hz, 1H), 2.30 (s, 3H), 2.27-2.05 (m, 3H), 2.01-1.79 (m, 3H), 1.76-1.58 (m, 2H), 1.58-1.46 (m, 1H); MS (LC / MS, M+H+):
[0404] Example 15: Preparation of 3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one: A mixture of 8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one (445 mg, 0.993 mmol, 1 eq.), Pd / C (90 mg, 20% wt) and EtOH (6.6 mL) was stirred at RT under 1 atm of H2(filled balloon) for 48 hrs. The mixture was filtered through a plug of Celite, washed with MeOH (50 mL) and concentrated in vacuo to give a crude oil. ¾ NMR (400 MHz, MeOD) δ 6.95 (d, J= 8.2 Hz, 2H), 6.77 (d, J= 8.5 Hz, 2H), 4.56 (m, 1H), 3.47 (m, 1H), 3.28-3.18 (m, 1H), 3.17-3.09 (m, 1H), 3.08-2.96 (m, 5H), 2.66-2.46 (m, 6H), 2.42 (dd, J= 6.0, 13.0 Hz, 1H), 2.14 (s, 3H), 2.10-2.00 (m, 1H), 2.00-1.91 (m, 1H), 1.91-1.80 (m, 4H), 1.80-1.70 (m, 1H); MS (LC / MS, M+H+
[0405] Example 16: Preparation of methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2- oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of 3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa- 8-azaspiro[4.5]decan-l-one (0.05 g, 0.14 mmol, 1 eq.), dichloromethane (2 mL) and triethylamine (0.44 g, 0.41 mmol, 3 eq.) was cooled to 0 °C before methyl chloroformate (0.027 g. 0.28 mmol, 2 eq.) was added to the solution. The reaction solution was allowed to warm to RT and stir for 3 hours. The reaction was diluted with dichloromethane and loaded onto Celite in vacuo and further purified by column chromatography on a C18 column. (ACN / H20, 0% ~ 100%, w / 0.1% formic acid). The resulting formate acid salt was dissolved in MeOH (2 mL) and Amberlite IRA-400(OH) resin was added. This mixture was allowed to stir at RT for 30 min and then filtered and concentrated in vacuo to afford pure free based product. ¾ NMR (400 MHz, CDC13) δ 7.08 (d, J= 8.4 Hz, 2H), 6.85 (d, J= 8.6 Hz, 2H), 4.59 (m, 1H), 4.02 (b, 1H), 3.85 (b, 1H), 3.72 (s, 3H), 3.35-3.24 (m, 1H), 3.23-3.10 (m,5H), 2.71-2.50 (m, 6H), 2.38 (dd, J= 6.0, 12.8 Hz, 1H), 2.28 (s, 3H), 2.07-1.72 (m, 5H), 1.69-1.47 (m, 2H); MS (LC / MS, M+H"): 415.8.
[0406] Example 17: Preparation of 8-acetyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for methyl 1- oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except acetic anhydride was substituted for methyl chloroformate: ¾ NMR (400 MHz, CDC13) δ 7.08 (d, J= 8.3 Hz, 2H), 6.85 (d, J= 8.5 Hz, 2H), 4.60 (m, 1H), 4.19 (m, 0.5 H), 4.04-3.84 (m, 1H), 3.72 (m, 0.5H), 3.45-3.22 (m, 2H), 3.15 (t, J= 4.8 Hz, 4H), 2.70-2.49 (m, 6H), 2.43-2.32 (m, 1H), 2.27 (s, 3H), 2.10 (s, 3H), 2.05-1.72 (m, -1.49 (m, 2H); MS (LC / MS, M+H"): 399.8.
[0407] Example 18: Preparation of N-methyl-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2- oxa-8-azaspiro[4.5]decane-8-carboxamide: The title compound was prepared according to the procedure for methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8- carboxylate, except N-methyl-lH-imidazole-l-carboxamide was substituted for methyl chloroformate: ¾ NMR (400 MHz, MeOD) δ 6.96 (d, J= 8.3 Hz, 2H), 6.78 (d, J= 8.2 Hz, 2H), 4.52 (m, 1H), 3.79 (dt, J= 4.7, 13.8 Hz, 1H), 3.68 (dt, J= 4.5, 13.8 Hz, 1H), 3.22 (m, 1H), 3.16-2.86 (m, 6H), 2.63 (s, 3H), 2.59-2.36 (m, 7H), 2.15 (s, 3H), 1.91-1.67 (m, 3H), 1.66-1.50 (m, 2H), 1.50-1.38 (m, 1H); MS (LC / +): 414.8.
[0408] Example 20: Preparation of tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l- yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A mixture of tert-butyl 3-(2-bromoethyl)- l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.500 g, 1.38 mmol, 1 eq.) , ACN (7 mL), l-(2- isopropylphenyl)piperazine (0.337 g, 1.65 mmol, 1.2 eq.) and K2C03(0.954 g, 6.9 mmol, 5 eq.) was heated and stirred at 80 °C for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was further purified by column chromatography (methanol / dichloromethane, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 7.16 (dd, J= 1.6, 7.4 Hz, 1H), 7.09-6.94 (m, 3H), 4.49 (m, 1H), 3.89 (b, 1H), 3.75 (b, 1H), 3.40 (sep, J= 6.9 Hz, 1H), 3.09 (m, 1H), 2.98 (m, 1H), 2.81 (t, J= 4.6 Hz, 4H), 2.65-2.39 (m, 5H), 2.30 (dd, J= 6.1, 12.8 Hz, 1H), 1.99-1.60 (m, 5H), 1.51 (m, 1H), 1.46-1.29 (m, 11H), 1.12 (s, 3H), 1.10 (s, 6H); MS (LC / MS, M+H+): 485.8
[0409] Example 21: Preparation of tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l- oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate, except 1,2,3,4-tetrahydroisoquinoline hydrochloride was substituted for l-(2-isopropylphenyl)piperazine: ¾ NMR (400 MHz, CDC13) δ 7.07-6.96 (m, 3H), 6.95-6.87 (m, 1H), 4.53 (m, 1H), 3.87 (b, 1H), 3.72 (b, 1H), 3.60-3.46 (m, 2H), 3.06 (m, 1H), 2.95 (m, 1H), 2.80 (t, J= 5.8 Hz, 2H), 2.64 (t, J= 6.0 Hz, 2H), 2.58 (t, J= 7.3 Hz, 2H), 2.28 (dd, J= 6.1, 12.9 Hz, 1H), 1.97-1.75 (m, 3H), 1.74-1.58 (m, 2H), 1.54-1.26 (m, 11H); MS (LC / MS, M+H"): 414.8
[0410] Example 22: Preparation of tert-butyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2- oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of tert-butyl 3-(2-bromoethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate (1.5 g, 4.11 mmol, 1.1 eq.) , THF (36 mL), l-(p-tolyl)piperazine (0.660 g, 3.74 mmol, 1 eq.) and triethylamine (0.416 g, 4.11 mmol, 1.1 eq.) was heated and stirred at 70 °C for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a cruderesidue that was further purified by column chromatography (methanol / dichloromethane, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 7.05 (d, J= 8.3 Hz, 2H), 6.82 (d, J= 8.5 Hz, 2H), 4.55 (m, IH), 3.96 (m, IH), 3.81 (m, IH), 3.22-2.98 (m, 6H), 2.67-2.45 (m, 6H), 2.36 (dd, J= 6.2, 12.9 Hz, IH), 2.25 (s, 3H), 2.00-1.66 (m, 5H), -1.34 (m, 10H); MS (LC / MS, M+H+): 457.8
[0411] Example 23: Preparation of tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7- yl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of tert-butyl 3- (2-bromoethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.5 g, 1.38 mmol, 1. eq.) , THF (12 mL), 2-methyl-7-(piperazin-l-yl)-lH-benzo[d]imidazole (0.549 g, 1.65 mmol, 1.2 eq.) and triethylamine (0.500 g, 4.95 mmol, 3.5 eq.) was heated and stirred at 70 °C for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was first purified by column chromatography (methanol / dichloromethane, 0% ~ 10%). The resulting fractions were further purified by column chromatography on a C 18 column. (ACN / H20, 0% ~ 100%, w / 0.1% NH4OH) ¾ NMR (400 MHz, CDC13) δ 7.16-6.97 (m, 2H), 6.65 (m, IH), 4.54 (m, IH), 3.98 (m, IH), 3.83 (m, IH), 3.40 (b, 4H), 3.17 (t, J= 11.1 Hz, IH), 3.06 (t, J= 11.5 Hz, IH), 2.68-2.42 (m, 9H), 2.36 (dd, J= 6.2, 13.0 Hz, IH), 1.99-1.66 (m, 5H), 1.58 (m, IH), 1.54-1.33 (m, 10H); MS (LC / MS, M+H+): 497.8
[0412] Example 24: Preparation of tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-l- yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l- yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 4-(2-(piperazin-l- yl)phenyl)morpholine was substituted for 2-methyl-7-(piperazin-l-yl)-lH-benzo[d]imidazole: ¾ NMR (400 MHz, CDC13) δ 6.94-6.87 (m, 2H), 6.87-6.78 (m, 2H), 4.51 (m, IH), 3.90 (m, IH), 3.81-3.66 (m, 5H), 3.34-2.84 (m, 10H), 2.67-2.37 (m, 6H), 2.31 (dd, J= 6.2, 12.9 Hz, 1H), 1.93-1.59 (m, 5H), 1.52 (m, 1H), 1.47-1. "): 528.8
[0413] Example 25: Preparation of 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa- 8-azaspiro[4.5]decan-l-one: To a solution of tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l- yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.450 g, 0.930 mmol, 1 eq.) in dichloromethane (3 mL) at 0 °C was added trifluoroacetic acid (3 mL). The reaction was allowed to stir at RT for 30 min before being diluted with MeOH and concentrated in vacuo to afford the product as a TFA salt. The resulting TFA salt was dissolved in MeOH (2 mL) and Amberlite IRA- 400(OH) resin was added. This mixture was allowed to stir at RT for 30 min and then filtered and concentrated in vacuo to afford pure free based product. ¾ NMR (400 MHz, MeOD) δ 7.16 (d, J= 7.5 Hz, 1H), 7.07-6.93 (m, 3H), 4.50 (m, 1H), 3.44 (sep, J= 6.9 Hz, 1H), 2.99 (dt, J= 4.3, 12.6 Hz, 1H), 2.89 (dt, J= 4.3, 13.2 Hz, 1H), 2.82 (t, J= 4.7 Hz, 4H), 2.74-2.37 (m, 9H), 1.91-1.78 (m, 3H), 1.77- 1.50 (m, 3H), 1.42 (m, 1H), 1.12 (s, 3H), 1.10 (s, 3H); MS (LC / MS, M+H ): 385.8
[0414] Example 26: Preparation of 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 3-(2-(4- (2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, except tert-butyl 3-(2- (3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate was substituted for tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate: ¾ NMR (400 MHz, MeOD) δ 7.18-7.09 (m, 3H), 7.09-7.03 (m, 1H), 4.64 (m, 1H), 3.68 (s, 2H), 3.25 (dt, J= 5.0, 13.1 Hz, 1H), 3.10 (dt, J= 5.0, 13.4 Hz, 1H), 2.99- 2.88 (m, 3H), 2.85-2.61 (m, 5H), 2.55 (dd, J= 6.1, 12.9 Hz, 1H), 2.09-1.95 (m, 3H), 1.90-1.70 (m, 3H), 1.63 (m, 1H); MS (LC / MS, M+H+): 314.8
[0415] Example 27: Preparation of 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)- 2-oxa-8-azaspiro[4.5]decan-l-one formate: A solution of 3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa- 8-azaspiro[4.5]decan-l-one (0.05 g, 0.14 mmol, 1 eq.), dichloromethane (2 mL) and triethylamine (0.44 g, 0.41 mmol, 3 eq.) was cooled to 0 °C before methanesulfonyl chloride (0.032 g. 0.28 mmol, 2 eq.) was added to the solution. The reaction solution was allowed to warm to RT and stir for 3 hours. The reaction was diluted with dichloromethane and loaded onto Celite in vacuo and further purified by column chromatography on a C18 column. (ACN / H20, 0% ~ 100%, w / 0.1% formic acid). ¾ NMR (400 MHz, DMSO) δ 7.01 (d, J= 8.5 Hz, 2H), 6.82 (d, J= 8.5 Hz, 2H), 4.59 (m, IH), 3.58-3.45 (m, IH), 3.44-3.33 (m, IH), 3.13-2.95 (m, 5H), 2.88 (s, 3H), 2.86-2.78 (m, IH), 2.62-2.31 (m, 7H), 2.19 (s, 3H), 1.97-1.57 ): 435.8
[0416] Example 28: Preparation of 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5] decan- 1 -one formate, except 3-(2-(4-(2-isopropylpheny l)piperazin- 1 -yl)ethyl)-2-oxa- 8-azaspiro[4.5]decan-l-one was substituted for 3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one: ¾ NMR (400 MHz, MeOD) δ 7.34-7.27 (m, IH), 7.23-7.08 (m, 3H), 4.67 (m, IH), 3.70 (dt, J= 4.8, 12.3 Hz, IH), 3.61-3.47 (m, 2H), 3.40-3.09 (m, 11H), 3.04 (m, IH), 2.88 (s, 3H), 2.56 (dd, J= 6.4, 12.8 Hz, IH), 2.29-2.10 (m, 2H), 2.05 (m, IH), 1.96-1.80 (m, 3H), 1.75 (m, IH), 1.24 (s, 3H), 1.22 (s, 3H); MS (LC / MS, M+H+): 463.7
[0417] Example 29: Preparation of 8-(methylsulfonyl)-3-(2-(4-(2- morpholinophenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin- l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate, except 3-(2-(4-(2- mo holinophenyl)piperazin-l-yl)etrlyl)-2-oxa-8-azaspiro[4.5]decan-l-one was substituted for 3- (2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: ¾ NMR (400 MHz, MeOD) δ 7.13-6.90 (m, 4H), 4.67 (m, 1H), 3.86 (t, J= 4.6 Hz, 4H), 3.70 (dt, J= 4.7, 12.3 Hz, 1H), 3.61-3.08 (m, 16H), 3.04 (m, 1H), 2.88 (s, 3H), 2.56 (dd, J= 5.9, 13.0 Hz, 1H), 2.29-2.11 (m, 2H), 2.05 (m, 1H), 1.97-1.81 (m, 3H), 1.75 (m, 1H); MS (LC / MS, M+H+): 507.2
[0418] Example 30: Preparation of 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin- l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2- oxa-8-azaspiro[4.5]decan-l-one formate, except 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7- yl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one was substituted for 3-(2-(4-(p- tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: ¾ NMR (400 MHz, MeOD) δ 7.47- 7.26 (m, 2H), 7.04 (d, J= 6.7 Hz, 1H), 4.69 (m, 1H), 3.79-3.28 (m, 12H), 3.14 (m, 1H), 3.01 (m, 1H), 2.87 (s, 3H), 2.79 (s, 3H), 2.58 (dd, J= 5.9, 12.9 Hz, 1H), 2.38-2.14 (m, 2H), 2.12-1.98 (m, 1H), 1.96- 1.80 (m, 3H), 1.75 (m, 1H); MS (LC / MS, M+H ): 476.2
[0419] Example 31: Preparation of 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one was substituted for 3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one: ¾ NMR (400 MHz, MeOD) δ 7.31-7.21 (m, 3H), 7.20-7.15 (m, IH), 4.67 (m, IH), 4.26 (s, 2H), 3.70 (dt, J= 4.9, 12.3 Hz, IH), 3.53 (dt, J= 5.2, 12.5 Hz, IH), 3.39 (t, J= 6.2 Hz, 2H), 3.31-3.10 (m, 5H), 3.03 (m, IH), 2.88 (s, 3H), 2.56 (dd, J= 6.0, 12.9 Hz, IH), 2.30-2.12 (m, 2H), 2.05 (m, IH), 1.9 -1.80 (m, 3H), 1.75 (m, IH); MS (LC / MS, M+H ): 392.7.
[0420] Example 32: Preparation of 8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)- 2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8- (methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate, except benzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.69 (m, 2H), 7.53 (m, IH), 7.46 (m, 2H), 7.00 (d, J= 8.3 Hz, 2H), 6.75 (d, J= 8.5 Hz, 2H), 4.44 (m, IH), 3.46 (m, IH), 3.22 (m, IH), 3.10 (t, J= 4.7 Hz, 4H), 2.97 (m, IH), 2.87 (m, IH), 2.75-2.44 (m, 6H), 2.19 (s, 3H), 2.12 (dd, J= 6.1, 13.0 Hz, IH), 2.02-1.77 (m, 4H), 1.72-1.53 (m, 3H); MS (LC / MS, M+H+): 498.2.
[0421] Example 33: Preparation of 8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p- tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except 4-methoxybenzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.62 (d, J= 9.0 Hz, 2H), 6.99 (d, J= 8.3 Hz, 2H), 6.91 (d, J= 8.9 Hz, 2H), 6.75 (d, J= 8.6 Hz, 2H), 4.45 (m, IH), 3.80 (s, 3H), 3.42 (m, IH), 3.18 (m, IH), 3.04 (t, J= 4.9 Hz, 4H), 2.95 (m, IH), 2.86 (m, IH), 2.57-2.39 (m, 6H), 2.19 (s, 3H), 2.11 (dd, J= 6.1, 12.9 Hz, IH), 2.01-1.86 (m, 2H), 1.86-1.50 (m, 5H); MS (LC / MS, M+H+): 528.2.
[0422] Example 34: Preparation of 8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin- l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except 4-chlorobenzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.56 (d, J= 8.6 Hz, 2H), 7.37 (d, J= 8.5 Hz, 2H), 6.93 (d, J= 8.4 Hz, 2H), 6.69 (d, J= 8.6 Hz, 2H), 4.40 (m, IH), 3.37 (m, IH), 3.10 (m, IH), 3.02 (t, J= 4.7 Hz, 4H), 2.96 (m, IH), 2.87 (m, IH), 2.59-2.34 (m, 6H), 2.13 (s, 3H), 2.06 (dd, J= 5.9, 12.9 Hz, IH), 1.95-1.81 (m, 2H), 1.81-1.67 (m, 2H), 1.66-1.49 (m, 3H); MS (LC / MS, M+H+): 532.2.
[0423] Example 35: Preparation of 8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p- tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except tetrahydro-2H-pyran-4-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.08 (d, J= 8.3 Hz, 2H), 6.84 (d, J= 8.5 Hz, 2H), 4.60 (m, 1H), 4.08 (dd, J= 3.6, 11.5 Hz, 2H), 3.80 (m, 1H), 3.57-3.42 (m, 4H), 3.41-3.30 (m, 3H), 3.22-3.06 (m, 5H), 2.69-2.47 (m, 6H), 2.30 (dd, J= 6.1, 12.9 Hz, 1H), 2.27 (s, 3H), 2.03-1.65 (m, 9H);+): 506.2.
[0424] Example 36: Preparation of 8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except thiophene-2-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.53 (dd, J= 1.2, 5.0 Hz, 1H), 7.46 (dd, 1.3, 3.8 Hz, 1H), 7.06 (dd, J= 3.8, 5.0 Hz, 1H), 6.99 (d, J= 8.4 Hz, 2H), 6.75 (d, J= 8.5 Hz, 2H), 4.46 (m, 1H), 3.49 (m, 1H), 3.24 (m, 1H), 3.12-2.97 (m, 5H), 2.92 (m, 1H), 2.61-2.41 (m, 6H), 2.19 (s, 3H), 2.14 (dd, J= 6.0, 13.0 Hz, 1H), 2.04-1.88 (m, 2H), 1.88-1.73 (m, 2H), 1.73-1.57 (m, 3H); MS (LC / MS, M+H+): 504.1.
[0425] Example 37: Preparation of 4-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-8-yl)sulfonyl)benzonitrile: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except 4-cyanobenzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.89 (d, J= 8.1 Hz, 2H), 7.85 (d, 7.8 Hz, 2H), 7.08 (d, J= 8.2 Hz, 2H), 6.84 (d, J= 8.5 Hz, 2H), 4.57 (m, 1H), 3.53 (m, 1H), 3.24 (m, 2H), 3.20- 3.07 (m, 5H), 2.68-2.48 (m, 6H), 2.28 (s, 3H), 2.21 (dd, J= 6.0, 13.0 Hz, 1H), 2.08-1.97 (m, 2H), 1.97- 1.65 (m, 5H); M+): 523.2.
[0426] Example 38: Preparation of 8-((6-chloroimidazo[2,l-b]thiazol-5-yl)sulfonyl)-3-(2-(4- (p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except 6-chloroimidazo[2,l-b]thiazole-5-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.90 (d, J= 4.5 Hz, 1H), 7.11-7.02 (m, 3H), 6.84 (d, J= 8.6 Hz, 2H), 4.57 (m, 1H), 3.74 (m, 1H), 3.52 (m, 1H), 3.26 (m, 1H), 3.20-3.06 (m, 5H), 2.67-2.47 (m, 6H), 2.32-2.21 (m, 4H), 2.13-1.97 (m, 2H), 1.97-1.82 (m, 2H), 1.82-1.65 (m, 3H); MS (LC / MS, M+H+): 578.1.
[0427] Example 39: Preparation of 8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p- tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except (methylsulfonyl)methanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.09 (d, J= 8.3 Hz, 2H), 6.86 (d, J= 8.6 Hz, 2H), 4.61 (m, 1H), 4.45 (s, 2H), 3.89 (m, 1H), 3.66 (m, 1H), 3.45 (m, 1H), 3.34 (m, 1H), 3.23 (s, 3H), 3.17 (t, J= 4.9 Hz, 4H), 2.73-2.52 (m, 6H), 2.37 (dd, J= 6.1, 12.9 Hz, 1H), 2.28 (s, 3H), 2.15-1.85 -1.65 (m, 3H); MS (LC / MS, M+H ): 514.2.
[0428] Example 40: Preparation of 2-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except cyanomethanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.09 (d, J= 8.3 Hz, 2H), 6.86 (d, J= 8.5 Hz, 2H), 4.64 (m, 1H), 4.02-3.91 (m, 3H), 3.69 (m, 1H), 3.58 (m, 1H), 3.48 (m, 1H), 3.18 (t, J= 4.9 Hz, 4H), 2.73-2.54 (m, 6H), 2.34 (dd, J= 6.1, 13.0 Hz, 1H), 2.29 (s, 3H), 2.13-2.02 (m, 2H), 2.02-1.89 (m, 2H), 1.89-1.71 (m, 3H); MS (LC / MS, M+H+): 461.2.
[0429] Example 41: Preparation of 8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)- 2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8- (methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate, except 1-propanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.09 (d, J= 8.3 Hz, 2H), 6.85 (d, J= 8.4 Hz, 2H), 4.61 (m, IH), 3.73 (m, IH), 3.48-3.35 (m, 2H), 3.34-3.25 (m, IH), 3.16 (t, J= 4.8 Hz, 4H), 2.92 (m, 2H), 2.69-2.50 (m, 6H), 2.30 (dd, J= 6.0, 12.9 Hz, IH), 2.28 (s, 3H), 2.07-1.65 (m, 9H), 1.07 (t, J= 7.4 Hz, 3H); MS (LC / MS, M+H+): 464
[0430] Example 42: Preparation of 3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-8- ((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except trifluoromethanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 6.96 (d, J= 8.3 Hz, 2H), 6.72 (d, J= 8.5 Hz, 2H), 4.50 (m, IH), 3.87 (m, IH), 3.70-3.23 (b, 3H), 3.03 (t, J= 4.9 Hz, 4H), 2.56-2.38 (m, 6H), 2.19 (dd, J= 6.2, 12.9 Hz, IH), 2.15 (s, 3H), 1.98-1.86 (m, 2H), 1.86-1.52 (m, 5H); MS (LC / MS, M+H+): 490
[0431] Example 43: Preparation of 8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except 2-propanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 6.95 (d, J= 8.2 Hz, 2H), 6.72 (d, J= 8.6 Hz, 2H), 4.47 (m, IH), 3.67 (m, IH), 3.44 (m, IH), 3.35 (m, IH), 3.25 (m, IH), 3.12-2.94 (m, 5H), 2.58-2.36 (m, 6H), 2.18 (dd, J= 6.0, 12.9 Hz, IH), 2.14 (s, 3H), 1.92-1.71 (m, 4H), 1.71-1.45 (m, 3H); MS (LC / MS, M+H ): 464
[0432] Example 44: Preparation of 8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except cyclopropanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.08 (d, J= 8.3 Hz, 2H), 6.85 (d, J= 8.5 Hz, 2H), 4.61 (m, 1H), 3.78 (m, 1H), 3.50 (m, 1H), 3.37 (m, 1H), 3.28 (m, 1H), 3.16 (t, J= 4.9 Hz, 4H), 2.70-2.50 (m, 6H), 2.36-2.25(m, 5H), 2.10-1.98 (m, 2H), 1.98-1.65 (m, 5H), 1.23-1.11 (m, 2H), 1.07-0.95 (m, 2H); MS (LC / MS, M+H ): 462
[0433] Example 45: Preparation of 3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-8-((3,3,3- trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except 3,3,3-trifluoropropane-l-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 6.95 (d, J= 8.3 Hz, 2H), 6.72 (d, J= 8.5 Hz, 2H), 4.49 (m, 1H), 3.64 (m, 1H), 3.38-3.27 (m, 2H), 3.23 (m, 1H), 3.09-2.93 (m, 6H), 2.59-2.36 (m, 8H), 2.17 (dd, J= 5.9, 13.0 Hz, 1H), 2.15 (s, 3H), 1.96-1.85 (m, 2H), 1.85-1.56 (m, 5H); MS (LC / MS, M+H+):
[0434] Example 46: Preparation of 8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except isobutanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~10%): ¾ NMR (400 MHz, CDC13) δ 7.08 (d, J= 8.3 Hz, 2H), 6.85 (d, J= 8.5 Hz, 2H), 4.61 (m, 1H), 3.70 (m, 1H), 3.45-3.33 (m, 2H), 3.29 (m, 1H) 3.16 (t, J= 4.8 Hz, 4H), 2.79 (dd, J= 2.2, 6.6 Hz, 2H), 2.70-2.49 (m, 6H), 2.37-2.20 (m, 5H), 2.07-1.97 (m, 2H), 1.97-1.67 (m, 5H), 1.12 (d, J= 6.7 Hz, 6H); MS (LC / MS, M+H"): 478
[0435] Example 47: Preparation of 8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except cyclopentanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 6.95 (d, J= 8.3 Hz, 2H), 6.72 (d, J= 8.6 Hz, 2H), 4.47 (m, 1H), 3.64 (m, 1H), 3.42-3.22 (m, 3H), 3.18 (m, 1H) 3.03 (t, J= 4.9 Hz, 4H), 2.57-2.37 (m, 6H), 2.18 (dd, J= 6.1, 12.9 Hz, 1H), 2.15 (s, 3H), 1.95-1.42 (m, 15H); MS (LC / MS, M+H+): 490
[0436] Example 48: Preparation of 8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except cyclohexanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 6.95 (d, J= 8.3 Hz, 2H), 6.72 (d, J= 8.4 Hz, 2H), 4.47 (m, 1H), 3.66 (m, 1H), 3.38 (m, 1H), 3.27 (m, 1H), 3.18 (m, 1H), 3.03 (t, J= 4.9 Hz, 4H), 2.77 (tt, J= 3.4, 12.0 Hz, 1H), 2.59-2.36 (m, 6H), 2.19 (dd, J= 6.0, 12.9 Hz, 1H), 2.15 (s, 3H), 2.06-1.94 (b, 2H), 1.91- 1.72 (m, 6H), 1.72-1.49 (m, 4H), 1.37 (qd, J= 3.3, 12.3 Hz, 2H), 1.23-0.99 (m, 3H); MS (LC / MS, M+H+): 504
[0437] Example 49: Preparation of 8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2- oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8- (methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate, except ethanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.08 (d, J= 8.2 Hz, 2H), 6.85 (d, J= 8.6 Hz, 2H), 4.61 (m, 1H), 3.75 (m, 1H), 3.51-3.35 (m, 2H), 3.30 (m, 1H), 3.15 (t, J= 4.9 Hz, 4H), 2.98 (q, J= 7.4 Hz, 2H), 2.70-2.48 (m, 6H), 2.31 (dd, J= 6.2, 13.0 Hz, 1H), 2.28 (s, 3H), 2.07-1.96 (m, 2H), 1.96-1.66 (m, 5), 1.38 (t, J= 7.4 Hz, 3H); MS (LC / MS, M+H+): 450
[0438] Example 50: Preparation of 8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except pyridine-3-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 9.00 (d, J= 2.3 Hz, 1H), 8.84 (dd, J= 1.5, 4.8 Hz, 1H), 8.06 (dt, J= 1.9, 8.0 Hz, 1H), 7.5 (dd, J= 4.9, 7.9 Hz, 1H), 7.08 (d, J= 8.3 Hz, 2H), 6.84 (d, J= 8.5 Hz, 2H), 4.55 (m, 1H), 3.56 (m, 1H), 3.29 (m, 1H), 3.24-3.05 (m, 6H), 2.66-2.47 (m, 6H), 2.27 (s, 3H) 2.09 (dd, J= 6.0, 13.0 Hz, 1H), 2.09-1.96 -1.64 (m, 5H); MS (LC / MS, M+H+): 499
[0439] Example 51 : Preparation of 8-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p- tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one formate, except 1 -methyl- lH-pyrazole-4-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.75 (s, 1H), 7.71 (s, 1H), 7.07 (d, J= 8.4 Hz, 2H), 6.84 (d, J= 8.6 Hz, 2H), 4.55 (m, 1H), 3.95 (s, 3H), 3.48 (m, 1H), 3.23(m, 1H), 3.13 (t, J= 4.9 Hz, 4H), 3.02 (m, 1H), 2.93 (m, 1H), 2.67-2.48 (m, 6H), 2.27 (s, 3H), 2.22 (dd, J= 6.1, 12.9 Hz, 1H), 2.11-1.96 (m, 2H), 1.96-1.64 (m, 5H); MS (LC / MS, M+H+): 502
[0440] Example 52: Preparation of 8-((lH-imidazol-4-yl)sulfonyl)-3-(2-(4-(p- tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2- oxa-8-azaspiro[4.5]decan-l-one formate, except lH-imidazole-4-sulfonyl chloride was substituted for methanesulfonyl chloride: ¾ NMR (400 MHz, MeOD) δ 7.88 (s, 1H), 7.74 (s, 1H), 7.09 (d, J= 8.4 Hz, 2H), 6.90 (d, J= 8.4 Hz, 2H), 4.58 (b, 1H), 3.67 (m, 1H), 3.53 (m, 1H), 3.40-3.05 (m, 10H), 2.99 (m, 1H), 2.85 (m, 1H), 2.38 (dd, J= 5.7, 12.9 Hz, 1H), 2.26 (s, 3H), 2.19-1.91 (m, 3H), 1.90-1.72 (m, 3H), 1.72-1.58 (m, 1H); MS (LC / MS, M+H"): 488
[0441] Example 53: Preparation of 8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one formate, except furan-2-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH / DCM, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 7.59 (s, 1H), 7.07 (d, J= 8.4 Hz, 2H), 7.02 (d, J= 3.4 Hz, 1H), 6.84 (d, J= 8.4 Hz, 2H), 6.52 (dd, J= 1.7, 3.3 Hz, 1H), 4.56 (m, 1H), 3.70 (m, 1H), 3.47 (m, 1H), 3.24 (m, 1H), 3.19-3.07 (m, 5H), 2.68-2.46 (m, 6H), 2.33-2.18 (m, 4H), 2.07-1.79 (m, 4H), 1.79-1.60 (m, 3H); MS (LC / MS, M+H+): 488
[0442] Example 54: Preparation of 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: A mixture of 8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one (3.25 g, 8.04 mmol, 1 eq.), Pd / C (0.65 g, 20% wt) and MeOH (54 mL) was stirred at RT under 1 atm of H2(filled balloon) overnight. The mixture was filtered through a plug of Celite, washed with MeOH (50 mL) and concentrated in vacuo to give a crude oil. The crude oil (2.43 g) was dissolved in dichloromethane (50 mL), followed by addition of triethylamine (5.55 mL, 38.8 mmol, 5 eq.). Cooled to 0 °C before the addition of methanesulfonyl chloride (2.83 g, 13.0 mmol, 1.1 eq.). The reaction was allowed to warm to RT and stir for 30 min. At this point the reaction was diluted with D.I. water and then extracted with dichloromethane (3 x 50 mL), the combined organic phase was dried over Na2S04 and concentrated in vacuo to give a crude product which was further purified by column chromatography (EtOAc / DCM, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 4.61 (m, 1H), 3.75-3.65 (m, 2H), 3.60 (m, 1H), 3.37-3.18 (m, 3H), 2.75 (s, 3H), 2.21 (dd, J= 6.0, 13.0 Hz, 1H), 2.02-1.91 (m, 2H), 1.91-1.62 (m, 5H), 0.83 (s, 9H), 0.00 (s, 6H).
[0443] Example 55: Preparation of 3-(2-hydroxyethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one: The title compound was prepared according to the procedure for tert-butyl 3-(2-hydroxyethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 3-(2-((tert- butyldimethylsilyl)oxy)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one was substituted for tert-butyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate and the product was initially purified by column chromatography on a C18 column. (ACN / H20, 0% ~ 100%, w / 0.1% formic acid), followed by purification on a silica gel column (MeOH / DCM, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 4.73 (m, 1H), 3.84 (t, J= 5.5 Hz, 2H), 3.68 (m, 1H), 3.41-3.32 (m, 2H), 3.29 (m, 1H), 2.83 (s, 3H), 2.33 (dd, J= 6.0, 13.0 Hz, 1H), 2.10-2.00 (m, 2H), 2.10-1.71 (m, 6H).
[0444] Example 56: Preparation of 3-(2-bromoethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro [4.5] decan- 1 -one : A solution of 3-(2-hydroxyethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one (0.890 g, 3.21 mmol, 1 eq.) and dichloromethane (12 mL) was cooled to 0 °C before triphenylphosphine (1.26 g. 4.81 mmol, 1.5 eq.) and carbon tetrabromide (1.6 g, 4.81 mmol,1.5 eq.) were sequentially added to the solution. The reaction solution was allowed to warm to RT and for 4 hrs. The resulting mixture was then filtered and concentrated in vacuo to give a crude mixture. This mixture was suspended in diethyl ether (50 mL) and filtered 2x using diethyl ether to wash the filter cakes. The final filtrate was loaded onto Celite in vacuo and further purified by column chromatography (EtOAc / DCM, 0% ~ 40%). ¾ NMR (400 MHz, MeOD) δ 4.72 (m, 1H), 3.67 (m, 1H), 3.54 (dd, J= 5.3, 7.6 Hz, 2H), 3.44-3.25 (m, 3H), 2.82 (s, 3H), 2.34 (dd, J= 6.0, 12.9 Hz, 1H), 2.31-2.21 (m, 1H), 2.21-2.10 (m, 1H), 2.10-1.98 (m, 2H), 1.88-1.71 (m, 3H).
[0445] Example 57: Preparation of 3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: A solution of 3-(2-bromoethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one (50 mg, 0.147 mmol, 1 eq.), l-(4- methoxyphenyl)-piprazine (59.33 mg, 0.308 mmol, 2.1 eq.) and Acetonitrile (2 mL) was microwaved for 1 hour at 120 °C. The solvent was then evaporated in vacuo and the product was suspended in 15 mL of saturated NaHCC and extracted in dichloromethane (3 x 15mL). The combined organic phase was dried over Na2S04 and concentrated in vacuo to give a crude mixture that was then dissolved in dichloromethane and purified by column chromatography (methanol / dichloromethane, 0% ~ 10%). ¾ NMR (400 MHz, CDC13) δ 7.4 (d, J= 9.2 Hz, 2H), 6.5 (d, J= 9.2 Hz, 2H), 4.61 (m, 1H), 3.77 (s, 3H), 3.67 (m, 1H), 3.36 (m, 2H), 3.29 (m, 1H), 3.1 (t, J= 7.1 Hz, 4H), 2.8 (s, 3H), 2.62 (m, 4H), 2.56 (t, J= 7.1 Hz, 2H), 2.29 (dd, J= 7.2, 6 Hz, 1H), 2.05 (m, 2H), 1.99-1.71 (m, 6H); MS (LC / MS, M+H"): 452.
[0446] Example 58: Preparation of 3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2- oxa-8-azaspiro[4.5]decan-l-one except that l-(4-trifluoromethylphenyl)-piprazine was substituted for l-(4-methoxyphenyl)-piprazine. ¾ NMR (400 MHz, CDC13) δ 7.5 (d, J= 8.76 Hz, 2H), 6.94 (d, J=8.7 Hz, 2H), 4.64 (m, IH), 3.68 (m, IH), 3..46-3.28 (m, 7H), 2.83 (s, 3H), 2.67-2.55 (m, 6H), 2.3 (dd, J= 7.1, 6.1 Hz, IH), 2.11-2.01 (m, 2H), 2.0-1.74 (m, 5H); MS (LC / MS, M+H+): 490
[0447] Example 59: Preparation of 4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8- azaspiro[4.5]decan-3-yl)ethyl)piperazin-l-yl)benzonitrile: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one except that triethylamine (0.06 mL, 0.44 mmol, 3 eq.) was added in the microwave mixture and l-(4-cyanophenyl)-piprazine was substituted for l-(4- methoxyphenyl)-piprazine.: ¾ NMR (400 MHz, CDC13) δ 7.49 (d, J= 8.4 Hz, 2H), 6.85 (d, J= 8.4 Hz, 2H), 4.61 (m, IH), 3.65 (m, IH), 3.43-3.26 (m, 7H), 2.81 (s, 3H), 2.64-2.52 (m, 6H), 2.28 (dd, J= 6.8, 5.9 Hz, IH), 2.02 (m, 2H), 1.96-1.74 (m, 5H); MS (LC / MS, M+H+): 447
[0448] Example 60: Preparation of 8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-l- yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one except that it was microwaved for 1.5 hours at 120 °C and l-(4- nitrophenyl)-piprazine was substituted for l-(4-methoxyphenyl)-piprazine. ¾ NMR (400 MHz, CDC13) δ 8.13 (d, J= 9.3 Hz, 2H), 6.82 (d, J= 9.3 Hz, 2H), 4.62 (m, IH), 3.66 (m, IH), 3.46-3.36 (m, 4H), 3.36-3.28 (m, 3H), 2.8 (s, 3H), 2.67-2.5 (b, 6H), 2.28 (dd, J= 6.8, 5.9 Hz, IH), 2.08-1.98 (m, 2H), 1.95-1.72 (m, 5H); MS (LC / MS, M+H+): 467
[0449] Example 61 : Preparation of 3-(2-(4-(4-chlorophenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one except that it was microwaved for 2 hours at 120 °C and l-(4- chlorophenyl)-piprazine was substituted for l-(4-methoxyphenyl)-piprazine. ¾ NMR (400 MHz, CDC13) δ 7.19 (d, J= 8.9 Hz, 2H), 6.82 (d, J= 8.9 Hz, 2H), 4.6 (m, 1H), 3.65 (m, 1H), 3.42-3.26 (m, 3H), 3.15 (t, J= 4.9 Hz, 4H), 2.8 (s, 3H), 2.66-2.52 (m, 6H), 2.27 (dd, J= 6.8, 5.9 Hz, 1H), 2.07-1.98 (m, 2H), 1.97-1.7 (m, 5H); MS (LC / MS, M+H+): 456
[0450] Example 62: Preparation of 3-(2-(4-(4-iodophenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-chlorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2- oxa-8-azaspiro[4.5]decan-l-one except that and l-(4-iodophenyl)-piprazine was substituted for l-(4- methoxyphenyl)-piprazine. ¾ NMR (400 MHz, CDC13) δ 7.49 (d, J= 8.8 Hz, 2H), 6.65 (d, J= 8.8 Hz, 2H), 4.58 (m, 1H), 3.64 (m, 1H), 3.4-3.24 (m, 3H), 3.15 (t, J= 4.8 Hz, 4H), 2.79 (s, 3H), 2.62-2.5 (m, 6H), 2.26 (dd, J= 6.8, 6 Hz, 1H), 2.0-1.96 (m, 2H), 1.95-1.69 (m, 5H); MS (LC / MS, M+H"): 548
[0451] Example 63: Preparation of 3-(2-(4-(4-fluorophenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-chlorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2- oxa-8-azaspiro[4.5]decan-l-one except that and l-(4-fluorophenyl)-piprazine was substituted for l-(4- methoxyphenyl)-piprazine. ¾ NMR (400 MHz, CDC13) δ 6.94 (m, 2H), 6.85 (m, 2H), 4.59 (m, 1H), 3.65 (m, 1H), 3.4-3.24 (m, 3H), 3.1 (t, J= 4.8 Hz, 4H), 2.8 (s, 3H), 2.65-2.5 (m, 6H), 2.27 (dd, J= 6.7, 5.9 Hz, 1H), 2.0 (m, 2H), 1.97-1.69 (m, 5H); MS (LC / MS, M+H+): 440.
[0452] Preparation of 3-moφholino-4-nitrobenzonitrile: A solution of 3-fluoro-4- nitrobenzonitrile (0.6 g, 3.61 mmol, 1 eq.) and morpholine (0.629 g, 7.22 mmol, 2 eq.) in dimethyl sulfoxide (6.57 mL) was heated at 60 °C for 4 hours. The reaction solution was diluted with water 20 mL and extracted with ethyl acetate (3x20 mL). The combined organic phase was dried over Na2S04 and concentrated in vacuo to give a crude product which was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 7.82 (d, J= 8.3 Hz, 1H), 7.40 (d, J= 1.5 Hz, 1H), 7.33 (dd, J= 1.6, 8.3 Hz, 1H), 3.86 (m, 4H), 3.11 (m, 4H); MS (LC / MS, M+H+): 234
[0453] Preparation of 4-(5-methyl-2-nittophenyl)morpholine: The title compound was prepared according to the procedure for 3-moφholino-4-nitrobenzonitrile, except 2-fluoro-4-methyl- 1 -nitrobenzene was substituted for 3-fluoro-4-nitrobenzonitrile. ¾ NMR (400 MHz, CDC13) δ 7.76 (d, J= 8.2 Hz, 1H), 6.93 (b, 1H), 6.88 (d, J= 8.3 Hz, 1H), 3.86 (m, 4H), 3.06 (m, 4H), 2.40 (s, 3H); MS (LC / MS, M+H ): 223
[0454] Preparation of 3-morpholino-4-nitrophenol: The title compound was prepared according to the procedure for 3-moφholino-4-nitrobenzonitrile, except 3-fluoro-4-nitrophenol was substituted for 3-fluoro-4-nitrobenzonitrile. ¾ NMR (400 MHz, MeOD) δ 7.90 (d, J= 9.0 Hz, 1H), 6.56 (d, J= 2.4 Hz, 1H), 6.49 (dd, J= 2.5, 9.0 Hz, 1H), 3.83 (m, 4H), 3.02 (m, 4H); MS (LC / MS, M+H+): 225
[0455] Preparation of 4-(2-ηίΐτο-5-((2-(ΐτίηΐ6ΐ1ιγΐ8ί1γ1)6ΐ1ιοχγ)ηΐ6ΐ1ιοχγ)ρ1ΐ6ηγ1)ηιοφ1ιο1ίη6: A solution of 3-morpholino-4-nitrophenol (1.34 g, 5.98 mmol, 1 eq.), 2-(trimethylsilyl)ethoxymethyl chloride (1.05 g, 6.28 mmol, 1.05 eq.) and N,N-diisopropylethylamine (2.31 g, 17.9 mmol, 3 eq.) in dichloromethane (30.0 mL) was stirred at 25 °C for 16 hours. The reaction solution was diluted with 40 mL of water and extracted with dichloromethane (3x40 mL). The combined organic phase was dried over Na2S04 and concentrated in vacuo to give a crude product which was used in the next step without further purification. ¾ NMR (400 MHz, CDC13) δ 7.93 (d, J= 9.7 Hz, 1H), 6.68 (m, 2H), 5.24 (s, 2H), 3.85 (m, 4H), 3.74 (m, 2H), 3.04 (m, 4H), 0.94 (m, 2H), 0.00 (s, 9H); MS (LC / MS, M+H+): 355
[0456] Preparation of 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-l- yl)phenyl)moipholine: A mixture of 4-(5^ε^1-2-ηίΐτορ1ΐ6^ι)ιηοφ1ιο1ίη6 (1.58 g, 7.11 mmol, 1 eq.), Pd on carbon (316 mg, 20% wt) and methanol (72 mL) was stirred at 25 °C under 1 atm of H2(filled balloon) for 48 hours. The mixture was filtered through a plug of Celite, washed with methanol (50 mL) and concentrated in vacuo to give the crude intermediate, 4-methyl-2-morpholinoaniline.
[0457] (((4-nitrophenyl)sulfonyl)azanediyl)bis(ethane-2, 1-diyl) bis(4-nitrobenzenesulfonate) (1.0 g, 1.5 mmol, 1 eq.), 4^εΐ1^1-2-ιηοφ1ιο1ίηο3ηί1ίη6 (0.346 g, 1.8 mmol, 1.2 eq.), N,N- diisopropylethylamine (1.55 g, 12.0 mmol, 4 eq.) and acetonitrile (4.7 mL) were mixed in a microwave reaction vial (10 mL) fitted with a no-invasive vial cap. The reaction vials containing the mixture were reacted in the microwave for 1 h at 175°C. After 1 h, the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane and washed with HC1 (10%, 3 x 30mL) and saturated NaHCC (40mL). The organic phase was dried over Na2S04 and concentrated in vacuo to afford the crude product. The title compound was purified by column chromatography on a silica gel column, (ethyl acetate / dichlorormethane, 0% ~ 10%): ¾ NMR (400 MHz, CDC13) δ 8.44(d, J= 8.9 Hz, 2H), 8.02 (d, J= 9.0 Hz, 2H), 6.82 (m, 2H), 6.74 (b, 1H), 3.71 (t, J= 4.2 Hz, 4H), 3.24 (b, 8H), 3.05 (m, 4H), 2.29 (s, 3H); MS (LC / MS, M+H+): 447
[0458] Preparation of 3-morpholino-4-(4-((4-nitrophenyl)sulfonyl)piperazin-l- yl)benzonitrile: The title compound was prepared according to the procedure for 4-(5-methyl-2-(4-((4- nitrophenyl)sulfonyl)piperazin-l-yl)phenyl)moφholine, except 3-morpholino-4-nitrobenzonitrile was substituted for 4-(5^6^1-2-ηί&ορηε^1^οφ1ιο1ίη6 and 4-amino-3-moφholinobenzonitrile for 4- methyl-2-morpholinoaniline. ¾ NMR (400 MHz, CDC13) δ 8.43 (d, J= 8.8 Hz, 2H), 8.01 (d, J= 8.8Hz, 2H), 7.30 (dd, J= 1.8, 8.2 Hz, 1H), 7.14 (d, J= 1.8 Hz, 1H), 6.90 (d, J= 8.3 Hz, 1H), 3.73 (t, J= 4.5Hz, 4H), 3.36 (m, 4H), 3.26 (m, 4H), 3.02 (t, J= 4.3 Hz, 4H); MS (LC / MS, M+H+): 458
[0459] Preparation of 4-(2-(4-((4-nitrophenyl)sulfonyl)piperazin-l-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine: The title compound was prepared according to the procedure for 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-l-yl)phenyl)morpholine, except 4-(2-nitro-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)moφholine was substituted for 4-(5- methyl-2-nitrophenyl)moφholine and 2-morpholino-4-((2-(trimethylsilyl)ethoxy)methoxy)aniline for 4-methyl-2-morpholinoaniline. ¾ NMR (400 MHz, CDC13) δ 8.41 (d, J= 8.8 Hz, 2H), 8.01 (d, J= 8.7 Hz, 2H), 6.80 (d, J= 8.7 Hz, 1H), 6.67 (dd, J= 2.7, 8.7 Hz, 1H), 6.60 (d, J= 2.6 Hz, 1H), 5.14 (s, 2H), 3.74 (m, 2H). 3.68 (t, J= 4.4 Hz, 4H), 3.23 (b, 4H), 3.16 (b, 4H), 3.03 (b, 4H), 0.95 (m, 2H), 0.00 (s, 9H); MS (LC / MS, M+H+): 579
[0460] Preparation of 4-(5-Γηεΐ1ιγ1-2-(ρίρ6Γ3ζίη-1-γ1)ρ1ΐ6ηγ1)ηιοφ1ιο1ίη6: Potassium carbonate (1.5g, 10.8 mmol 12 eq.) was added to a mixture of acetonitrile and dimethylsulf oxide (CH3CN / DMSO 49: 1, 2.4 mL) and heated to 50°C. Thiophenol (0.988 g, 8.96 mmol, 10 eq.) was added dropwise via syringe to the mixture with stirring. After 30 minutes a solution of 4-(5-methyl-2- (4-((4-nitrophenyl)sulfonyl)piperazin-l-yl)phenyl)moφholine (0.410 g, 0.896 mmol, 1 eq.) in acetonitrile and dimethyl sulfoxide (acetonitrile / dimethyl sulfoxide 49: 1, 4.5 mL) was added dropwise. The reaction mixture was stirred for 3 hours, quenched with excess NaOH solution (40%) and concentrated under reduced pressure. The residue was extracted with dichloromethane (5x30mL) and the organic phase was dried over MgSC , and concentrated in vacuo to give a crude oil. The oil was purified by reverse phase chromatography (acetonitrile in H20, gradient from 1%~100% with 0.1% formic acid) to afford the formic acid salt of the desired piperazine. The salt was dissolved in dichloromethane, washed with saturated NaHCC solution, and the organic phase concentrated in vacuo to provide the product. ¾ NMR (400 MHz, CDC13) δ 6.87-6.76 (m, 2H), 6.71 (s, 1H), 3.84 (t, J= 4.5 Hz, 4H), 3.18 (b, 4H), 3.07 (b, 4H), 2.98 (b, 4H), 2.29 (s, 3H); MS (LC / MS, M+H"): 262
[0461] Preparation of 3^οφ^1ίηο-4-φίρ6Γ3ζίη-1^1^6ηζοηίΐπ1ε: The title compound was prepared according to the procedure for 4-(5^6^1-2-φίρεΜζίη-1^1)ρ1ΐ6^1)ιηοφ1ιο1ίη6, except 3- morpholino-4-(4-((4-nitrophenyl)sulfonyl)piperazin-l-yl)benzonitrile was substituted for 4-(5-methyl- 2-(4-((4-nitrophenyl)sulfonyl)piperazin-l-yl)phenyl)morpholine. ¾ NMR (400 MHz, CDC13) δ 7.24 (dd, J= 1.8, 8.2 Hz, 1H), 7.08 (d, J= 1.8 Hz, 1H), 6.88 (d, J= 8.4 Hz, 1H), 3.81 (t, J= 4.6 Hz, 4H), 3.21 (b, 4H), 3.11 (b, 4H), 3.00 (b, 4H); MS (LC / MS, M+H+): 273
[0462] Preparation of 4-(2-(piperazin-l-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)The title compound was prepared according to the procedure for 4-(5-methyl-2- φίρεΜζίη-Ι^ΓίρΙιε^ΓίιηοφηοΙίηε, except 4-(2-(4-((4-nitrophenyl)sulfonyl)piperazin-l-yl)-5-((2- (trimethylsilyl)ethoxy)methoxy)phenyl)moφholine was substituted for 4-(5-methyl-2-(4-((4-ηίΐΓο Γι6ηγ1)8π1&ηγ1) ί 6Γαζίη-1-γ1) 1ΐ6ηγ1^οφ1ιο1ίη6. ¾ NMR (400 MHz, CDC13) δ 6.83 (d, J= 8.6 Hz, 1H), 6.67 (dd, J= 2.7, 8.5 Hz, 1H), 6.59 (d, J= 2.8 Hz, 1H), 3.82 (t, J= 4.7 Hz, 4H), 3.74 (m, 2H), 3.18 (b, 4H), 3.10-2. M+H+): 394
[0463] Preparation of tert-butyl 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-l- yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of tert-butyl 3-(2- bromoethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.05 g, 0.138 mmol, 1 eq.), 4-(5- methyl-2-(piperazin-l-yl)phenyl)moφholine (0.044 g, 0.166 mmol, 1.2 eq.), and triethylamine (0.070 g, 0.69 mmol, 5 eq.) in acetonitrile (2 mL) was microwaved at 120 °C for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give a crude product. The title compound was purified by column chromatography on a silica gel column.(methanol / dichloromethane, 0% ~ 10%) ¾ NMR (400 MHz, CDC13) δ 6.87-6.76 (m, 2H), 6.71 (s, 1H), 4.59 (m, 1H), 3.98 (m, 1H), 3.90-3.73 (m, 5H), 3.31-2.94 (m, 10H), 2.70-2.47 (m, 6H), 2.39 (dd, J= 6.2, 12.8 Hz, 1H), 2.28 (s, 3H), 2.03-1.70 (m, 5H), 1.60 (m, 1H), 1.55-1.38 (m, 10H); MS (LC / MS,M+H+): 543
[0464] Preparation of tert-butyl 3-(2-(4-(4-cyano-2-morpholinophenyl)piperazin-l-yl)ethyl)- l-oxo-2 -oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(4-methyl-2-moφholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate, except 3^οφ^1ίηο-4- ίρ6Γ3ζίη-1-γ1^6ηζοηητί1ε was substituted for 4-(5^6 1-2-(ρίρ6Μζίη-1-γ1)ρη6ηγ1^οφηο1ίη6. ¾ NMR (400 MHz, CDC13) δ 7.26 (dd, J= 1.8, 8.3 Hz, 1H), 7.09 (d, J= 1.6 Hz, 1H), 6.89 (d, J= 8.3 Hz, 1H), 4.57 (m, 1H), 3.96 (m, 1H), 3.89-3.73 (m, 5H), 3.40-2.98 (m, 10H), 2.72-2.45 (m, 6H), 2.37 (dd, J= 6.1, 12.8 Hz, 1H), 2.03-1.67 (m, 5H), 1.58 (m, 1H), 1.54-1.38 (m, 10H); MS (LC / MS, M+H+): 554
[0465] Preparation of 8-(ηιε ΐ8η1&ηγ1)-3-(2-(4-(2-ηιοφ1ιο1ίηο-4-((2-(trimethy lsilyl)ethoxy)methoxy)pheny l)piperazin- 1 -yl)ethy l)-2-oxa-8-azaspiro[4.5] decan- 1 -one : The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(4-methyl-2- morpholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 4- (2-(piperazin-l-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine was substituted for 4-(5- methyl-2-(piperazin-l-yl)phenyl)moφholine and 3-(2-bromoethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one for tert-butyl 3-(2-bromoethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate. ¾ NMR (400 MHz, CDC13) δ 6.83 (d, J= 8.6 Hz, 1H), 6.66 (dd, J= 2.7, 8.6 Hz, 1H), 6.59 (d, J= 2.7 Hz, 1H), 5.14 (s, 2H), 4.61 (m, 1H), 3.81 (t, J= 4.4 Hz, 4H), 3.74 (m, 2H), 3.66 (m, 1H), 3.35 (m, 2H), 3.26 (m, 1H), 3.21-2.94 (b, 8H), 2.80 (s, 3H), 2.70-2.41 (m, 6H), 2.30 (dd, J= 5.6, 12.9 Hz, 1H), 2.08-1. (LC / MS, M+H ): 653
[0466] Preparation of 3-(2-(4-(4-methyl-2-moφholinophenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: A solution of tert-butyl 3-(2-(4-(4-methyl-2- morpholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.077 g, 0.142 mmol, 1 eq.) in trifluoroacetic acid:dichlroromethane (1 :3, 2 mL) was allowed to stir at 25 °C for 30 minutes. The reaction solution was diluted with methanol (2 mL) and concentrated in vacuo to give a crude intermediate as a trifluoroacetic acid salt. The resulting material was dissolved in dicloromethane (10 mL) and washed with sat. NaHC03(aq.) solution (10 mL). The aqueous layer was backwashed with dicloromethane (2x10 mL) and the combined organic layers were dried over Na2S04 and concentrated in vacuo to give a crude intermediate as a free base.
[0467] The resulting free base (0.052g, 0.114 mmol, 1 eq.) was dissolved in dicloromethane (2 mL) and cooled to 0 °C, and trimethylamine (0.058 g, 0.57 mmol, 5 eq.) and methanesulfonyl chloride (0.026, 0.228 mmol, 2 eq.) were added. The reaction solution was allowed to stir at 25 °C for30 minutes and then concentrated in vacuo to give a crude solid. The title compound was purified by column chromatography on a silica gel column, (methanol / dichloromethane, 0% ~ 10%) ¾ NMR (400 MHz, CDC13) δ 6.79-6.68 (m, 2H), 6.64 (s, 1H), 4.54 (m, 1H), 3.75 (t, J= 4.4 Hz, 4H), 3.59 (m, 1H), 3.37-2.88 (b, 11H), 2.74 (s, 3H), 2.69-2.33 (b, 6H), 2.27-2.16 (m, 4H), 2.02-1.92 (m, 2H), 1.92- 1.62 (m, 5H); MS (LC / MS, M+H+): 521
[0468] Preparation of 4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8-azaspiro[4.5]decan-3- yl)ethyl)piperazin-l-yl)-3-morpholinobenzonitrile: The title compound was prepared according to the procedure for 3 -(2-(4-(4-methy l-2-morpholinophenyl)piperazin- 1 -y l)ethyl)-8-(methy lsulfony l)-2-oxa- 8-azaspiro[4.5]decan-l-one, except tert-butyl 3-(2-(4-(4-cyano-2-morpholinophenyl)piperazin-l- yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate was substituted for 3-(2-(4-(4-methyl-2- morpholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate. ¾ NMR(400 MHz, CDCI3) δ 7.29 (dd, J= 1.8, 8.3 Hz, 1H), 7.12 (d, J= 1.7 Hz, 1H), 6.91 (d, J= 8.3 Hz, 1H), 4.63 (m, 1H), 3.85 (t, J= 4.3 Hz, 4H), 3.67 (m, 1H), 3.55-2.96 (b, 11H), 2.83 (s, 3H), 2.75-2.40 (b, 6H), 2.30 (dd, J= 6.0, 12.9 Hz, 1H), 2.12-1.99 (m, 2H), 1.99-1.71 (m, 5H); MS (LC / MS, M+H+): 532
[0469] Preparation of 3-(2-(4-(4-hydroxy-2-morpholinophenyl)piperazin-l-yl)ethyl)-8- (methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l-one: To a small vial, 8-(methy lsulfony l)-3 -(2-(4-(2- morpholino-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro [4.5]decan-l-one (0.190 g, 0.291 mmol, 1 eq.) was added and dissolved in hexamethylphosphoramide (1.5 mL). Tetra-n-butylammonium fluoride trihydrate (0.230 g, 0.873 mmol, 3 eq.) was added, followed by 300 tng of 4A molecular sieves. The reaction mixture was stirred at 60 °C for 48 hours before being filtered and concentrated in vacuo to give a crude oil. The title compound was purified by column chromatography on a silica gel column, (methanol / dichloromethane, 0% ~ 10%) ¾ NMR (400 MHz, CDCI3) δ 6.70 (d, J= 9.2 Hz, 1H), 6.40-6.32 (m, 2H), 4.53 (m, 1H), 3.75 (t, J= 4.3 Hz,4H), 3.58 (m, 1H), 3.38-2.84 (b, 11H), 2.74 (s, 3H), 2.70-2.33 (b, 6H), 2.21 (dd, J= 5.9, 12.8 Hz, 1H), 2.01-1.80 (m, 4H), 1.79-1.60 (m, 3H); MS (LC / MS, M+H+): 523.Formulations
[0470] The present invention also relates to compositions or formulations which comprise the 5-hydroxytryptamine receptor 7 activity modulators according to the present invention. In general, the compositions of the present invention comprise an effective amount of one or more compounds of the disclosure and salts thereof according to the present invention which are effective for providing modulation of 5-hydroxytryptamine receptor 7 activity; and one or more excipients.
[0471] For the purposes of the present invention the term "excipient" and "carrier" are used interchangeably throughout the description of the present invention and said terms are defined herein as, "ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition."
[0472] The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.
[0473] The present teachings also provide pharmaceutical compositions ...
Claims
WHAT IS CLAIMED IS:
1. A compound having formula (I) :Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:A is selected from a group consistingX is selected from the group consisting of O, S, SO, SO2, NR;n1is 0, 1, 2;n2is 0, 1, 2;R is selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,, COR2, C02R2a, CONR2bR2c, S02NR2bR2c, and S02R2d;Rla, Rlb, Rlc, Rld, and Rleare at each occurrence independently selected from the group consisting of H, OH, NO2, halogen, CN, Ci-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, Ci-6 linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, Ci-6 linear haloalkyl, C3-7 branched haloalkyl, Ci-6 linear haloalkoxy, -S(Ci-6linear alkyl), S(C3-7branched alkyl), -S(C3-7cycloalkyl), COR6, C02R7,CONR8aR8b, S02NR8aR8b, NR9aR9b, NR9aCOR10, NR9aS02Rn, and NR9aS02NR12aR12b;R2is selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R2ais selected from the group consisting of Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl; R2bis selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R2cis selected from the group consisting of H, Ci-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, Ci-eR3is selected from a group consisting of Ci-e linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,R4is an optionally substituted aryl;R5aand R5bare each independently optionally substituted aryl;R6is at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R7is at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R8ais at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R8bis at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;Rais at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R9bis at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R10is at each occurrence independently selected from the group consisting of H, Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;Rnis at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R12ais at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R12bis at each occurrence independently selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R13is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;R14is selected from the group consisting of Ci-e linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl; n is 1, 2, or 3;m is 1 or 2;and q is 1, 2, or 3. of claim 1, having the formula (II):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof. of claim 1, having the formula (III):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.The compound of claim 1, having the formula (IV):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
5. The compound of claim 1, having the formula (V):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
6. The compound of claim 1, having the formula (VI):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
7. The compound of claim 1, having the formula (VII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
8. The compound of claim 1, having the formula (VIII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
9. The compound of claim 1, having the formula (IX):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
10. The compound of claim 1, having the formula (X):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
11. The compound of claim 1, having the formula (XI):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
12. The compound of claim 1, having the formula (XII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.The compound of claim 1, having the formula (XIII):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
14. The compound of claim 1, having the formula (XIV):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.The compound of claim 1, having the formula (XV):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
16. The compound of claim 1, having the formula (XVI):Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and complexes thereof.
17. A compound of claim 1, wherein the compound is selected from the group consisting of: 18.(R)-3-(2-(4-phenylpiperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(R)-3-(2-(4-(4-hydroxyphenyl)piperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(R)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-N-methyl-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8- carboxamide,(R)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(R)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(R)-tert-butyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, (R)-tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane- 8-carboxylate,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazm^azaspiro [4.5 ] de can- 1 -one ,(R)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-4-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)benzonitrile,(R)-8-((6-chloroimidazo[2,l-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one, and(R)-2-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)acetonitrile,(R)-8-( ropylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4 ]decan- one,(R)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (R)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (R)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-( yridin-3-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4 ]decan-l-on^(R)-8-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-((lH-imidazol-4-yl)sulfonyl)-3-(2-^1-one,(R)-8-(furan-2-y lsulfony l)-3 -(2-(4-(p-toly l)piperazin- 1 -y l)ethy l)-2-oxa-8-azaspiro [4.5] decan- 1 -one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(R)-4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-l- yl)benzonitrile,(R)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3-(2-(4-(4-chlorophenyl)piperazin-l-yl)ethyl)-8-(methy lsulfony l)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3-(2-(4-(4-iodophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3-(2-(4-(4-fluorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-phenylpiperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(S)-3-(2-(4-(4-hydroxyphenyl)piperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(S)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-N-methyl-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8- carboxamide,(S)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(S)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(S)-tert-butyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, (S)-tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane- 8-carboxylate,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-8-(phenylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-4-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)benzonitrile,(S)-8-((6-chloroimidazo[2,l-b]thiazol-5-yl)sulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-ox azaspiro[4.5]decan-l-one,(S)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one, and(S)-2-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)acetonitrile,(S)-8-( ropylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-8-((tri^one,(S)-8-(isopropylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (S)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (S)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-8-(isobutylsulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(ethylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4 ]decan-l-one,(S)-8-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(S)-8-((lH-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(S)-8-(fiiran-2-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(S)-4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-l- yl)benzonitrile,(S)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-chlorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-iodophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-fluorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,or a pharmaceutically acceptable form thereof.
19. A composition comprising an effective amount of at least one compound according to claim 1.
20. A composition according to claim 19, further comprising at least one excipient.
21. A composition according to claim 20, wherein the at least one compound is at least one member comprising:(R)-3-(2-(4-phenylpiperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(R)-3-(2-(4-(4-hydroxyphenyl)piperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(R)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-N-methyl-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8- carboxamide,(R)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(R)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(R)-tert-butyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, (R)-tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane- 8-carboxylate,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-8-( henylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-(^one,(R)-4-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)benzonitrile,(R)-8-((6-chloroimidazo[2,l-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p olyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one, and(R)-2-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)acetonitrile,(R)-8-( ropylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (R)-3 -(2-(4-(p-toly l)piperazin- 1 -y l)ethy l)-8-((trifluoromethy l)sulfony l)-2-oxa-8-azaspiro [4.5] decan- 1 - one,(R)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (R)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (R)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-( yridin-3-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4 ]decan-l-on^(R)-8-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-((lH-imidazol-4-yl)sulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(R)-8-(furan-2-y lsulfony l)-3 -(2-(4-(p-toly l)piperazin- 1 -y l)ethy l)-2-oxa-8-azaspiro [4.5] decan- 1 -one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(R)-4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-l- yl)benzonitrile,(R)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3 -(2-(4-(4-chloropheny l)piperazin- 1 -yone,(R)-3-(2-(4-(4-iodophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3-(2-(4-(4-fluorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-phenylpiperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(S)-3-(2-(4-(4-hydroxyphenyl)piperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(S)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-N-methyl-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8- carboxamide,(S)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(S)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(S)-tert-butyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, (S)-tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane- 8-carboxylate,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-8-(phenylsulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(S)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-4-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)benzonitrile,(S)-8-((6-chloroimidazo[2,l-b]thiazol-5-yl)sulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(S)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one, and(S)-2-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)acetonitrile,(S)-8-( ropylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4 ]dec one,(S)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (S)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (S)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(S)-8-(isobutylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(ethylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(S)-8-((lH-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(S)-8-(fiiran-2-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin -yl)ethyl)-8-(^1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[1-one,(S)-4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-l- yl)benzonitrile,(S)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-chlorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-iodophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-fluorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,or a pharmaceutically acceptable form thereof.
22. A method of treating a disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, said method comprising administering to a subject an effective amount of at least one compound according to the claim 1 to treat the disease.
23. The method of claim 22, wherein the at least one compound is administered in a composition further comprising at least one excipient.
24. The method of claim 22, wherein the at least one compound is at least one member comprising:(R)-3-(2-(4-phenylpiperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(R)-3-(2-(4-(4-hydroxyphenyl)piperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(R)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-N-methyl-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8- carboxamide,(R)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(R)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(R)-tert-butyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, (R)-tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane- 8-carboxylate,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-8-( henylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-^-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-4-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)benzonitrile,(R)-8-((6-chloroimidazo[2,l-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one, and(R)-2-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)acetonitrile,(R)-8-( ropylsulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-8-((ta^one,(R)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (R)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (R)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(R)-8-( yridin-3-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4 ]decan-l-on^(R)-8-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(R)-8-((lH-imidazol-4-yl)sulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(R)-8-(furan-2-y lsulfony l)-3 -(2-(4-(p-toly l)piperazin- 1 -y l)ethy l)-2-oxa-8-azaspiro [4.5] decan- 1 -one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(R)-4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-l- yl)benzonitrile,(R)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3-(2-(4-(4-chlorophenyl)piperazin-l-yl)ethyl)-8-(methy lsulfony l)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3-(2-(4-(4-iodophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(R)-3-(2-(4-(4-fluorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-phenylpiperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(S)-3-(2-(4-(4-hydroxyphenyl)piperazin-l-yl)ethyl)-2,8-dioxaspiro[4.5]decan-l-one,(S)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-methyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-N-methyl-l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8- carboxamide,(S)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(S)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate,(S)-tert-butyl l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, (S)-tert-butyl 3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-l-oxo-2-oxa-8-azaspiro[4.5]decane- 8-carboxylate,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(2-moφholinophenyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(2-methyl-lH-benzo[d]imidazol-7-yl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(lH)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-8-(phenylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-^ olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one,(S)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-( olyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4 ]decan- one,(S)-4-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)benzonitrile,(S)-8-((6-chloroimidazo[2,l-b]thiazol-5-yl)sulfo^azaspiro [4.5 ] de can- 1 -one ,(S)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro[4.5]decan-l-one, and(S)-2-((l-oxo-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8- yl)sulfonyl)acetonitrile,(S)-8-( ropylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-8- one,(S)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (S)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one, (S)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(S)-8-(isobutylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(ethylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-8-((l-methyl-lH-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8- azaspiro [4.5 ] de can- 1 -one ,(S)-8-((lH-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(S)-8-(fiiran-2-ylsulfonyl)-3-(2-(4-( -tolyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan- 1-one,(S)-4-(4-(2-(8-(methylsulfonyl)-l-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-l- yl)benzonitrile,(S)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-l-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-chlorophenyl)piperazm^one,(S)-3-(2-(4-(4-iodophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,(S)-3-(2-(4-(4-fluorophenyl)piperazin-l-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-l- one,or a pharmaceutically acceptable form thereof.
25. The method of claim 22, wherein the disease associated with dysregulation of 5- hydroxytryptamine receptor 7 activity comprises: inflammatory bowel disease, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, or bipolar disorder.
26. The method of claim 23, wherein the disease associated with dysregulation of 5- hydroxytryptamine receptor 7 activity comprises: inflammatory bowel disease, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit / hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, or bipolar disorder.
